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Abstract 
 
Solventogenic clostridia offer a sustainable alternative to petroleum-based production of butanol—an 
important chemical feedstock and potential fuel additive or replacement.  Clostridium beijerinckii is an 
attractive microorganism for butanol production because it (1) naturally produces the highest recorded 
butanol concentrations as a byproduct of fermentation; and (2) can co-ferment pentose and hexose sugars 
(the primary products from lignocellulosic hydrolysis).  Prior to my Ph.D. work, C. beijerinckii 
metabolism had been primarily studied from a reductionist perspective, with research focused on a 
handful of pathways, reactions, and phenotypes. Interrogating the metabolism of this microorganism 
using a systems biology approach broadens this perspective to study the global effects of genetic and 
environmental perturbations. 
 
For my Ph.D. dissertation, I used constraint-based modeling and metabolic profiling to holistically 
investigate C. beijerinckii metabolism, with the ultimate goal of garnering new insights to guide strain 
design for increased butanol production. The work described herein makes four important contributions to 
advance C. beijerinckii research: (1) the first constraint-based genome-scale model of C. beijerinckii 
metabolism (iCM925) and demonstration that constraint-based analysis of iCM925 can accurately 
reproduce physiological behavior and provide insight into the underlying mechanisms of microbial 
butanol production; (2) hypothesis generation using model iCM925 for alternative acetate production 
mechanisms in mutant strain pta::int(17); (3) model-guided knockout candidates for improved butanol 
production; (4) the first time-series metabolomics study for C. beijerinckii, used to identify distinct 
metabolic phases and suggest new metabolite annotations. 
 
Going forward, it is my hope that the research presented herein will serve as a launching pad to systemic 
C. beijerinckii research endeavors. Model iCM925 offers a useful tool to researches wishing to better 
understand C. beijerinckii metabolic behavior and metabolically engineer C. beijerinckii for sustainable 
production of fuels and chemicals. The metabolomics study provides novel insight into the dynamic 
changes occurring over the C. beijerinckii life cycle that can be used for hypothesis generation in future 
experiments. Systems-based approaches to understanding and manipulating metabolism such as those 
employed here are important in the on-going efforts to develop predictive and informative tools to study 
high-throughput data types in both industrial biotechnology and biomedicine.    
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Chapter 1. Introduction 
 
 
1.1 Motivation and approach   
 
The diminishing supply of non-renewable feedstocks and concern over environmental ramifications of 
their use in fuel and chemical production highlights the need for technological advances to improve the 
economic viability of sustainable production methods.  Production of butanol is of particular industrial 
interest due to its broad scope of applications as a chemical feedstock and compelling properties as an 
alternative transportation fuel [1].  Butanol can be sustainably produced by microbial fermentation of 
cellulosic hydrolysates, however, the challenge is that butanol concentration during fermentation remains 
below the threshold needed for economic profitability. Clostridium beijerinckii offers a compelling 
starting point for improving microbial butanol production because it naturally produces butanol as a 
fermentation byproduct and can simultaneously utilize hexose and pentose sugars [2, 3]. Both upstream 
and downstream improvements to C. beijerinckii butanol production have been made by the Blaschek 
group at Illinois [4]. The primary aim (and outcome) of my thesis work was to employ a systems biology 
approach to improve our understanding of C. beijerinckii metabolism and guide metabolic engineering 
experiments.  
 
1.1.1 Butanol as a commodity chemical and biofuel 
 
Since its discovery in 1862 by Louis Pasteur, butanol—first used in the production of synthetic rubber—
has been an important commodity chemical.  During World War I, acetone (produced as a byproduct of 
butanol fermentation) was produced to make smokeless ammunition—creating a large surplus of butanol 
in the process. The stored butanol was used during Prohibition to make butyl-acetate (a replacement for 
the no longer available amyl acetate), a component in quick-drying lacquers used in car manufacturing.  
With the rise of the petroleum industry and an increase in fermentation substrate cost, microbial butanol 
production declined.  Today, butanol is still an important chemical feedstock used to produce derivatives 
such as acrylate, methacrylate esters, glycol ethers, and butyl acetate for a broad scope of industrial uses, 
ranging from paint products and plastics to food and pharmaceutical products [1].    
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Additionally, butanol has become an intriguing alternative transportation fuel due to its superior qualities 
as compared to ethanol and sustainable production methods.  Butanol is a four-carbon alcohol with an 
energy density that is 83% that of gasoline—18% higher than that of ethanol.  Lower vapor pressure, 
corrosivity, and water affinity add to the significant edge butanol has over ethanol.  Butanol can be used 
as a mixture with gasoline or alone, and is compatible with our current fuel infrastructure and vehicle fleet 
[2].  Butanol also has potential use as a fuel for airplanes, as was demonstrated during World War II when 
Japan converted its sugar refineries into plants to produce butanol as an aviation fuel [5]. 
 
1.1.2 Sustainable production of butanol 
 
Importantly, butanol can be sustainably produced by the fermentation of pentose and hexose sugars 
present in lignocellulosic biomass hydrolysates. Lignocellulosic biomass (e.g., switchgrass, miscanthus, 
sugarcane, corn stover) is one of the most abundant renewable resources on the planet, and provides a 
way to harness the sun’s energy into usable products [3]. Lignocellulosic biomass is composed primarily 
of hemicellulose, cellulose, and lignin. Hemicellulose can be broken down into pentose sugars, and 
cellulose can be broken down enzymatically into hexose sugars.  These sugars can then be converted into 
important chemicals by microbial fermentation, and the remaining lignin can be burned to fuel the 
fermentation process.  Because biomass utilizes CO2 in photosynthesis, the combustion of fermentation 
products such as butanol is considered to be carbon neutral [4, 5]. 
 
Even though the technology to produce fuels and chemicals from lignocellulosic biomass exists, there are 
many challenges to making the process economically viable. As shown in Figure 1, the production 
process involves four primary steps: (1) pretreatment, where the biomass is made amenable to enzymatic 
hydrolysis; (2) hydrolysis, where the biomass is broken down into fermentable sugars; (3) fermentation, 
where microbes ferment the sugars into valuable products; and (4) separations, where the products are 
purified.  The ability to produce and tolerate high concentrations of butanol in fermentation (step (3)) is 
one of the leading challenges to achieving economical production of bio-based butanol, and improving 
this process is the primary focus of my thesis work. Even though steps (1), (2), and (4) do not lie within 
the scope of my work, they are also important areas of research and need be considered to ensure 
seamless integration with the final process.  
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Figure 1: Overview of the butanol production process.  To produce butanol from lignocellulsoic biomass the 
feedstock must be pretreated to remove lignin and begin degradation of hemicellulose. The remaining hemicellulose 
and cellulose is converted into pentose and hexose sugars (respectively) by enzymatic hydrolysis. These sugars can 
be fermented to butanol by C. beijerinckii. Finally, the butanol is purified in the separation process. 
 
1.1.3 Butanol production by solventogenic clostridia  
 
To date, solventogenic clostridia have been the most successful butanol fermentation microorganisms.  
Model fermentation microorganisms—such as Escherichia coli and Saccharomyces cerevisiae—have 
also been engineered to produce butanol and its branched chain derivatives (e.g., isobutanol) [6-8].  
However, the solventogenic clostridia offer two clear advantages as butanol-producing microorganisms: 
(i) the evolved ability to produce and tolerate butanol at concentrations up to 21 g/L—important because 
butanol is highly toxic to microorganisms at even low concentrations [4, 6-8], and (ii) the ability to co-
ferment pentose and hexose sugars, the primary sugars found in lignocellulosic hydrolysates [2, 3].  These 
characteristics should reduce the number of genetic modifications needed to make bio-based butanol 
production economically competitive.  
 
Among the solventogenic clostridia, Clostridium acetobutylicum ATCC 824 and C. beijerinckii produce 
the highest n-butanol concentrations; the mutant strain C. beijerinckii BA101 achieves the highest 
reported concentration (17-21 g/L) across all microorganisms [4, 7, 8]. The parent strain of BA101, C. 
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beijerinckii strain NCIMB 8052, holds several advantages for industrial butanol production: (1) it has 
proven amenable to experimental modifications that increase butanol tolerance and production [8]; (2) the 
solventogenic genes reside on the chromosome rather than on a separate megaplasmid  (as is the case for 
C. acetobutylicum), potentially increasing resistance to degeneration [9]; (3) it can successfully produce 
butanol in continuous culture conditions [10]; and (4) it has a broad substrate utilization spectrum [2, 3, 
11].  Importantly, a successful C. beijerinckii knockout system was recently developed by Wang et al. 
[12]. Taken together, these traits give C. beijerinckii particular appeal as a clostridial catalyst for 
industrial butanol production. 
 
Like other solventogenic clostridia, C. beijerinckii produces solvents (butanol and acetone) as products of 
a biphasic metabolism (Figure 2) [13]. First, butyrate and acetate are produced in what is known as the 
acidogenesis phase. This phase is followed by the solventogenesis phase, in which butyrate and acetate 
are re-assimilated and production of butanol and acetone begins.  Importantly, key genes related to the 
switch have been identified [14]. Numerous phenomena—decreased pH, acid accumulation, intracellular 
ATP concentration, nutrient limitation, interplay between carbon and electron flow pathways, and 
sporulation—have also been hypothesized to contribute to the switch from acidogenesis to 
solventogenesis [14, 15]. Most of these phenomena are directly tied to cellular metabolism, or more 
specifically, to changes among the enzymes and metabolites that comprise the intracellular metabolic 
network.   
 
1.1.4 A systems biology approach to understanding and manipulating C. beijerinckii metabolism  
 
Prior to completion of the work described herein, C. beijerinckii research centered on what is known as 
the “reductionist” approach, in which experimental approaches are used to dissect a biological system 
(e.g., a biochemical pathway) into a “parts list” and each component is studied individually. While this 
approach has led to enormous scientific advances, it is unable to holistically capture the complex 
dynamics of a large biological system. Systems biology has emerged as a promising discipline that 
integrates both experimentation and computation to characterize and mathematically model the complex 
interactions in a biological system as a whole [16, 17]. Particularly with the rise in high-throughput data 
types, systems biology approaches are needed to make sense of the vast amounts of biological 
information that is available to us.  Two primary systems biology approaches were applied for the work 
presented herein: (1) constraint-based genome-scale modeling (2) time-series metabolic profiling.  
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The advantage of constraint-based genome-scale modeling is that it does not require detailed kinetic 
information about each reaction present in the metabolic network of an organism. Instead, the genome-
scale model is a matrix representation of the reaction stoichiometry (based on enzymes coded in the 
genome). This matrix is then constrained by a series of balances (e.g., mass, energy) and bounds (e.g., 
flux rates) to define a solution space of plausible network states, which represent possible phenotypes 
(Figure 2). In this way, the genome-scale metabolic model provided me with a basis for understanding 
metabolic behavior and investigating stoichiometric modifications for improved butanol production.  
Methods for reconstructing and analyzing metabolic networks have been well established for 
microorganisms, and genome-scale models have been built for all branches of life [20].  Over 50 genome-
scale models have been built to date, and numerous successes in rational engineering have been 
demonstrated, particularly in model microorganisms such as E. coli and S. cerevisiae [24-26].   
 
 
Figure 2: Constraint-based modeling overview. Constraint-based genome-scale models are a mathematical 
representation of stoichiometric equations present in the metabolic network of an organism. The stoichiometric 
model is subjected to a series of balances and bounds to define a solution space comprising all non-excluded 
network states. As such, the bounded solution space represents all possible phenotypes for the organism and can be 
queried to better understand metabolic behavior or predict genetic modifications.  
 
The genome-scale model allowed me to look at static metabolic behavior as defined by the genome. To 
investigate dynamic metabolic behavior as well I conducted a time-series metabolomics study. The 
metabolome provides information about which metabolites are present in a biochemical network under 
specific conditions. Qualitatively and/or quantitatively identified metabolites can provide insight into the 
physiological state of the cell and comparative analysis of global metabolomics data can reveal key 
differences in the abundance of specific compounds at different time points or in different conditions [18].   
A time-series experiment is of particular use when the dynamics are important, such as in an organism 
with a biphasic metabolism like C. beijerinckii. By having metabolomics data in addition to a genome-
scale metabolic model, it is possible to map experimentally observed metabolic changes to biochemical 
reactions, proteins, and genes.  
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1.2 Research objectives and dissertation overview 
 
The big picture objectives of this dissertation were to (1) advance understanding of whole-cell metabolic 
behavior in C. beijerinckii and (2) develop a guide for metabolic engineering experiments. These aims 
were accomplished using systems biology approaches to holistically characterize C. beijerinckii 
metabolism, namely constraint-based genome-scale modeling and time-series metabolic profiling. The 
organization of this dissertation is as follows:  
 
• Chapter 1 provides an introduction to sustainable butanol production as well as background 
information explaining the choice of C. beijerinckii as a butanol fermentation organism and the 
systems biology approach to understanding and manipulating C. beijerinckii metabolism.  
• Chapter 2 provides a detailed overview of butanol production in C. beijerinckii. It reviews the 
progress that has been made towards improving butanol production and tolerance in C. 
beijerinckii and C. acetyobutylicum, as well as in model organisms such as Escherichia coli and 
Saccharomyces cerevisiae.  
• Chapter 3 presents an introduction to constraint-based modeling and what was (at the time of 
publication) a comprehensive review of all published genome-scale models. For each model the 
review discusses the intended application, noteworthy aspects of construction and/or validation, 
and any reported metabolic engineering successes.  The included models are organized by 
biotechnology and biomedical applications. 
• Chapter 4 details the genome-scale metabolic model for C. beijerinckii, including the semi-
automated reconstruction of the metabolic network, experimentation and model validation 
process, and initial simulations and analysis.  
• Chapter 5 is a compilation of all of the simulations and predictions made using the genome-scale 
metabolic model and includes model simulation details, hypothesis generation for the observed 
mutant phenotypes, and knockout predictions for improved butanol production.  
• Chapter 6 details the time-series metabolomics study conducted for C. beijerinckii, including 
culture conditions, sampling protocol, extraction and derivitization protocol, GC/MS analysis 
specifications, data organization, and a discussion of the main findings. 
• Chapter 7 highlights the conclusions from this research and a discussion on future directions.  
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Chapter 21: Understanding butanol production in Clostridia and an 
overview of previous genetic engineering efforts to improve butanol 
production in microbes  
 
 
2.1 Butanol production by solventogenic clostridia  
 
2.1.1 Biochemistry of solvent production by solventogenic clostridia 
 
Glucose is fermented via the Emden–Meyerhof–Parnas pathway to pyruvate (Figure 3). Solventogenic 
clostridia produce two major types of products, solvents (acetone, butanol, ethanol) and gases (carbon 
dioxide and hydrogen), and one major type of fermentation intermediate product, organic acids (acetic 
and butyric acid). Solventogenic clostridia are obligate anaerobes and generate only two net molecules of 
ATP during glycolytic metabolism of glucose to pyruvate (Figure 3). The acetic and butyric acid pathway 
reactions have important roles in solventogenic clostridia metabolism because synthesis of these acids is 
accompanied by generation of ATP, which is important for cell growth and metabolism. Both butyric and 
acetic acid are re-assimilated during the solventogenic phase. The formation of butyric acid during the 
acidogenic phase is important for maintenance of the redox equilibrium because nicotinamide adenine 
dinucleotides (NADHs) produced during glycolysis are only oxidized in the butyric acid formation 
pathway, not in the acetic acid formation pathway, resulting in the regeneration of NAD+ (important for 
continuation of glycolysis and generation of pyruvate by C. beijerinckii (Figure 3A)).  
 
A mechanism that involves metabolism of pyruvate for acetic and butyric acid production (Figure 3A; 
two molecules of ATP produced) and uptake of acetic and butyric acid for solvent production (Figure 
3C) is energetically more attractive than a reaction scheme (no ATP produced) that results in direct 
production of solvents (Figure 3B). Under certain conditions, lactic acid may be produced (Figure 3A), 
                                                      
1 Material in this chapter was reproduced with permission from the following publication: Ezeji T, Milne C, Price 
ND, Blaschek HP: Achievements and perspectives to overcome the poor solvent resistance in acetone and butanol-
producing microorganisms. Appl Microbiol Biotechnol 2009, 85:1697. Milne acknowledges contributions from 
Ezeji, Price, and Blaschek. The original publication is available at www.springerlink.com or by following this link: 
http://link.springer.com/article/10.1007/s00253-009-2390-0.  
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and some of the two precursors of butyric acid, acetoacetyl-CoA, and butyryl-CoA are directly converted 
by solventogenic clostridia to the neutral products—acetone and butanol, respectively (Figure 3B). The 
CoA moiety from acetoacetatyl-CoA is transferred to acetate. The resulting acetoacetate is 
decarboxylated to acetone by a reaction catalyzed by acetoacetate decarboxylase (Figure 3A,C). 
However, direct production of solvents from pyruvate occurs because acids and small amounts of solvents 
are produced during acidogenic phase growth of C. beijerinckii in batch fermentations [14, 19]. 
 
Addition of reducing compounds such as viologen dyes or carbon monoxide purging of the fermentation 
medium may cause metabolic shifts and result in a favorable carbon flow to butanol production instead of 
butyrate production [20] [21] [22]. Although part of the NADH produced by the Emden–Meyerhof–
Parnas pathway is acted upon by NADHferredoxin reductase to produce reduced ferredoxin and hence 
molecular hydrogen [23], the reaction may shift from pyruvate to lactic acid formation to facilitate rapid 
NADH and NAD+ regeneration (Figure 3A). A reduced ferredoxin is the physiological electron donor of 
hydrogenase in C. acetobutylicum, and bacterial-type ferredoxins are low molecular weight carrier 
proteins containing two [4Fe4S] clusters involved in low-potential oxidationreduction reactions [24, 25]. 
Five open reading frames (ORFs) have been annotated in the C. acetobutylicum genome for coding 
putative ferredoxins [26], and ORF CAC0303 was shown to express the major ferredoxin in the 
solventogenic C. acetobutylicum cells [27]. Pyruvate oxidation to acetyl-CoA requires ferredoxin(Fd) 
reduction. Reduced Fd (FdH2) is oxidized by hydrogenase (NADPH) or (NADH), which regenerates Fd, 
NAD+, or NADP+ and releases molecular hydrogen. The reaction is reversible, and depending on culture 
conditions, either FdH2 or NADH may be formed. The reverse reaction (NADH formation from FdH2) is 
inhibited by NADH and proceeds only after rapid removal of the NADH [21, 28]. Despite the critical role 
of ferrodoxin reductase in the maintenance of a low redox potential during solvent fermentation in 
solventogenic clostridia [29], there is no information in the literature that describes how NADH-
dependent or NADPH-dependent ferrodoxin reductase is affected by presence of butanol and butanol 
toxicity. 
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Figure 3A-C: Simplified metabolism of biomass by solventogenic clostridia. 1, Starch hydrolysis (α-amylase, β-
amylase, pullulanase, glucoamylase, and α-glucosidase); 2, glucose uptake by the phosphotransferase system (PTS) 
and conversion to pyruvate by the Emden–Meyerhof–Parnas pathway; 3, pyruvate-ferrodoxin oxidoreductase; 4, 
thiolase or acetyl-CoA acetyltransferase; 5, 3- hydroxybutyryl-CoA dehydrogenase; 6, crotonase; 7, butyryl-CoA 
dehydrogenase; 8, phosphate butyltransferase (phosphotrans-butyrylase); 9, butyrate kinase; 10, phosphate 
acetyltransferase (phosphostransacetylase); 11, acetate kinase; 12, NADH and NADPH-ferredoxin oxidoreductase; 
13, lactate dehydrogenase; 14, butyraldehyde dehydrogenase and alcohol/aldehyde dehydrogenase; 15, butanol 
dehydrogenase; 16, acetoacetyl-CoA:acetate/butyrate:CoA transferase; 17, acetoacetate decarboxylase; 18, 
acetaldehyde dehydrogenase; 19, ethanol dehydrogenase 
 
2.1.2 Cell membrane fluidity, cell death, and solvent tolerance in acetone and butanol-producing 
microorganisms 
 
The major challenge with solvent fermentation is that it suffers from a number of limitations (e.g., low 
concentration, yield, and productivity) in part due to butanol stress and toxicity to the microbial cells [4, 
30]. Researchers have made several parallel observations between butanol stress and other forms of stress 
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that can be imposed on the microbial cell. Heat shock stress is probably the most examined form of stress 
and results in the repression of synthesis of many cellular proteins, while a specific set of about 20 heat 
shock proteins (hsps) are induced in response to temperature increases. These proteins are involved in the 
cellular response and adaptation to stress, as many of these proteins are also induced by exposure of 
bacterial cells to other forms of stresses, including alcohols [31, 32]. Solventogenic clostridia respond to 
the perturbing effect of butanol as a result of expression of several heat shock protein genes and 
modifying the fatty acid (saturation) composition of membrane lipids. Expression of stress proteins was 
enhanced in C. acetobutylicum by increasing concentration of butanol by as little as 11 mM (about 6% of 
the total butanol produced by the cells) during the acidogenic phase [32]. The de novo synthesis of similar 
proteins during the solventogenic phase and in the absence of an added stress suggests a connection 
between the stress response and solventogenesis [32]. 
 
The toxicity of alcohols appears to increase with chain length, with long-chain alcohols being more toxic 
at a lesser concentration than short-chain alcohols [33]. Alcohol toxicity to microbial cells has been 
suggested to occur as a result of damage to the cell membrane [34] and direct inhibition of metabolism 
[35]. Vollherbst-Schneck et al. [36], during their evaluation of the effect of butanol on lipid composition 
and fluidity of C. acetobutylicum ATCC 824, found that when grown in the presence of butanol, C. 
acetobutylicum synthesized greater amounts of saturated acyl chains of fatty acids at the expense of 
unsaturated chains. The presence of added butanol affected the cellular acyl fatty acids chain composition 
in the same way as did growth at the peak (stationary phase) of butanol production [36]. This increase in 
saturation of cellular lipids may have occurred in order to compensate for the increase in fluidity of cell 
membranes that is induced by butanol [37]. Increase in cell fluidity facilitates leakage of cellular contents 
and subsequently cell death. 
 
The observed membrane change makes it the principal target for cellular adaptation to potentially toxic 
amounts of extracellular alcohol [38]. This assertion was highlighted in 1976 by Ingram, who reported 
that the membrane fatty acid composition of E. coli K-12 was radically altered when the strain was grown 
in the presence of butanol and other alcohols. The proportion of longer-chain (18:1) fatty acids was found 
to increase at the expense of relatively shorter-chain (<C18) fatty acids [39]. Development of a butanol-
tolerant clostridial mutant that is able to produce greater amounts of butanol in batch culture systems has 
yielded variable results [40, 41]. Liyanage et al. [41] found that antisense inhibition of gene expression of 
glycerol dehydrogenase in C. beijerinckii wild-type resulted in a 25% decrease in glycerol dehydrogenase 
activity and an increase in butanol tolerance. It was initially considered that overexpression of the 
cyclopropane fatty acid synthase gene (cfa) of C. acetobutylicum, ATCC 824, and the concomitant 
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change in lipid composition might increase solvent tolerance and allow for greater solvent production in 
C. acetobutylicum. Zhao et al. [40] overexpressed the cfa gene in the wild-type, and the generated strain 
had greater cyclopropane fatty acid content during the early logphase cycle as well as greater initial acid 
and butanol resistance than the wild-type. Contrary to all expectations, solvent production in the cfa-
overexpressing strain was decreased considerably, while the amounts of acetate and butyrate remained 
high—suggesting that overexpression of the cfa gene results in changes in membrane properties that 
decrease the complete induction of solventogenesis [40].  
 
2.2 Microbial strain design for improved butanol production 
 
When tackling the problem of improving existing or introducing new butanol production capabilities in a 
microorganism, there are two primary challenges to consider: (1) butanol production rate and (2) the 
toxicity of the solvent itself. The endeavor to engineer an industrially suitable butanol producing microbe 
has typically followed one of two approaches: (1) enhancement of butanol production mechanisms and 
toxicity defenses in solventogenic clostridia and (2) metabolic engineering well-characterized 
microorganisms (Escherichia coli and Saccharomyces cerevisiae) to produce butanol and related solvents.  
 
2.2.1 Enhancing butanol resistance and production in solventogenic clostridia 
  
The solventogenic clostridia have historically been the most studied acetone-butanol-producing 
organisms. Two genome sequenced solventogenic microorganisms—C. acetobutylicum 824 and C. 
beijerinckii NCIMB 8052—have been the focus of significant analysis and adaptive engineering in an 
effort to increase resistance to and production of solvents (particularly butanol) in the fermentation broth. 
While significant advancements have been made, low solvent concentration remains a hurdle for 
commercialization of biologically produced butanol and acetone. Typically, the concentration of total 
solvents in the bioreactor during fermentation rarely exceeds 20 g/L, with butanol concentrations rarely 
exceeding 13 g/L [42]. Efforts in strain improvement have increased butanol concentration to as much as 
19 g/L, but concentrations approaching 40 g/L could significantly reduce the energy used for butanol 
recovery [43]. 
 
C. acetobutylicum ATCC 824 A new method for strain development in C. acetobutylicum was 
introduced in 1994 by Mermelstein et al., employing a plasmid vector system for introducing foreign 
DNA into ATCC 824 by electrotransformation [44]. This genetic transfer technique has been the most 
widely used to investigate the effect of overexpressing or inactivating various genes on solvent tolerance 
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and production in solventogenic clostridia. Solvent tolerance of engineered strains of C. acetobutylicum is 
typically evaluated by exposure to different concentrations of butanol commonly referred to as a “butanol 
challenge”. Because it is easier to genetically manipulate than C. beijerinckii (discussed below), C. 
acetobutylicum has served as the “model” butanol producing clostridia strain and thus has the largest 
history of genetic modification.  
 
Strain PJC4BK—produced by inactivating butyrate kinase—was shown to produce 16.7 g/L of butanol, a 
final concentration that surpassed the maximum wild-type concentration of 13 g/L [45]. In 2000, Harris et 
al. compared the solvent formation and tolerance abilities of PJC4BK to a newly developed strain, 
pJC4BK(pTAAD), with overexpression of the alcohol dehydrogenase gene aad. Both pJC4BK and 
pJC4BK(pTAAD) surpassed the wild-type threshold of 13 g/L. Notably, the higher butanol concentration 
level was achieved without specific selection for butanol tolerance, suggesting that the production of 
butanol is not triggered by, or directly correlated to, butanol concentration or tolerance limits. Strain 
pJC4BK(pTAAD) did not produce increased levels of butanol relative to pJC4BK, indicating that butanol 
production is not solely limited by alcohol dehydrogenase activity. However, pJC4BK(pTAAD) did 
produce increased amounts of ethanol as well, corresponding to a total alcohol tolerance and production 
of 21.2 g/L. The increased alcohol toxicity threshold with no specific selection for alcohol tolerance 
suggests that alcohol induced cell membrane disruption may not be the primary effect [45, 46]. Another 
study by Harris et al. [47] again investigated the effect of overexpression of alcohol dehydrogenase in 
SolRH(ptAAD) compared to the engineered strain SolRH, both lacking the solvent formation repressor 
SolR. SolRH achieved final solvent concentrations which were essentially equal to the plasmid control, 
but SolRH (pTAAD) produced 17.6 and 8.2 g/L butanol and acetone, respectively.  
 
In 2003, a C. acetobutylicum strain 824(pGROE1) was produced by overexpressing genes in the class I 
stress response operon groESL [48]. This strain demonstrated 85% less growth inhibition from butanol 
than the control strain, resulting in 17.1 g/L butanol and 8.6 g/L acetone. Furthermore, overexpressing 
groESL resulted in longer period of active metabolism, increased expression of motility and chemotaxis 
genes, and decreased expression of major stress response genes. A follow-up study used DNA array-
based transcription profiles of 824(pGROE1) under 0.25% v/v and 0.75% v/v butanol challenges as well 
as a 0.75% challenge on the control strain 824(pSOS95del) in order to differentiate genes that are likely 
associated with general butanol stress response and those that are associated with increased butanol 
tolerance [49]. Genetic changes found to relate to general butanol stress response included the 
overexpression of major stress protein genes, solvent and butyrate formation genes, and the 
butyrylcoenzyme A biosynthesis operon genes, as well as decreased expression of the fatty acid synthesis 
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operon, glycolytic genes and sporulation genes. Genes suspected to be specifically involved in increased 
butanol tolerance include rlpA, artP, and a hemin permease encoding gene. A second transcriptional 
analysis study compared the expression patterns of 824(pMSPOA)—a strain with overexpression of the 
sporulation gene spo0A—with that of the spo0A knock-out strain SKO1 and a plasmid control [50]. As 
with the previous study, most differentially expressed genes were related to a general stress response. The 
824(pMSPOA) strain demonstrated increased tolerance and prolonged metabolism when subjected to 
butanol stress, and genes associated with immediate butanol stress response—hence likely contributing to 
increased tolerance—were identified. When 824(pMSPOA) was compared to 824(pGROE1), 160 total 
differentially expressed genes were identified under butanol challenge conditions. The main difference 
seen between the two strains was the time (during fermentation) at which genes showed high 
expression—in one strain, increased expression was seen early on, but in the other, the increased 
expression had a more delayed response. Counter intuitively, both studies found that butanol stress 
appeared to overexpress solvent formation genes and under-express fatty acid synthesis genes. 
 
Borden and Papoutsakis expanded the search for genes to target the ability of C. acetobutylicum to 
withstand greater solvent concentrations using a genomic library. Plasmids were inserted into wild-type 
C. acetobutylicum cells via electroporation, and the cells were challenged with various amounts of 
butanol [51]. Sixteen genes were identified as contributing to the ability of the cells to withstand greater 
concentrations of butanol; pCAC1869 in particular showed a 45% increase in tolerance. Similarly, 
pCAC0003 was found to have a 24% increase in butanol tolerance. CAC1869 is suspected to be a 
transcriptional regulator and was found to have maximal transcription preceding induction of the 
solventogenic genes—aad, ctfA, and ctfB. This gene is actively transcribed throughout the transitional 
phase. 
 
In 2008, Sillers et al. over-expressed aldehyde/alcohol dehydrogenase (aad) using the ptb promoter to 
encourage early expression of aad in conjunction with down regulation of CoA-transferase (ctfB) [52]. 
Their strain, 824(pCASAAD), was found to produce 13-14 g/L each of ethanol and butanol, significantly 
higher than strain 824(pAADB1), in which aad was overexpressed using the endogenous promoter with 
ctfB down regulation. Strain 824(pCASAAD) was also found to more completely utilize butyrate. Also in 
this study, thiolase (thl) was over-expressed in conjunction with down regulation of ctfB, but no 
significant change in butanol production was observed. A later study by Mann and Lütke-Eversloh again 
looked at the role of thiolase in butanol production [53]. These authors expressed an engineered thiolase 
gene, thlAOPT , in C. acetobutylicum ATCC 824 and improved ethanol and butanol titers by 46% and 18%, 
respectively. Taking another approach, acetone production in C. acetobutylicum was nearly eliminated in 
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a 2013 study by Hou et al. [54].  These authors demonstrated improved butanol production in an adc 
negative mutant with added expression of gshAB genes from E. coli for robustness and expression of the 
butanol synthesis genes hbd, thl, crt, bcd, adhE, and ctfAB.  
 
The two highest butanol producing strains of C. acetobutylicum were produced in two separate studies by 
Jang et al. In 2012, Jang et al. engineered a mutant strain (strain BEKW(pPthlAAD**) ) of C. 
acetobutylicum ATCC 824 by increasing butanol production via the direct production route from acetyl-
CoA through butyryl-CoA (in contrast to the indirect route through butyrate) [55]. This was done by first 
knocking out the butyrate kinase (buk) and phosphotransacetylase (pta) genes and then over-expressing 
gene adhE1D485G, encoding aldehyde/alcohol dehydrogenase. The final strain, C. acetobutylicum 
BEKW(pPthlAAD**), was found to produce 18.9 g/L of butanol—160% more than the wild-type 
strain. More recently, Jang et al. developed strain C. acetobutylicum BKM19 using random mutagenesis 
[56]. The starting strain in this study was C. acetobutylicum PJC4BK—the butyrate kinase deficient strain 
discussed above. Mutagenesis was carried out using N-methyl-N′-nitro-N-nitrosoguanidine, as was done 
in 1991 by Annous and Blaschek to develop the C. beijerinckii BA101 (see below) [7]. In batch 
fermentation, the BKM19 strain was found to produce 17.6 g /L butanol, 10.5 g/L ethanol, and 
4.4 g/L acetone from—30.5% and 90.5% more total solvent than the PJC4BK and ATCC 824 strains, 
respectively.  
 
C. beijerinckii NCIMB 8052 C. beijerinckii is phenotypically quite similar to C. acetobutylicum, but its 
genome is 50% larger than C. acetobutylicum, and genetic strain modification efforts are not yet as 
advanced. One of the earliest developed butanol-tolerant strains was a mutant of C. beijerinckii NCIMB 
8052 (at the time of publication it was thought that the strain was C. acetobutylicum ATCC 824) called 
SA-1. This strain was developed using serial transfer, a procedure where cultures at OD585 0.8 (or the 
highest attainable) are transferred into fresh media containing increasing concentrations of n-butanol. SA-
1 had a 121% increase in tolerance over wild-type when grown on 6% extruded corn broth [57]. Similar 
experiments later led to strain SA-2, grown on brain heart infusion and P2 (minimal) medium. SA-2 had a 
27% increase in butanol tolerance over wild-type and was hypothesized to have adjusted its lipid 
membrane content in order to maintain a stable environment for cellular functions [37]. In both SA-1 and 
SA-2, increased tolerance did not result in a greater overall butanol yield, suggesting that tolerance is not 
the only variable limiting butanol yield.  
 
In 1991, direct acting N-methyl-N′-nitro-N-nitrosoguanidine was used as a mutagen to create the C. 
beijerinckii mutant BA101—capable of producing greater amounts of solvent than any C. acetobutylicum 
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strain engineered thus far [42, 58]. C. beijerinckii BA101 is stable and has hyper-amylolytic and hyper-
butanologenic characteristics [7]. When grown on semi-defined P2 medium and in batch fermentation, C. 
beijerinckii BA101 produces up to 19 g/L butanol and a total solvent concentration of 29 g/L, over 100% 
improvement when compared to the wild-type C. beijerinckii NCIMB 8052. Even though specific 
selection for solvent tolerance was not conducted, C. beijerinckii BA101 exhibits increased tolerance to 
butanol, with 100% cell inhibition occurring at 23 g/L butanol rather than 11 g/L characteristic of C. 
beijerinckii NCIMB 8052 [42]. The exact mechanism for the observed increase in tolerance is unknown. 
 
2.2.2 Engineering model industrial microorganisms for butanol production and resistance  
 
With the history of biobutanol production by the natural solvent-producing clostridia, there are some clear 
inherent advantages in improving and using these native clostridial systems for producing butanol. 
However, there are also several challenges to using these bacteria relative to model fermentation 
organisms such as E. coli and S. cerevisiae: (1) fewer tools are available for genetic manipulation of 
Clostridium metabolism, (2) clostridia have slower growth rates, and (3) clostridia are obligate anaerobes. 
For these reasons, an alternative model for economical production of solvents using well-characterized 
hosts such as S. cerevisiae and E. coli for solvent production has been and is currently being researched. 
 
E. coli The first efforts towards using E. coli to produce solvents was the expression of four C. 
acetobutylicum ATCC 824 genes (adc, ctfA, ctfB, and thl) in E. coli for enhanced acetone production [59]. 
Strain ATCC 11303 (pACT) produced 5.4 g/L acetone when grown in glucose-fed shake flasks—a 
concentration comparable to wild-type C. acetobutylicum. Acetone's great volatility limits toxic effects, 
and thus tolerance was not found to be a concern [59]. With the addition of a secondary alcohol 
dehydrogenase and subsequent strain optimization, this acetone-producing strain was adapted to produce 
4.9 g/L of isopropanol [60]. E. coli has also been engineered to produce 1-butanol using the pathway from 
C. acetobutylicum (containing genes thl, hbd, crt, bcd, etfAB, and adhE2) [61]. The engineered strain 
produced 13.9 mg/L butanol, and by overexpressing the E. coli acetyl-CoA acetyltransferase instead of 
the clostridial acetoacetyl-CoA thiolase, butanol concentration was improved. By deleting pathways 
competing for acetyl-CoA and NADH (ldhA, adhE, and frdBC) as well as genes to increase pyruvate 
dehydrogenase activity and decrease acetate production (fnr and pta), butanol production reached 373 
mg/L (strain JCL88); this value was increased to 552 mg/L when grown in rich media. In a similar study, 
Inui et al. introduced the thiL, crt, bcd, etfAB, hbd, and adhE2 (note the use of a different thiolase gene 
than Atsumi et al.) genes from C. acetobutylicum and demonstrated butanol production levels of 1.2 g/L 
[62].  Nielsen et al. [63] later achieved 580 mg/L of butanol production using individual expression of 
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pathway genes alongside co-expression of fdh1 from yeast (for cofactor regeneration) and overexpression 
of the gapA gene from E. coli to increase glycolytic flux and the acetylCoA pool. Without specific 
selection for butanol tolerance or engineering for increased toxicity thresholds, E. coli tolerated up to 
1.5% butanol—a value competitive with clostridia [64]. 
 
After the initial success with solvent production by E. coli using genes from C. acetobutylicum, Atsumi et 
al. [61] developed a process for production of higher alcohols (e.g., 1-butanol) that avoids CoA-mediated 
chemistry used by native solvent-producing organisms. By utilizing the E. coli amino acid biosynthesis 
pathway, isobutanol [64, 65], 1- butanol [66], 2-methyl-1-butanol [61, 65, 67], 3-methyl-1-butanol [64, 
66, 68], and 2 phenylethanol [61, 65] are made from the valine, norvaline, isoleucine, leucine, and 
phenylalanine biosynthesis pathways, respectively. By diverting 2-keto acid intermediates to alcohol 
synthesis, this study demonstrated up to 22 g/L of isobutanol [64]. To achieve this, only genes for two 
additional enzymes (2-keto acid decarboxylase and alcohol dehydrogenase) were needed. To maximize 
the production of each product in turn, genes to enhance the intermediate 2-keto acid of interest were 
overexpressed, and genes corresponding to competing reactions were deleted. In some instances, native E. 
coli genes were replaced with more active genes from other hosts. Native 1-butanol producing organisms 
(clostridia) tolerate up to 2% w/v of the product, and E. coli was found to initially be intolerant to 1.5% 
w/v isobutanol (a less toxic solvent). After performing serial transfers to enhance tolerance, the E. coli 
strain survived in up to 2% w/v isobutanol. 
 
Later, the initial isobutanol response network of E. coli was characterized using gene expression, 
transcription factor-gene interaction data, gene knockouts, and network component analysis [69]. An 
additional comparison showed similar response networks for both isobutanol and n-butanol. Notably, this 
study also found that isobutanol stress leads to the disruption of important membrane components (most 
importantly, quinones) that subsequently affected respiratory, phosphate, and iron control. Network 
component analysis determined 67 transcription factors to be active as a result of isobutanol stress, 16 
(relating to stress mitigation, metabolism regulation, and nucleoproteins) of which were significantly 
perturbed. Most significantly perturbed were transcription factors effecting respiration (in particular, the 
transcription factors ARcA, PdhR, and FNR), and further verification of this supported the assumption 
that solvent toxicity leads to cell membrane malfunction. Analysis of the response networks showed that 
conditions affecting isobutanol resistance apply to n-butanol as well, except that 1-butanol had a greater 
repression effect on amino acid synthesis in microorganisms than did isobutanol. A deletion study 
removing arcA, fur, and phoB did not significantly increase tolerance, supporting the hypothesis that 
tolerance response is a complex result of multiple mutations. Previous studies with C. acetobutylicum, 
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which showed that stress by increased 1-butanol concentrations elicits a response similar to heat shock 
proteins, were supported by the network analysis showing that E. coli displayed greatly enhanced 
activation of a heat shock sigma factor in response to isobutanol. 
 
Atsumi et al. improved upon the isobutanol producing strain reported in 2008 by over-expressing either 
yqhD or adhA [70]. In 2011 Smith and Liao performed random mutagenesis with norvaline selection to 
create a strain of E. coli (strain NV3r1) capable of producing 21.2 g/L of isobutanol [71]. Also in 2011, 
Bastian et al. created an entirely NADH isobutanol production pathway using targeted mutagenesis to 
switch the cofactor dependence of the native E. coli IlvC [72].  Their strain was shown to reach 100% of 
the isobutanol theoretical yield under anaerobic conditions. With a similar goal in mind, Trinh et al. used 
elementary mode analysis to redesign E. coli metabolism to anaerobically produce isobutanol. They found 
ethanol production along with isobutanol production to be obligatory for anaerobic growth [73]. In terms 
of n-butanol, recent engineering efforts in E. coli have led to a strain capable of producing levels of 
butanol that are on par with the solventogenic clostridia. In 2011, Bond-Watts et al. developed an E. coli 
strain capable of producing 4.6 g/L of n-butanol by utilizing a synthetic pathway assembled using three 
different host organisms [74]. The synthetic pathway contained the Ralstonia eutropha haA gene, the C. 
acetobutylicum hbd, crt, and adhE2 genes, and the T. denticola ter gene; to provide reducing equivalents 
to E. coli, the native aceEF-lpd operon was also over-expressed. A similar study by Shen et al. (also 
published in 2011) demonstrated 15 g/L of n-butanol production in E. coli by imposing a NADH and 
acetyl-CoA driving forces and an irreversible Ter reaction [75].  
 
S. cerevisiae S. cerevisiae naturally produces small amounts of isobutanol and 3-methyl-1-butanol as 
byproducts of fermentation, giving it a basal ability to resist solvent toxicity. Recently, S. cerevisiae was 
engineered to produce 2.5 mg/L of n-butanol through the cloning of the 1-butanol pathway and various 
isozymes chosen from C. beijerinckii, E. coli, and Ralstonia eutropha into S. cerevisiae [76]—with C. 
beijerinckii genes showing the best results. This amount of solvent production, however, is still far less 
than concentrations achieved by the most effective Clostridium strains for butanol production 
(approximately 20 g/L) and the most recently engineered E. coli strains. Given that S. cerevisiae can 
tolerate up to 2% butanol [77, 78]  and only 2.5 mg/L butanol was produced during fermentation, butanol 
toxicity does not appear to be the limiting factor. An earlier study investigating S. cerevisiae response to 
butanol found that butanol inhibits translation at the initiation step [79]. S. cerevisiae has more recently 
been used as a host for the production of isobutanol, as is discussed in depth in the review by Buijs et al. 
[80]. The review asserts that the highest reported production level (18.6 g/L) was in a patent by Lies et al. 
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2.2.3 Solvent-resistant microorganisms as potential butanol production hosts  
 
As an alternative approach, future efforts to genetically engineer microorganisms for increased tolerance 
to butanol may focus on investigations of host microorganisms that have a natural resistance to solvent 
but that have not demonstrated significant solvent formation. This approach was reported recently by 
investigators who screened 24 hosts, spanning seven genera, with the aim of identifying microorganisms 
that possess great butanol tolerance capability [78]. Of the yeast strains, S. cerevisiae ATCC 26602 and 
ATCC 20252, as well as Candida sonorensis, were able to grow on 2% of 1-butanol. In all cases, growth 
was only 10% to 20% that of the control (without butanol challenge) cultures. Of the non-yeast species, 
Lactobacillus delbrueckii and Lactobacillus brevis grew on 2% butanol with relative growth rates of 55% 
and 58%, respectively, with L. brevis maintaining 30% relative growth rate on 3% butanol. In another 
study, Bacillus subtilis was found to tolerate up to 2% butanol [77]. Knoshaug and Zhang [78] found 
tolerance to be dependent on temperature: at higher temperatures, strains grew faster but had lower 
butanol tolerance thresholds, while strains at lower temperature had increased butanol tolerance 
thresholds but grew slower. 
 
A separate study investigated the butanol resistance of three solvent-tolerant and one solvent-sensitive P. 
putida strains [81]. Each strain was adapted using serial transfer, and a mutant strain capable of growth on 
6% butanol was generated. 13C tracer-based flux analysis was performed to investigate the strain response 
to butanol relative to the untreated strain. For untreated strains, glucose uptake rate increased while 
growth decreased—without a corresponding increase in byproducts—and corresponded to a redistribution 
of intracellular flux. Specifically, carbon was redirected to the tricarboxylic acid (TCA) cycle, which 
increased regeneration rates of redox cofactors. The authors therefore hypothesized that butanol leads to 
an increased need for cell maintenance energy. The solvent-tolerant strain appeared to have an adapted 
cell membrane to lower cell maintenance needs—demonstrating reduced glucose uptake, TCA cycle 
usage, and redox cofactor regeneration rates. Recently, Nielsen et al. [63] explored the production ability 
of two butanol-tolerant organisms, including two strains of P. putida, using polycistronic expression of 
butanol biosynthetic genes. The two P. putida strains produced 44 and 50 mg/L butanol, respectively, 
when grown on glucose and 122 and 112 mg/L butanol, respectively, when grown on glycerol. The study 
by Ruhl et al. showing tolerance thresholds of up to 6% butanol, however, suggests potential for 
increasing production in the solvent-producing strain. 
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Chapter 32: Accomplishments in genome-scale in silico modeling for 
industrial and medical biotechnology 
 
Genome-scale in silico models have been shown to be a powerful resource to guide rational engineering 
of biological systems for in both industrial and medical biotechnology applications. This chapter reviews 
both the modeling approach and many of the demonstrated applications.  
 
3.1 Constraint-based modeling and genome-scale models 
 
An accurate genome-scale model (GEM) can help predict the system-wide effect of genetic and 
environmental perturbations on an organism, and hence drive metabolic engineering experiments.  Since 
the development of the first GEM in 1999 (Haemophilus influenza [82]), systems modeling approaches 
have worked towards efficiently utilizing increasingly available high-throughput biological data (e.g., 
genomics, transcriptomics, proteomics, metabolomics) to bring genomes to life.  An important challenge 
in this field is to enable the rapid development of predictive computational models for any sequenced 
organism by harnessing these high-throughput experimental technologies.  The compelling need for this 
ability is evidenced by the gap between the number of sequenced organisms and corresponding GEMs 
(Figure 4). 
                                                      
2 Material in this chapter was reproduced with permission from the following publication: Milne CB, Kim PJ, Eddy 
JA, Price ND: Accomplishments in genome-scale in silico modeling for industrial and medical biotechnology. 
Biotechnol J 2009, 4:1653. The original publication is available online by following this link: 
http://onlinelibrary.wiley.com/doi/10.1002/biot.200900234/abstract.  
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Figure 4. Completed genome sequences and genome-scale models (GEMs) available to date. 
 
Three classes of networks have been reconstructed in biochemical detail and converted into GEMs.  
Metabolic GEMs quantify a cell’s metabolic potential, and thus allow researchers to probe new 
phenotypes and network states [83].  Transcriptional regulatory networks (TRNs) describe 
transcription-factor-promoter interactions and associated environmental influences to provide information 
about environment-specific enzyme activity.  As such, TRNs can be fused with metabolic GEMs to form 
more predictive integrated metabolic-regulatory network models [84-87].  The newest genome-scale 
network type, transcriptional-translational models [88], captures information passage from DNA to 
RNA to proteins.  Each network-based GEM is built upon a stoichiometric formalism allowing for the 
mathematical representation of biochemical information (see [83, 89-91]).  This review focuses heavily 
on metabolic GEMs because they are the most commonly formulated and span a broad range of 
applications. 
 
Numerous constraint-based methods are available to explore the phenotypic potential of the three GEM 
types, and by extension the associated biological system.  To assist in understanding the case studies 
discussed  herein, we briefly summarize some of these procedures (see [92] for review).  In constraint-
based analysis, physico-chemical and environmental constraints are applied as balances (e.g., mass, 
energy) and bounds (e.g., flux capacities, thermodynamics).  These constraints define a solution space 
describing all possible functions (allowable phenotypes) of the system.  Flux balance analysis (FBA) 
determines the distribution of reaction fluxes that optimize a biological objective function (e.g., biomass, 
ATP) [93, 94].  This capability is particularly useful for simulating the effect of genetic perturbations 
(e.g., gene knockouts or mutations) on the resulting metabolic phenotype.  Two extensions of traditional 
FBA, regulatory FBA (rFBA) [84, 87] and dynamic FBA (dFBA) [95],  enable analysis and hypothesis 
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generation where external metabolite concentrations and environmental conditions vary with time.  
Minimization of metabolic adjustment (MOMA) assumes that, after a mutation, the organism seeks to 
minimize the total metabolic change relative to the wild-type (unlike FBA, which assumes a new 
optimized network state) [96]. OptKnock [97] is a computational procedure used to design strains with 
enhanced capabilities by identifying gene deletions that align the cellular objective (e.g., growth) with the 
engineering objective (e.g., biofuel production).  The effects of gene additions from related organisms can 
be  included in an analogous fashion using OptStrain [98]. 
 
 
Figure 5. Applications of GEMs in industrial and medical biotechnology. 
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Constraint-based GEM analysis has been used for a broad range of applications in industrial and medical 
biotechnology (Figure 5).  To date, there are over 50 organism-specific GEMs (Table 1) that have been 
surprisingly successful in predicting cellular behavior (e.g., the effects of gene deletions on growth or 
secretion rates).  In biotechnology applications, GEMs are commonly used to guide enhancement of a 
particular property of interest (e.g., biofuel or pharmaceutical production) or to better understand systemic 
behavior.  Hence, two specific uses for GEMs are: (i) elucidation of the global properties of network 
structures and (ii) constraint-based modeling for predicting the phenotypic effects of genetic and 
environmental perturbations.   
 
Organism Domain Model Details # rxns / # mets / # genes Refs Demonstrated/Intended Applications 
Lactobacillus plantarum b 643 / 531 / 721 [99] lactate [100] 
Lactococcus lactis b 621 / 422 / 358 [101] lactate [101], diacetyl [101] 
Streptococcus thermophilus b 522 / --- / 429 [102] lactate, acetaldehyde 
Pseudomonas putida b 
 
950 / 911 / 746 [103] polyhydroxyalkanoates [103, 104], 
bioremediation, biocatalytic chemicals, 
improvement of fossil fuel quality, 
promoting plant growth, pest control 
Pseudomonas putida 877 / 886 / 815 [104] 
Clostridium acetobutylicum b 502 / 479 / 432 [105] acetone, butanol, ethanol, hydrogen 
Clostridium acetobutylicum 552 / 422 / 474 [106] 
Methanosarcina barkeri a 509 / 558 / 692 [107] methane 
Desulfovibrio vulgaris b --- / --- / --- [108] methane 
Methanococcus maripaludis a --- / --- / --- [108] methane 
Acinetobacter baylyi b 875 / 701 / 774 [109] pollutant degradation, lipases, proteases, 
bioemulsifiers, cyanophycine, various 
biopolymers 
Geobacter metallireducens b 697 / 769 / 747 [110] reducing Fe(III), bioremediation of 
uranium, plutonium, technetium & vadium, 
fuel cell development 
Geobacter sulfurreducens b 523 / 541 / 588 [111] reducing Fe(III), bioremediation of 
uranium, plutonium, technetium & vadium 
[112], fuel cell development [112] 
Arabidopsis thaliana  e --- / --- / --- [113] photosynthetic plant cell, various 
secondary metabolites, flavonoid, 
polyamine metabolism 
Chlamydomonas reinhardtii  e 259 / 113 / 174 [114] photosynthetic green algae, hydrogen 
production 
Halobacterium salinarum a 711 / 557 / 490 [115] producing bacteriorhodopsin  
Synechocystis sp b 831 / 704 / 633 [116] photosynthetic cyanobateria, ethanol 
production [116] 
 
Table 1. Genome-scale metabolic models to date.  Under “Domain”, bacteria, eukaryote, and archaea are marked as 
“b”, “e”, and “a”, respectively. 
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Organism Domain Model Details # rxns / # mets / # genes Refs Demonstrated/Intended Applications 
Staphylococcus aureus b 640 / 571 / 691 [117] antibiotic target [117-120] 
Staphylococcus aureus 774 / 712 / 551 [118] 
Staphylococcus aureus  
 (multiple strains) 
1444~97 / 1399~1437 / 522~47 [120] 
Haemophilus influenzae b 461 / 451 / 412 [82] antibiotic target [82, 121] 
Pseudomonas aeruginosa b 883 / 760 / 1056 [122] antibiotic target [122] 
Mycobacterium tuberculosis b 849 / 739 / 726 [123] antibiotic target [119, 123-126] 
Mycobacterium tuberculosis 939 / 828 / 661 [124] 
Helicobacter pylori b 476 / 485 / 341 [127] antibiotic target [119, 127] 
Salmonella typhimurium b 1087 / 744 / 1038 [128] antibiotic target [128] 
Salmonella typhimurium 1964 / 1036 / 945  
Neisseria meningitidis  496 / 471 / 555 [129] vaccine development, antibiotic target 
Yersinia pestis  b 1020 / 825 / 818 [130] vaccine development, antibiotic target 
Leishmania major e 1112 / 1101 / 560 [131] antibiotic target [131] 
Mycoplasma genitalium b 262 / 274 / 189 [132] antibiotic target [132] 
Porphyromonas gingivalis b 679 / 564 / --- [133] control of negative inflammatory responses 
[133] 
Corynebacterium glutamicum  b 446 / 411 / 446 [134] lactic and succinate [135], L-lysine [134], 
glutamate, ethanol 
Corynebacterium glutamicum  502 / 423 / 277 [135] 
Bacillus subtilis b 1437 / 1138 / 1103 [136] antibiotics, industrial enzymes and 
proteins, nucleosides and vitamins 
Streptomyces coelicolor b 971 / 500 / 711 [137] secondary metabolites (antibiotics, 
immunosuppressants, anti-cancer agents) 
[138, 139] 
Homo sapiens e 3311 / 2766 / 1496 [140] biomarker of inborn error [141], 
understanding disease comorbidity toward 
diagnosis and prevention [142], 
identification of mutations causing defects 
in Leigh’s cells [143], predicting tissue-
specific activity of metabolic genes [144] 
Homo sapiens 2823 / 2671 / 2322 [145] 
Mus musculus e 1344 / 1042 / --- [146] mouse hybridoma cells for enhanced 
production of monoclonal antibodies [146] 
Mannheimia succiniciproducens b 686 / 519 / 425 [147] succinate [147] 
Escherichia coli b 2077 / 1039 / 1260 [148] lycopene [149, 150], succinate [97, 151, 
152], lactate [97, 153], malate [154], L-
valine [155], L-threonine [156], additional 
amino acids [157], ethanol [158], hydrogen 
[98, 159], vanillin [98], 1,3-propanediol 
(PDO) [97], gene KO [160-162], 
antibacterial target [119] 
 
Table 1 (cont.).  
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Organism Domain Model Details # rxns / # mets / # genes Refs Demonstrated/Intended Applications 
Saccharomyces cerevisiae 
 (fully-compartmentalized) 
e 1412 / 1228 / 904 [163] ethanol [164, 165], succinate [166], 
glycerol [166], vanillin [166], 
sesquiterpene [167], gene KO [168-170] 
Saccharomyces cerevisiae
 (lipids emphasized) 
1446 / 1013 / 800 [171] 
Saccharomyces cerevisiae
 (consensus model) 
1857 / 1168 / 832 [172] 
Aspergillus niger e 1197 / 1045 / 871 [173] succinate [174], citrates and oxalates [173], 
additional organic acids, industrial 
enzymes, proteins (chymosin, human 
interferon) 
Aspergillus nidulans e 676 / 733 / 666 [175] model organism for studies of development 
biology & gene regulation, sharing many 
applicative properties of A. niger 
Aspergillus oryzae e 1053 / 1073 / 1314 [176] fermented sauces, industrial enzymes 
Buchnera aphidicola b 263 / 240 / 196 [177] symbiotes producing histidine [177] 
Rhizobium etli b 387 / 371 / 363 [178] symbiotic nitrogen fixation [178] 
 
 
Table 1 (cont.). 
 
3.2 Industrial biotechnology applications of genome-scale in silico metabolic models 
Metabolic GEMs provide a valuable tool to harness microorganisms as cell factories to sustainably 
produce chemicals and pharmaceuticals.  The ability to integrate targeted modifications within the context 
of the whole organism helps model-guided approaches to minimize undesired secondary effects.  An 
iterative model generation, hypothesis formation, and model refinement process is central to the systems 
biology approach (Figure 6).  Current metabolic GEMs for industrial biotechnology fall into four main 
application categories: food production, biopolymers, biofuels, and bioremediation. 
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Figure 6. Iterative process of model generation, hypothesis formation, and model refinement to guide strain 
design for enhanced microbial production. 
 
3.2.1 Food production and engineering 
   
In the food and beverage industry, metabolic GEMs have been created to explore and improve 
fermentation byproduct formation by lactic acid bacteria (LAB).  In addition to lactate, LAB produce 
bacteriocins, exopolysaccharides, polyols, B vitamins and compounds that affect food texture, taste, and 
preservation [179].   
 
Lactobacillus plantarum is used in industrial food fermentations and advertised as a probiotic organism.  
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FBA was used to compare the typical estimation method for ATP production (based on lactate and acetate 
formation) to that predicted by the metabolic GEM, and was found to match.  The accuracy of the acid-
formation based method had been questioned because some inputs to lactate and acetate formation do not 
yield ATP. During the ATP production analysis, it was discovered that transamination of aromatic and 
branched chain amino acids contributes to ATP production.  A second investigation with the GEM 
investigated the discrepancy between experimental and FBA predicted growth rates and lactate formation. 
FBA predicted mixed acid production (primarily acetate, ethanol, formate) when optimized for growth, 
while homolactic fermentation is observed experimentally.  Additionally, the FBA-predicted growth rate 
was higher than expected. These differences were thought to result from the experimental observation that 
L. plantarum uses an ATP inefficient route for lactate production, and thus does not maximize ATP 
production as its cellular objective (the FBA assumption used)—likely stemming from its evolution in 
nutrient-rich environments.  This observation was investigated further in a study that evolved an 
experimental strain for growth on glycerol [99].  The poor substrate expectedly forced the strain into 
optimization for growth, and lactate production was predicted to be optimal with a growth rate of 0.24 h-1, 
compared to 0.324 h-1 found in silico.  Thus, the experimental mutant developed to follow traditional 
FBA assumptions agreed better with in silico predictions.  
 
In addition to typical LAB production applications in the food industry, Lactococcus lactis has 
applications relating to the in situ production of flavor, texture and health contributing food components.  
The GEM for L. lactis was used to predict modifications for enhanced production of diacetyl, a flavor 
compound in dairy products [101].  FBA and MOMA were used to optimize for production of the 
intermediate 2-acetolactate.  In silico predictions starting with a known mutant strain yielded an 
additional deletion for increased acetate formation.  In a subsequent deletion study on the new mutant, 
three more gene deletions predicted a redirect of carbon flux to 2-acetolactate production.  Another 
application of L. lactis has been as an oral delivery vehicle for recombinant protein vaccines.  To 
investigate this, the L. lactis GEM was updated to include recombinant protein synthesis reactions and 
used to optimize production of recombinant proteins [180].  Specifically, this study optimized production 
of Green Fluorescent Protein (GFP) (a model heterologous protein) using dFBA.  The top performing 
strain predictions were tested in vivo and found to have 15% increased GFP production.  The increase in 
expression was lower than predicted using the GEM, however the qualitative effect was still observed.  
 
Streptococcus thermophilus is commonly used in the production of yogurt and cheeses involving high 
cooking temperatures.  The metabolic GEM enabled the comparison of S. thermophilus with L. 
plantarum and L. lactis metabolism [102].  Considering its evolution in protein-rich milk environments, 
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S. thermophilus was surprisingly found to produce 18 amino acids.  The GEM also identified a unique 
acetaldehyde (yogurt flavor) production pathway.  
 
3.2.2 Production of biopolymers 
   
Today, most synthetic materials (e.g., plastics) are produced via petroleum refining.  In an effort to reduce 
dependence on unsustainable processes, alternative production routes for plastics are desirable.  For 
example, poly-3-hydroxyalkanates (PHAs) are microbial produced biodegradable polyesters that could 
potentially replace petrochemical-based plastics.  PHA production was investigated using two metabolic 
GEMs of Pseduomonas putida.  The first GEM was used to suggest precursor metabolites and showed 
that select fatty acids and carbohydrates were the best PHA precursors [103].  This was expected because 
carbon sources leading to high levels of acetyl coenzyme A (acetyl-CoA) are good PHA production 
candidates.  Soon after the publication of this P. putida model, a second metabolic GEM [104], also 
studied to improve PHA production, was published.  PHA and biomass (growth) pathways utilize the 
same metabolic precursors, so FBA predicts no PHA production when optimizing for growth.  To 
overcome this, OptKnock was applied to the second GEM to increase the pool of the primary precursor 
acetyl-CoA.  Six mutations were predicted, one of which demonstrated a 29% acetyl-CoA increase.   
 
3.2.3 Production of biofuels  
   
Biofuels have potential to provide a sustainable and environmentally-friendly fuel source.  Metabolic 
GEMs hold great promise to guide strain design for improved biofuel production by microorganisms 
[181].  In addition to the model fermentation organisms for ethanol, Escherichia coli and Saccharomyces 
cerevisiae, GEMs for lesser-characterized organisms that naturally exhibit useful properties are attractive 
for biofuel production.  Currently, GEMs to improve ethanol, butanol, hydrogen, and methane production 
have been developed and studied. The hydrogen producing algae Chlamydomonas reinhardtii is discussed 
in the section on photosynthetic organisms. 
 
Alcohol Production – For alcohol production, a global understanding of metabolic behavior is critical.  
Microbe production of alcohols is limited by the toxicity of these compounds at high concentration.  
Understanding the solution space defined by the metabolic network reveals whether the organism has 
reached its maximum production potential and is limited by toxicity (requiring engineering approaches 
that delve into dynamics and regulation). If not, the stoichiometric threshold has not been reached and 
alcohol production can be enhanced by redistributing carbon flux.  The E. coli and S. cerevisiae models 
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have been used to improve ethanol production and are discussed later.  Similarly, Clostridium 
acetobutylicum—the natural butanol production organism that advantageously co-ferments pentose and 
hexose sugars—has two GEMs [105, 106] that can be used to increase biobutanol production.  In [26], 
207 lethal reactions were found on minimal media, 140 on partially supplemented medium and 85 on 
supplemented medium.  [27] found 194 essential reactions.    
 
Methane Production – Methanogens anaerobically convert low-carbon substrates to methane, and can 
degrade industrial, agricultural and toxic wastes containing large amounts of organic material.  A GEM 
was reconstructed for Methanosarcina barkeri to study methanogenesis, representing the first archaeon 
GEM [107].  This model led to 55 new functional genome annotations, was used to suggest a minimal 
media, and uncovered the stoichiometry of three previously uncharacterized aspects of methane 
production.   Mutualistic methane production was investigated in the coupled study of Desulfovibrio 
vulgaris and Methanococcus maripaludis metabolic behavior, the first demonstration of a flux balance 
model for a two-organism system [108].  Though not genome-scale, it represents an interesting 
application of traditional constraint-based analysis.  The two-system model was developed by separately 
reconstructing the central metabolism of D. vulgaris and M. maripaludis, and then integrating the 
networks as a single syntrophic system by compartmentalization.  Unlike in eukaryotic models, 
compartments were separated by the extracellular environment, making transporter existence in both 
species critical.  From this model, it was discovered that formate was not required as an electron shuttle 
between the organisms, but that growth was not possible without hydrogen transfer. 
 
3.2.4 Applications in bioremediation 
   
Bioremediation takes advantage of a microbe’s ability to reduce and potentially eliminate toxic effects of 
environmental pollutants.  Additionally, microbes capable of degrading harmful waste produce useful 
chemicals as byproducts, and hence are intriguing production organisms as well [182].  
 
Acinetobacter baylyi is an innocuous soil bacterium that degrades pollutants and produces lipases, 
proteases, bioemulsifiers, cyanophycine, and biopolymers.  A. baylyi is easily transformed and 
manipulated by homology-directed recombination, enabling straightforward metabolic engineering [183].  
The GEM is accompanied by an extensive library of mutants, and was validated against wild-type growth 
phenotypes in 190 environments and gene essentiality data for nine environments [109].   
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Geobacter metallireducens reduces Fe(III) and is used in bioremediation of uranium, plutonium, 
technetium, and vadium.  Its ability to produce electrically conductive pili makes it useful for harvesting 
electricity from waste organic matter and as a biocatalyst in microbial fuel cell applications.  Using G. 
metallireducens’ GEM, growth on different electron donors and electron acceptors was investigated 
[110].  Model analysis revealed energy inefficient reactions in central metabolism, and experimental data 
suggested that the inefficient reactions were inactive during biomass optimization on acetate, but up-
regulated when grown with complex electron donors.  Additionally, the model was tested for flux 
predictions by comparison with 13C labeling flux analysis.  Simulations suggested the TCA cycle was 
used to oxidize 91.6% of acetate, in agreement with 90.5% in 13C labeling experiments.  
 
Geobacter sulfurreducens has similar industrial applications to G. metallireducens. OptKnock was 
applied to the G. sulfurreducens GEM [111] to improve extracellular electron transport [112].  Gene 
deletions in the fatty and amino acid pathways and in central metabolism were predicted to increase 
respiration and cellular ATP demand.  To study the ATP demand increase, an ATP drain was added to the 
GEM.  The model showed that the rise in ATP usage correlated to decreased biomass flux and increased 
respiration rate.  Experimental results confirmed that an ATP drain demonstrates the predicted results.  
Increasing electron transfer in G. sulfurreducens has advantages in both bioremediation and microbial 
fuel cell development, though increased fuel cell current was not found with this mutant strain.   
 
3.2.5 Photosynthetic organisms 
   
The sun's energy can be captured either directly by using photosynthetic organisms as cell factories, or 
indirectly through plant biomass.  Photosynthetic organisms can (i) remove CO2 from the environment, 
thereby reducing the impact of global warming; (ii) use light to produce carbon-based products; and (iii) 
create energy gradients.  While there is one plant GEM available (Nature Precedings [113]), this section 
will focus on photosynthetic microbes.  
 
The algae Chlamydomonas reinhardtii is most commonly utilized for biofuel and biohydrogen 
production.  The C. reinhardtii GEM was reconstructed using an iterative method that integrates 
experimental transcript verification with computational modeling [114].  An initial metabolic network 
revealed genes needing experimental definition and validation, the completion of which refines the model 
through verification of hypothetical transcript existence.  Resulting pathway gaps were filled by 
incorporating alternative enzymes sets, providing the basis for further transcript verification and network 
modeling.   
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Halobacterium salinarum is an extreme halophilic archaeon capable of surviving with light as its only 
energy source.  It produces bacteriorhodopsin (a light-driven proton pump)—the only known structure 
with non-chlorophyll based photosynthesis—for use in optical security, optical data storage, and 
hologram creation.  H. salinarum can also store energy (like a battery) using a large potassium gradient.  
Its GEM [115] was used to investigate aerobic essential amino acid degradation, and to integratively 
study energy generation, nutrient utilization, and biomass production.   
 
Cyanobacteria are a subset of prokaryotes that execute oxygenic photosynthesis.  Synechocystis sp. is a 
fresh water cyanobacterium for which powerful genetic tools are available (e.g., transformation tools, 
genetic markers).  As a potential biofuel production organism, Synechocystis could convert CO2 to 
carbon-based products.  To test this ability, two genes were experimentally transformed into the metabolic 
network of Synechocystis to complete an ethanol-producing pathway.  The CO2 fixation to pyruvate was 
diverted to ethanol production, allowing for direct conversion of CO2 to ethanol using only light energy.  
To investigate the systemic effects of the added pathway, the two reactions corresponding to the gene 
additions were added to the GEM [116].  Analysis showed that the mutant strain should also now produce 
succinate and malate, as was subsequently verified experimentally. 
 
3.3 Medical biotechnology applications of genome-scale in silico metabolic models  
 
In addition to applications in industrial biotechnology, systems-level metabolic modeling has been widely 
utilized in medical biotechnology.  To capture the potential of constraint-based analysis and further 
improve drug production and target identification, metabolic GEMs spanning a range of diseases have 
been formulated.  Demonstrated applications are grouped into three categories: anti-pathogen target 
discovery, drug and nutrient production, and mammalian systems.  
 
3.3.1 Anti-pathogen target discovery  
 
Microbial strains are the causative agents of numerous human diseases.  Pathogen GEMs are thus 
primarily used to identify drug targets that would inhibit cellular function.  Importantly, the GEM for 
humans [140, 145] informs these pathogen studies by identifying enzyme targets essential for the 
pathogen and not for humans.  Most modeling studies of pathogens generate sets of essential genes and 
reactions under conditions representing their host environment to identify new antibiotic targets (Figure 
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7).  A smaller number of studies report potential chemical inhibitors of these targets, and models have 
even been used to predict the specific effects of various drug compounds on the organism.   
 
 
Figure 7. Iterative modeling of pathogens to identify new antibiotic targets and therapeutic strategies. 
 
Modeling of Staphylococcus aureus, a bacterium infecting multiple regions of the body, aims to 
elucidate the origin of its antibiotic resistance and to identify new drug targets.  Its first metabolic GEM 
was used to identify essential genes and reactions on both rich and minimal media [117].  In this study, 
the authors generated a literature-derived list of potential combative drugs (chemical inhibitors 
corresponding to essential reaction targets) for the predicted targets.  A later study identified metabolites 
essential for S. aureus survival [119].  A second GEM was extensively validated against experimental 
data and used to predict 158 lethal intracellular reaction knockouts [118].  Five of these knockouts had 
already been experimentally identified as lethal.  Further analysis showed that biosynthesis pathways for 
glycans and lipids were particularly susceptible to deletions, making them interesting for antibiotic 
development.  The most recent S. aureus modeling study combined metabolic reconstruction methods 
with genomic and sequence homology data to build a set of models representing the 13 different S. aureus 
strains [120].  44 genes were predicted to be unconditionally essential across all strains.  While a number 
of the essential genes were reported to have roles in fatty acid biosynthesis, the majority of the 10 
common synthetic-lethal gene pairs identified belong to amino sugar biosynthesis pathways.  
 
Respiratory Pathogens – Haemophilus influenzae causes otitis media as well as acute and chronic 
respiratory infections, most often in children.  Even with the H. influenzae type b (Hib) vaccine, an 
estimated 380,000 to 600,000 Hib deaths sill occur world-wide each year.  Furthermore, non-typeable H. 
influenzae strains lacking the vaccine target are becoming a major pathogen in both children and adults.  
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The H. influenzae GEM was initially used to identify 11 genes predicted as critical in minimal substrate 
conditions [82].  Interestingly, six of the 11 genes were also determined to be critical in more complete 
substrate conditions reflecting the human host environment of H. influenzae.  A later study integrated 
protein expression data with the model to predict essential enzymatic proteins in aerobic and microaerobic 
conditions [121].   
 
Mycobacterium tuberculosis is a significant cause of human disease in the third world, killing over two 
million people annually.  Two metabolic GEMs for M. tuberculosis exist: GSMN-TB [123] and iNJ661 
[124].  The GSMN-TB model contains five genes encoding enzymes that are known drug targets, all 
correctly predicted to be essential [123].  In a later study, FBA was combined with gene expression data 
to interrogate the metabolic network and predict the effects of different drugs, drug combinations, and 
nutrient conditions on mycolate biosynthesis [126].  Mycolates are key components of the mycobacterial 
cell wall, and mycolate metabolism is a target of well-known antituberculosis drugs. A separate study 
using iNJ661 identified mycolate as an essential metabolite [184].  Combined, these results suggest that 
mycolate biosynthesis and degradation pathways are viable targets for new drug discovery.  Applying 
sampling and flux coupling methods to iNJ661, 50 known TB drug targets were mapped to hard-coupled 
reaction (HCR) sets, where a single drug target knocks out an entire set’s functionality [124].  
Terminating the activity of other enzymes in an HCR theoretically has the same effect, suggesting novel 
targets.  Most recently, gene and reaction essentiality results obtained from both GEMs were integrated 
into a larger in silico target identification pipeline for M. tuberculosis that incorporates protein-protein 
interaction network analysis, experimentally derived essentiality data, sequence analyses, and structural 
assessment of targetability [125].  
 
Another important respiratory pathogen studied through genome-scale modeling is Pseudomonas 
aeruginosa.  The ability of P. aeruginosa to form biofilms in low oxygen environments allows it to 
chronically infect the lungs of cystic fibrosis patients.  P. aeruginosa is also responsible for nosocomial 
infections and acute infections in immunocompromised patients.  In silico gene deletions performed with 
its metabolic GEM showed strong agreement with published knockout data [122]. 
 
Gastrointestinal Pathogens – Helicobacter pylori targets the gastric mucosa, leading to diseases such as 
gastritis, peptic ulceration and gastric cancer.  Seven essential genes were predicted in the initial H. pylori 
GEM under four test conditions, representing varying aerobic levels and nutrient availability [185].  
Importantly, the overall variation between conditions revealed that gene essentiality is dependent on the 
in silico environment.  Using an updated H. pylori GEM, a later study identified 128 essential genes, and 
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the results were validated using published experimental data [127].  Most essential genes predicted 
belonged to either the cell wall or vitamin and cofactor subsystems.  In a study predicting essential 
metabolites for cell growth [119], meso-2,6-diaminoheptanedioate was confirmed as a potential target, 
while ADP-d-glycero-d-manno-heptose was identified as a potentially novel target. 
 
Salmonella typhimurium is a source of human gastroenteritis and causes systemic infection in mice 
studied as a model for human typhoid fever.  A variation of the typical target-prediction approach 
identified potential strategies for vaccine development [128].  Specifically, gene expression data was used 
to infer the host environmental conditions to which S. typhimurium might be exposed during infection.  
Model simulations predicted genes essential for intracellular survival, providing potential targets for 
generating avirulent attenuated strains for vaccines.  A second S. typhimurium GEM showed good 
agreement between simulation and experimental results for growth patterns under different substrate 
conditions [186].  
 
Pathogens Infecting Other Systems – Neisseria meningitidis causes meningitis and meningococcal 
septicemia, and is classified into serogroups (groups containing a common antigen) A, B, and C.  
Serogroup B is common in developed countries and has no vaccine.  The membrane protein PorA has 
been identified as a major inducer of, and target for, bactericidal antibodies.  As genetically engineered 
strains expressing more than one PorA subtype are now being produced, GEMs can aid in process 
development of the cultivation step.  The metabolic GEM was therefore used to define a minimal medium 
for N. meningitidis growth (successfully tested in batch and chemostat cultures) [129].  
 
Yersinia pestis  infects the lymphatic system and causes bubonic plague, a disease without a vaccine that 
still affects thousands of people annually.  The metabolic GEM was used to identify 74 lethal gene 
deletions and 39 synthetic lethals [130].  Similarly, in silico gene deletion studies on the Leishmania 
major GEM [131], the first GEM for a protozoan, revealed numerous essential genes (e.g., trypanothione 
reductase encoding genes) that are absent in humans. L. major is the causative agent of cutaneous 
leishmaniasis in mammalian hosts and is similar to other Leishmania species causing diffuse cutaneous, 
mucocutaneous and visceral forms of the disease.   
 
Mycoplasma genitalium is the closest known representation of the minimal gene set required for bacterial 
growth.  Additionally, M. genitalium is sexually transmitted and causes nongonococcal urethritis in men, 
genital tract inflammatory diseases in women, and is thought to increase the risk of HIV-1 contraction.  
Presently, model predictions have helped to identify minimal media growth components [132].   
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Human oral pathogens such as Porphyromonas gingivalis are the leading cause of carious and 
periodontal disease.  Lipopolysaccharides (LPS) present in the bacterial outer membrane trigger the 
human immune system.  The P. gingivalis GEM identified several gene deletions preventing LPS 
production [133].  One predicted strain was confirmed to suffer negative effects, though it was still viable.  
Blocking LPS production would allow for control of the negative inflammatory responses. 
 
3.3.2 Production of drugs and nutrients  
  
Attractively, some microbial organisms produce antibiotics and other compounds conveying health 
benefits to humans (e.g., vitamins).  Analysis of metabolic GEMs for both traditional and novel drug 
production microorganisms serves to improve production efficiency and assist in identifying new drug 
production routes.   
 
Nutrients & Dietary Supplements – Corynebacterium glutamicum is used industrially to produce amino 
acids, particularly L-lysine and L-glutamate, and can produce ethanol and organic acids under oxygen 
deprivation conditions.  The first metabolic GEM assisted in prediction of targets for improved lysine 
production, showing that lysine production via direct dehydrogenase gives a higher product yield [134].  
Soon after publication of the first GEM, a second metabolic GEM was published and used to find 
candidate gene deletions to increase organic acid production under oxygen deprived conditions [135].  To 
improve lactate production, succinate-producing reactions required interruption.  Disruption of oxidative 
phosphorylation reactions also predicted improved production of lactate because NADH oxidation 
demand increased.  Finally, reactions in the pentose phosphate pathway were predicted to increase lactate 
production because an alternative reaction was needed to produce NADPH (malate to pyruvate) and the 
increase in pyruvate was converted to lactate.  Succinate production was also predicted to be improved by 
interrupting the lactate producing reactions.   
 
Pharmaceuticals – Aside from E. coli, Bacillus subtilis is one of the best-characterized prokaryotes.  Its 
ability to produce antibiotics, high quality enzymes and proteins, nucleosides, and vitamins makes it an 
important industrial organism.  Two genome-scale metabolic models have been created, the second of 
which used the SEED annotation [136, 187].  Analysis showed that 79% of the reactions from the earlier 
model were present in the later model, with 64% agreement in gene-reaction mapping.  The newer model 
contains a larger number of reactions due to improved annotation and more detailed characterization of 
biomass composition.   
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Streptomyces coelicolor also produces antibiotics, as well as secondary metabolites such 
as immunosuppressants and anti-cancer agents.  It has been demonstrated experimentally that increasing 
the supply of primary metabolites (those directly involved in cell function and growth)—via decreased 
flux through primary metabolic pathways—leads to increased secondary metabolite production in various 
Streptomyces strains.  The S. coelicolor GEM [137] was used to study the effect of reduced 
phosphofructokinase (PFK) activity on increasing secondary metabolite production [138].  The model 
subset used showed that applying constraints to limit secretion of other secondary metabolites (acetate, 
acetaldehyde, ethanol, formate, and proline) did not increase antibiotic production when PFK activity was 
reduced.  The predicted decrease in specific growth rate and increase in pentose phosphate pathway flux 
was observed experimentally.  Another study applied flux variability analysis to the original metabolic 
GEM to investigate the effects of different culture feed conditions on glucose assimilation and antibiotic 
production [139].   
 
3.3.3 Mammalian systems 
   
Metabolism is a critical aspect of human physiology, and metabolic malfunction is a major contributing 
factor in many human diseases.  Metabolic modeling of mammalian cells can be used to study tissue 
specific function [144] and human disease [141, 142].  Mammalian cell cultures (non-human) can also be 
used in the production of biopharmaceuticals such as monoclonal antibodies and vaccines [188].   
 
The recent completion of a global reconstruction of the metabolic network in Homo sapiens [140, 
145] represents a significant milestone in human systems biology.  In addition to the typical network 
capabilities determined by constraint-based modeling, Human Recon 1 has enabled analysis of 
relationships between network topology and human metabolic diseases [142].  In a more specific 
example, a novel computational approach was applied to the GEM to identify biomarkers for inborn 
errors of metabolism [141].  This method revealed a set of 233 metabolites whose concentration is 
predicted to increase or decrease as a result of 176 possible dysfunctional enzymes.  Human Recon 1 has 
also been used to explore tissue-specific metabolism across a number of major organ systems. The model 
was combined with tissue-specific gene expression data to predict tissue-specific activity of metabolic-
disease genes and secreted metabolites [144].  An independently reconstructed human GEM 
[145] revealed the potential of systems modeling in human metabolism to aid in drug discovery [122].  
Recently, efforts have focused on reconciling these reconstructions. 
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Mus musculus, the common laboratory mouse, has been found to have 99% similarity with the human 
genes in coding regions [189].  With extensive experimental data available, the mouse provides a terrific 
model organism for studying genetic systems of relevance to humans.  The M. musculus metabolic GEM 
was used to simulate hybridoma cell line production of monoclonal antibodies (mAbs), and results were 
compared to cell culture data [190].  The model successfully predicted growth and production of lactate 
and ammonia, known byproducts of mammalian cell cultures that cause cell death and inhibit mAb 
synthesis.  However, the model did not predict the production of a third commonly-observed byproduct, 
alanine, and did not explain the high production of lactate, ammonia, and alanine in animal cells.  In 
2009, an updated GEM was the subject of in silico analysis to identify strategies for optimizing cell 
density and mAb production in hybridoma cultures [146].  This GEM produced all expected amino acids.  
Based on cell culture measurements under various nutrient conditions and model simulations of internal 
metabolic states, potential feed-media conditions for enhancing cell density and mAb production were 
suggested. 
 
3.4 Genome-scale in silico metabolic models with applications in both industrial and medical 
biotechnology 
 
3.4.1 Mannheimia succiniciproducens for succinate production 
   
Succinate has importance in the food, agricultural, chemical, and pharmaceutical industries, and can be 
used in the synthesis of biodegradable polymers and green solvents [191].  Currently, succinate is 
produced industrially from liquid petroleum gas via a chemical process.  
 
To optimize microbial succinate production, a GEM was constructed for Mannheimia 
succiniciproducens [147].  Simulations of three mutant strains designed to increase succinate production 
were conducted.  Good agreement was found between the experimental and in silico predictions for 
growth rate, and for succinate and acetate production by one strain.  The prediction for formate was not in 
such good agreement, but the model accurately predicted that lactate, pyruvate, and malate would not be 
produced.  The flux simulation agreed with experiments in its prediction of the route to succinate.  Two of 
the three mutants were more complex and results were initially not in agreement with experiment, but 
were similar after applying additional constraints to the model for one of the complex strains.  The best 
succinate producing strains found using FBA yielded 92.59% of the maximum possible succinate 
production with only 25.50% reduction in growth rate.  Constraint-based analysis on the model was later 
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used to identify an ideal operating range of CO2 to maximize cell growth rate and succinate production 
for a given glucose uptake rate [184].   
 
3.4.2 E. coli 
  
E. coli and S. cerevisiae are two of the best studied microbial species to date [192, 193], and serve as 
critically important organisms from which much about biology has been learned. The E. coli  metabolic 
GEM has been extensively used in a wide spectrum of applications, including increased production of  
lycopene [149, 150], succinate [97, 151, 152], lactate [97, 153], malate [154], L-valine [155], L-threonine 
[156], additional amino acids [157], ethanol [158], hydrogen [98, 159], vanillin [98], and 1,3-propanediol 
(PDO) [97].  As one of the earliest GEMs and most extensively experimentally studied microorganisms, 
E. coli model has been updated multiple times [148, 194, 195]. 
 
Quadruple gene deletions proposed by OptKnock were tested experimentally and resulted in a strain 
capable of increased lactate production (0.87-1.75 g/L per 2 g/L glucose) [153].  Adaptive evolution 
experiments on the engineered strains showed coupling of lactate production and growth, and the new 
strains increased lactate secretion rates.  Constraint-based analysis of the E. coli GEM also guided strain 
design for increased production of the food additive malate, predicting the addition of a M. 
succiniciproducens reaction [154].  In another food engineering study, OptStrain identified three reactions 
to be introduced into E. coli for vanillin production [98].  OptKnock was then used to systematically 
search for gene deletions to enhance vanillin yield.  For biofuels, an algorithm called OptReg [158] 
examined the effects of up-regulation of genes and to those of down-regulation and gene knock-outs to 
identify genes capable of enhancing ethanol production. With a focus on health applications, a MOMA-
based procedure was used to sequentially examine and select sets of multiple gene deletions enabling 
optimal yields of the antioxidant lycopene, while still maintaining sufficient growth rates [149].  In 
another study, comparative genome analysis of E. coli and M. succiniciproducens was performed to 
predict five candidate genes to overproduce succinate in E. coli [151, 152].  
    
A combination of strategies was used to develop an enhanced L-valine producing E. coli strain [155].  
First, an L-valine producing strain was constructed by removing known feedback inhibition mechanisms 
and attenuation controls, and amplifying L-valine biosynthetic enzymes activity.  This strain was 
improved in a stepwise manner using information derived from transcriptome profiling (i.e., the 
identification of a global regulator and exporter of L-valine).  MOMA was applied to identify triple-
knockout targets.  The effect of the triple-knockout mutation was more drastic with respect to L-valine 
38 
 
production in a strain overexpressing the global regulator gene and the exporter encoding gene than in a 
strain without these overexpressed genes.  Analysis was also performed to uncover amplification targets 
for improved L-threonine production [156].  The strain was engineered to reduce byproduct accumulation 
during fed-batch culture by diverting the flux to L-threonine through overexpression of another GEM-
identified gene. 
   
Due to the inherent robustness of E. coli metabolism, only a subset of the metabolic genes was known to 
be lethal in single-gene deletion experiments [196].  Alternative approaches addressed this limitation by 
identifying synthetic lethals, or even higher-order lethal sets.  These efforts dramatically expanded the 
range of knockout candidates.  These lethal multiple-gene knockouts were identified in silico [119, 160-
162], and antibacterial targets found through metabolite analyses [160] have been further explored [119]. 
  
3.4.3 S. cerevisiae  
  
The yeast S. cerevisiae is one of the most widely studied model organisms for eukaryotes; research 
detailing its genetics, biochemistry, and physiology has provided a wealth of insight into mechanisms and 
behavior in higher-level organisms.  S. cerevisiae is also capable of large-scale fermentation for the 
production of fuels, chemicals, pharmaceuticals, materials, nutritional compounds, and food ingredients.  
 
The first S. cerevisiae GEM [197] was later expanded to establish a fully compartmentalized metabolic 
GEM [198], which was later updated [163].  An independently constructed GEM features a more detailed 
description of a lipid metabolism [171].  To reconcile the information in different models, a consensus 
GEM based on community knowledge has been collaboratively reconstructed, though this network 
reconstruction still lacks a biomass equation [172]. 
   
Ethanol is the predominant product in anaerobic fermentations with S. cerevisiae.  With the availability of 
metabolic GEMs, constraint-based analyses can now be applied in new ways to systematically identify 
genetic engineering routes to increase ethanol production.  For example, simulations predicted an 
insertion of the gapn gene as a strategy that could increase the ethanol yield, both with glucose as the sole 
carbon source as well as with a mixture of glucose and xylose, and experiments successfully validated 
this prediction [164].  Employing dFBA, another study demonstrated that the degree of 
compartmentalization in GEMs can impact the predicted mutant phenotypes [165]. 
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Also in yeast, OptGene (an improvement of OptKnock) was used to identify potential metabolic 
engineering targets for increased production of succinate, glycerol, vanillin, and sesquiterpene [166, 167].  
Growth phenotype predictions made using the S. cerevisiae GEM with simulated single-gene knockouts 
were consistent with experimental observations [168].  The phenotypic effects of multiple gene knockouts 
in the context of biological robustness and epistasis were also explored [169, 170].   
  
3.4.4 Aspergillus 
   
Aspergillus is a filamentous fungus important to the medical and biotechnological (industrial and 
agricultural) communities.  Aspergillus produces mycotoxins capable of contaminating crops, and can 
cause disease in immuno-compromised animals and humans.  More constructively, Aspergillus are used 
in the production of bulk chemicals, enzymes, and pharmaceuticals.  These applications have made 
Aspergillus a popular fungal species in research.   
 
Aspergillus niger is an industrial workhorse used to produce high yield products ranging from citrates 
and gluconates to important enzymes and proteins (e.g., human interferon).  The A. niger metabolic GEM  
[199] was used to identify a gene deletion pair predicted to increase succinate production [174].  This 
mutant was tested experimentally, and as predicted, a significant increase in succinate production was 
observed when grown on both glucose and xylose.  Unexpectedly, an increase in fumarate was seen when 
grown on xylose (though not when grown on glucose), suggesting that A. niger uses either the oxidative 
TCA cycle or the glyoxylate shunt for succinate production.  A. niger  converts up to 95% of the available 
carbon to organic acid, and, if unbuffered, can rapidly drop the pH to below 2.  It has been found 
experimentally that depending on the ambient pH, A. niger produces a different organic acid.  To study 
this process, the GEM was expanded to include information relating to the number of protons released for 
one mole of each acid.  Using this GEM, the optimal strategy for acidifying the surrounding environment 
can be found computationally.  The pH levels for citrate and oxalate were reproduced, verifying in silico 
the hypothesis that A. niger produces these to acidify its surrounding environment [173].  Other 
Aspergillus metabolic reconstructions include Aspergillus nidulans and Aspergillus oryzae (Table 1).  A. 
nidulans  [175] is a model organism for studying cell development and gene regulation, and A. oryzae 
[176] has historically been used to produce soy sauce, miso and sake.  A. oryzae is also used for the 
production of fungal enzymes such as alpha-amylase, glucoamylase, lipase, and protease.   
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3.4.5 Host-symbiote relationships  
  
The GEM-based study of host-symbiote relationships can shed light on the shared behavior and provide 
insight into industrial production abilities of the symbiote.  Host-symbiote relationships have two primary 
modes of computational investigation: GEMs can be reconstructed for each participant and analyzed 
alone, or they can be constructed as an integrated network (see methanogens section). Obligate symbiotes 
in particular benefit from genome-scale in silico analysis as they cannot be cultured, and thus 
experimental results cannot be readily obtained. 
 
Buchnera aphidicola is an endosymbiote of the pea aphid whose metabolic GEM has been constructed to 
investigate symbiote-host interaction [177].  Interestingly, it was found that the B. aphidicola genome is 
essentially a subset of the E. coli genome [200].  Not surprisingly, a large percentage of genes from this 
network were predicted to be required for growth (84% by FBA and 95% by MOMA), showing that the 
metabolic network for this organism is much less robust and complex than most.  The bacterium cannot 
grow without secreting the essential amino acid, histidine, for use by its host.  Further, the amount of 
essential amino acid produced by the bacterium in silico can be controlled by host supply of carbon and 
nitrogen substrates—possibly explaining the regulation of amino acid output to the host. 
 
Another symbiotic bacterium, Rhizobium etli, fixes atmospheric nitrogen into ammonium.  A metabolic 
GEM for R. etli is of interest for plant development and in agriculture.  R. etli obtains carbon sources from 
the plant and in turn provides ammonium, alanine and aspartate.  Instead of using a biomass objective in 
its metabolic GEM [178], an objective function containing all compounds needed for symbiotic nitrogen 
fixation was formulated.  This was done because the nitrogen fixation phase of the organism's life is of 
most interest, and in this phase does not grow.  A double gene deletion was identified with a predicted 
increase in nitrogen fixation. 	  
3.5 Genome-scale in silico regulatory models  
 
While genome-scale metabolic modeling strategies can be powerful, they are not completely predictive.  
In addition to incomplete or incorrect aspects of the reconstructions, one reason for failed predictions 
results from the lack of metabolite-level or transcriptional regulation of metabolism.  Constraint-based 
analysis of metabolic GEMs typically assumes all metabolic enzymes are transcribed and available under 
all conditions, which is rarely the case.  Thus, there is a compelling need to use procedures that 
incorporate metabolic regulation.  Specifically, metabolic regulation can be categorized into two groups: 
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transcriptional regulation that controls enzyme expression and metabolite-level regulation (e.g., allosteric 
regulation).  There is often interplay between both regulation types, such as when transcriptional 
regulation is itself affected by metabolite concentrations (e.g., feedback/feedforward 
inhibition/activation).   
 
TRNs enhance metabolic simulations by providing information about transcriptionally active enzymes 
under different conditions.  Recent efforts have attempted to reconstruct integrated networks, comprising 
both metabolic reactions and the regulatory rules that govern metabolic phenotypes, in order to more 
accurately represent metabolic phenotypes.  One method linking the transcriptional state of an organism 
with metabolism is rFBA [84, 87].  rFBA uses Boolean rules to set gene activity for an enzyme as either 
ON or OFF based on the state of transcription factors and the environment.   
 
The first integrated metabolic-regulatory network at the genome scale was reconstructed for E. coli [85].  
This integrated model included 1,010 genes: 906 from the metabolic network [195], and 104 regulatory 
genes, whose products (i.e., transcription factors) together with other stimuli control the expression of 479 
of the 906 metabolic enzymes and transports.  The model predicted the outcomes of gene expression and 
growth phenotyping experiments, revealed knowledge gaps, and enabled the identification of additional 
components and interactions in each network.  Steady-state regulatory FBA (SR-FBA), which 
reformulated rFBA using mixed integer linear programming [201], was later used to search the multiple 
solutions of rFBA rather than obtain only a particular flux state as with the Boolean-logic updating 
method for rFBA.  More recently, a matrix formalism [202] was applied to the most updated integrated 
metabolic-regulatory model: among the 1260 genes in the metabolic model [148], 503 gene targets were 
regulated by the expression state of 125 transcription factors [203].  In addition to computing the 
transcription state of the genome, this formalism was used to describe intrinsic properties of the 
transcriptional regulatory states which could be analyzed by methods such as Monte Carlo sampling 
across a subset of all possible environments. 
 
The first large-scale integrated metabolic-regulatory model in a eukaryotic organism was constructed 
for S. cerevisiae [87], containing 55 nutrient-regulated transcription factors that control a subset of the 
750 genes in the metabolic network [198].  The rFBA approach [84] predicted gene expression changes 
and growth phenotypes of gene knockout strains.   
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3.6 Conclusions  
 
This was an extensive review of the biotechnology applications of genome-scale modeling efforts to date, 
demonstrating the vast array of organisms already available for model-guided strain design and 
investigation of biochemical behavior.  With the rise in high-throughput measurement technologies and 
the growing number of sequenced genomes, the continued construction of in silico GEMs will provide 
increasingly powerful tools to investigate biological systems.  While existing models and corresponding 
analysis techniques have been developed primarily for metabolism, transcriptional regulation and 
transcription-translation processes are emerging.  Many of the studies highlighted herein reveal the utility 
of GEMs for generating predictions for experimental testing and design, as well as providing valuable 
insight into metabolic function.  Commonly, in silico simulations are employed to study the effects of 
genetic perturbations on the stoichiometric abilities of a cell.  In this way, these studies have used GEMs 
to predict engineering strategies to enhance properties of interest in an organism and/or inhibit harmful 
mechanisms of pathogens or in disease.    
 
Looking forward, technology and computational method development continues to improve the predictive 
capability and usefulness of in silico GEMs.  These efforts focus on “integration,” whether in regard to 
heterogeneous high-throughput data types, or different scales and scopes of biological processes.  As 
technological advances enable increasingly comprehensive and accurate measurements of intracellular 
and extracellular metabolite concentrations [204], these data will greatly inform GEM reconstruction and 
analysis, including for dynamics. Integration of cellular regulation and signaling with metabolic 
information is important for predicting diverse network states. The successes with the genome-scale TRN 
in E. coli [85, 86, 203] and S. cerevisiae [87] demonstrate the potential of metabolic networks controlled 
by gene expression.  Similarly, the recent invention of a genome-scale transcriptional-translational 
network model (demonstrated in E. coli [88]) will allow for integrated analysis of transcriptomic and 
metabolic states.  Contrary to these successes though, analysis of allosteric regulation between 
metabolites and enzymes is still lacking in GEMS because of sparse high-throughput data and applicable 
computational methods to uncover these genome-scale relationships.  Similar technical problems exist for 
intracellular signaling networks as GEMs, although integration of metabolic, transcriptional regulatory, 
and signaling networks has been investigated [86, 205].  As network integration becomes commonplace, 
consistent formatting and naming conventions must become a priority to assist in seamless melding of 
information. Achieving integration of the different biochemical processes will open another avenue to 
ultimately realize whole-cell simulation. 
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Chapter 43: Metabolic network reconstruction and genome-scale 
model of butanol-producing strain Clostridium beijerinckii NCIMB 
8052 
 
To assist with engineering C. beijerinckii to more efficiently produce butanol, I built the first genome-
scale metabolic model (named iCM925) for C. beijerinckii NCIMB 8052. There have been four genome-
scale models built for clostridia—two for C. acetobutylicum [105, 106, 206] and one each for the 
cellulolytic strains C. thermocellum [207] and C. cellulolyticum [208].  C. beijerinckii is unique from 
these in that it is the most productive wild-type butanol-producing clostridia known to date [4, 6-8].  
Containing 925 genes, 938 reactions, 881 metabolites, and 67 membrane transport reactions, the iCM925 
model is the largest genome-scale model for a clostridial species.  The iCM925 model accurately 
simulates substrate uptake and product formation rates for batch culture, and correctly captures the 
relationships between the formation of products such as butanol and hydrogen.  As such, the C. 
beijerinckii model will be instrumental in future efforts to reengineer C. beijerinckii NCIMB 8052 to 
produce higher titers of butanol.  
 
4.1 Reconstructing the metabolic network and building the genome-scale model   
 
The first step towards building a genome-scale metabolic model is reconstructing the genome-scale 
metabolic network—typically done using publically available annotation databases and published 
literature. A list of reactions that are either catalyzed by enzymes encoded in the genome or have been 
defined experimentally is collected and then expanded to define relationships between genes, enzymes, 
reactions, metabolites, and pathways in the network.  To establish the genome-scale metabolic model, the 
network reactions are subjected to a series of physico-chemical constraints—either calculated or based on 
physiological data—to simulate defined cultural conditions.  Given the limited literature and biochemical 
data available for C. beijerinckii, I reconstructed the metabolic network using a semi-automated approach 
                                                      
3 Material in this chapter was reproduced with permission from the following publication: Milne CB, Eddy JA, Raju 
R, Ardekani S, Kim PJ, Senger RS, Jin YS, Blaschek HP, Price, ND: Metabolic network reconstruction and 
genome-scale model of butanol-producing strain Clostridium beijerinckii NCIMB 8052. BMC Sys Bio 2011, 5:130. 
The original publication is available online by following this link: http://www.biomedcentral.com/1752-0509/5/130.  
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to obtain annotation data from three major databases, and I used computational algorithms to further 
refine the network.  
 
4.1.1 The initial genome-scale metabolic network 
 
The available genome annotations for lesser-characterized organisms are largely generated by 
computational, informatics-based procedures (i.e., they often lack manual curation), and there is a paucity 
of experimentally-confirmed biochemical data.  To facilitate reconstruction, expand the scope of the C. 
beijerinckii network, and evaluate confidence for each gene-protein-reaction (GPR) relationship included, 
annotation data from three independent databases was merged: KEGG (Kyoto Encyclopedia for Genes 
and Genomes) [209], BioCyc [210], and The SEED [211, 212].  To reduce the time required to assemble 
annotation data into a well-connected genome-scale network, I employed a semi-automated 
computational approach to retrieve and integrate information from each database. 
 
The foundation for the network, comprising 525 reactions, was obtained from the KEGG database.  This 
network was expanded to include an additional 75 and 136 unique reactions from The SEED and BioCyc 
databases, respectively.  Careful reconciliation and integration of the obtained biochemical data was 
required because the three databases do not follow a uniform nomenclature for reactions, metabolites, and 
pathways.  The nomenclature used by the BiGG database (the largest available repository for genome-
scale metabolic models) was followed in order to enable easier comparison with other in silico models 
[213].  This mapping step was quickly accomplished by using a matrix formalism to overlay the different 
databases (see Methods) based on stoichiometry.  The mapping between BioCyc and KEGG for reaction 
and metabolite names in C. beijerinckii is available in Additional File 1 in the online publication.   
 
The overlap between annotation information collected from KEGG, BioCyc, and The SEED was 
analyzed to help assess the confidence for each reaction included in the network.  Reactions found in all 
three databases were considered to have the greatest reliability, followed by reactions in two of the 
databases, and finally by reactions found in only one database.  Surprisingly, out of the collective 776 
suggested reactions, only 264 reactions were found to be present in all three annotations (Figure 8).  
Given that many genome-scale models are built in this manner, the small overlap observed for C. 
beijerinckii suggests that researchers must exercise caution when constructing networks for new 
organisms based on bioinformatics-based annotations.  The reconstruction and phenotypic testing of 
genome-scale models then provides an important means to integrating, curating, and validating annotation 
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information.  Further analysis of the relationship between database contribution and model accuracy (used 
to evaluate annotation quality for C. beijerinckii) is discussed below. 
 
 
 
Figure 8: Annotation database comparison. Reaction overlap for the three annotation databases used to build the 
genome-scale metabolic network. 
 
In addition to establishing confidence for each included reaction, the predicted gene-associations for 
reactions found in two or more of the annotation databases (see Additional File 2 in online publication for 
database-based GPR comparison) were evaluated.  In cases where annotations did not agree between 
databases, associations were selected for the model based on the strongest BLASTp [214] evidence (i.e., 
genomic identity between the associated enzyme and similarly annotated database proteins).  
Reassuringly, most annotation disagreements were found to be a result of a missing gene–reaction 
relationship rather than a contrasting association; this suggests that overlapping reactions comprise a well 
annotated area of the network.  
 
4.1.2 The refined C. beijerinckii metabolic network 
 
The draft metabolic network derived from genome annotation data—even with combined information 
from multiple databases—contained gaps (i.e., missing reactions) that prevented simulation of cell growth 
and accurate physiological behavior (e.g., butanol production).  Network gaps create unconnected 
sections/regions in the network, thereby preventing production or consumption of a metabolite.  In turn, 
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the “dead-end” metabolite has often been observed experimentally as consumed or produced, or is needed 
to simulate cell growth.  Network gaps must therefore be filled using literature information and/or 
genomic evidence beyond what was included in the annotation databases.  
 
Identifying network gaps and selecting candidate gap-filling reactions with strong supporting evidence 
can be time consuming, especially for lesser-characterized organisms like C. beijerinckii.  Consequently, 
the GapFind and GapFill [215] algorithms were used to computationally identify and resolve gaps, thus 
minimizing the amount of manual curation needed.  Candidate reactions suggested by GapFill were 
chosen from the BiGG database; this database contains genome-scale models that have undergone 
extensive refinement and validation, and thus is a resource of high-confidence reactions [213].  After 
reviewing candidate reactions for sufficient BLAST [214] evidence, an additional 22 putative annotations 
(and 22 additional network reactions) were identified for the C. beijerinckii genome (see Additional File 2 
in online publication)—seven of which were required for simulated cell growth.   
 
Even after using GapFind and GapFill, manual addition of reactions was needed to fill important gaps that 
remained in the network.  Notably, the draft network was missing a butanol dehydrogenase enzyme, a 
ferredoxin NAD+ reductase, and did not contain the necessary biochemical transformations for production 
of known phospholipids.  Reactions for both an NAD+ and NADP+ butanol dehydrogenase enzyme 
(BUTOHDx and BUTOHDy), known to exist in solvent producing clostridia [13, 216], were added based 
on BLAST [214] scores for the C. beijerinckii gene Cbei_2421.  A gene association for ferredoxin NAD+ 
reductase was not found—even though the NADP+ reductase is matched to Cbei_0661 and Cbei_2182—
but the reaction (FDXNRx) was added based on literature evidence [13].  The phospholipid pathway was 
characterized using a similar approach to Lee et al. [105], drawing upon experimental data for fatty acid 
biosynthesis [217].  In total, 38 reactions were added as a result of manual curation—11 of which were 
added based on BLAST [214] comparison with reactions from the Senger & Papoutsakis C. 
acetobutylicum model [106, 206] and 22 of which were added for the formation of phosopholipid and 
biomass components.  
 
One of the most significant gaps in the draft C. beijerinckii network prevented model-simulated 
production of oxoglutarate, a major component of central metabolism; this gap stemmed from missing 
genetic evidence for enzymatic reactions need to complete the TCA cycle.  The TCA cycle in the model 
was ultimately completed based on conclusions from two experimental studies, in which carbon labeling 
showed that C. acetobutylicum uses a bifurcated TCA cycle culminating in succinate secretion [218, 219].  
The initial reconstruction did not support a bifurcated TCA cycle: the network was missing a citrate 
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synthase (CS), succinyl-CoA synthetase (SUCOAS), and a succinate transport (SUCCex) reaction.  In 
addition, the directionality of existing reactions did not support the experimentally observed flux.  To 
allow for simulation of the bifurcated cycle and enable oxoglutarate production, the three missing 
reactions were added (without genetic evidence), and restricted reaction directionality to that observed in 
the study.  
 
4.1.3 The genome-scale model (iCM925) 
 
From the refined metabolic network, the genome-scale model was built by representing the reactions, 
gene associations, pathway information, and reaction directionality in matrix form (see Additional Files 1 
and 3 in online publication for model file).  This model for C. beijerinckii, hereafter named iCM925 in 
accordance with the model naming convention proposed by Reed et al. [195], contains 938 reactions, 881 
metabolites, and 925 genes—representing 18% of total protein coding genes in the genome [220, 221].  
Transport reactions across the cell membrane—collected from the BioCyc and KEGG databases, as well 
as from the published C. acetobutylicum models [105, 106, 206] and the genome-scale models for 
Bacillus subtilis [136, 187]—make up 67 of the 938 reactions.  iCM925 contains the largest number of 
genes, reactions and metabolites compared to the four other clostridial models (Table 2); this could be a 
result of model construction methods, but likely reflects the fact that C. beijerinckii has a 50% larger 
genome than the other clostridia.  
 
Table 2: Network statistics for genome-scale models of clostridia.  Statistics for each published genome-scale 
clostridia model and comparison with iCM925. 
 
The reactions in iCM925 span 95 pathways (organized into 13 major groups in Figure 9), as defined by 
KEGG pathway nomenclature.  Carbohydrate and amino acid metabolism represent the largest portions of 
the network.  For each pathway, the percentage of reactions that can be utilized in glucose minimal media 
simulations was calculated (Figure 9) in order to evaluate model connectivity.  Overall, 47% of reactions 
across all pathways are blocked, which is on par with other in silico genome-scale models [222].  Many of 
 
C. beijerinckii 
iCM925 
C. acetobutylicum 
(Lee)[ 105] 
C. acetobutylicum 
(Senger)[ 106, 
206] 
C. cellulolyticum 
[208] 
C. thermocellum 
iSR432 [207] 
Genome 6.0 Mb 4.1 Mb 4.1 Mb 4.1 Mb 3.8 Mb 
Protein 
Coding 
Genes 5100 3748 3748 3488 3236 
Model 
Genes 925 432 474 431 432 
Reactions 938 507 552 621 577 
Metabolites 881 479 422 603 525 
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these blocked reactions were concentrated within pathways that are almost entirely blocked, such as 
metabolism of terpenoids and polyketides—suggesting that many of the blocked reactions are actually a 
result of blocked pathways.  Pathways involving carbohydrate metabolism (compared to a more 
connected pathway such as nucleotide metabolism) may have a higher number of blocked reactions under 
glucose media conditions because they contain numerous reactions intended for metabolism on alternative 
sugar substrates.  
 
Figure 9: Pathway distribution for reactions in iCM925. The number of reactions that can carry flux are depicted 
in blue and the number that cannot carry flux are depicted in red for each area of metabolism.  Percentages indicate 
overall percent contribution of that pathway to the model.  Blocked reactions were determined by simulating growth 
on glucose minimal media. 
 
The pathway contribution of each annotation database (see Additional File 2 in online publication) was 
assessed to determine (i) if any database displayed more complete coverage in one area of metabolism 
(e.g., carbohydrate metabolism) and (ii) if one database contributed more blocked reactions to the model.  
For each of the 13 pathway categories depicted in Figure 9, similar coverage was found between KEGG, 
BioCyc, and the SEED; this indicates that the small overlap found between databases is not simply a 
result of one database contributing more heavily to a particular area of metabolism.  Additionally, each 
database contributed a similar number of blocked reactions: 22% of the blocked reactions came from 
BioCyc, 21% from KEGG, 10% from The SEED, 18% from two or more databases, and 17% from all 
three databases.    Therefore, one database was not found to outperform another in terms of model 
connectivity.   
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4.2 Model validation and exploratory simulations  
 
To test the ability of model iCM925 to simulate experimentally-observed behavior, a series of batch 
fermentations were conducted to compare measured substrate uptake and product formation rates with 
model predictions.  The model was found to provide a solid basis with which to study the unique 
characteristics of C. beijerinckii metabolism and guide future metabolic engineering experiments for 
enhanced butanol production capability. 
 
4.2.1 Validation of iCM925 
 
To evaluate the predictive accuracy of iCM925, flux balance analysis (FBA, see Methods) was used to 
reproduce experimental fermentation behavior.  The FBA formalism represents all known reactions in the 
cell as a stoichiometric matrix, and uses linear programming to maximize a user defined objective 
function (e.g., growth) under a steady state assumption [93, 94].  Importantly, FBA can be used to 
simulate experimental parameters such as growth rates, uptake rates, and byproduct secretion rates—
enabling quantitative evaluation of model agreement with physiological behavior.  
 
Data used to determine uptake and secretion rates for batch cultures was obtained by monitoring 
substrate, product, and cell concentrations in NCIMB 8052 cultures.  In a targeted gene expression study, 
Shi and Blaschek found that solvent formation began during mid-exponential growth (7-8 hours). This 
was characterized by increased expression levels of solvent formation genes and accompanied by 
decreased expression of genes associated with acids formation [14].  Similar to Shi and Blaschek, the 
switch from butyrate to butanol formation in the present study was found to occur at 8-10 hours.  
Simulations were performed on the subsequent period of exponential growth, in which butanol is 
produced.  Fermentation studies were conducted at four temperatures (30°C, 33°C, 35°C, 40°C) to obtain 
multiple sets of data with which to compare model simulations, but only results for 35°C are reported in 
the main text, as it is most representative of typical fermentation conditions.  Complete experimental data 
for all tested conditions is available in Additional File 2 in the online publication. 
 
Experimental estimates for substrate uptake and product secretion rates (in units of mmol/gDW/hr) were 
determined for butanol, acetone, ethanol, acetate, and butyrate using product concentration and growth 
rate (see Methods, Additional File 2 in online publication).  All model simulations were conducted with 
biomass production (defined by the biomass equation) as the assumed cellular objective.  The biomass 
equation represents all macromolecules found in one C. beijerinckii cell, and was defined using known 
50 
 
experimental compositions and compositions inferred from the genome (see Additional File 2 in online 
publication for details).  When performing simulations, specified uptake and secretion rates were 
constrained to fall within one standard deviation of experimentally measured rates, while the remaining 
rates were determined by FBA.   
 
The first simulation of iCM925, with only glucose and acetate uptake rates constrained, predicted 
production of only acetone and butyrate, along with an elevated growth rate (Figure 10A, see Additional 
File 2 in online publication for comparisons at different temperatures).  This product profile is not 
surprising for the assumed optimal growth objective, given the experimentally supported understanding of 
cellular redox in C. beijerinckii.  Specifically, disposal of excess electrons is achieved in cell culture 
through the generation of butyrate, butanol, and hydrogen.  However, disposal via hydrogen and butyrate 
would allow for ATP production with minimal loss of carbon, thereby improving the biomass objective.  
Thermodynamic limitations of the hydrogenase reaction prevent such disposal biologically [13, 223], but 
such constraints were not incorporated into iCM925 because clear experimental hydrogen formation rates 
were unavailable.  Acetone production in the model could also be traced to acetate re-uptake: the 
formation of acetone utilizes acetoacetate, a byproduct of acetate re-uptake by CoA-transferase.  
 
 
 
Figure 10: Comparison of iCM925 simulations with experimental data. Model and experimental values for 
product fluxes, uptake fluxes and growth rates represent conditions for the 35°C fermentation.  Error bars indicate 
the observed experimental range and diamonds represent the various simulation results. (A) shows the simulation 
results for the case where only acetate and glucose uptake rates are constrained. (B) shows the case where these 
uptake rates, as well as butanol, acetone, and butyrate formation rates are constrained. In (B), the blue diamonds 
represent the case where non-growth associated ATP maintenance is zero and the yellow diamonds represent the 
case where the non-growth associated ATP maintenance is 8.5. 
  
To confirm that iCM925 is capable of simulating production of all expected metabolites at experimentally 
determined rates, additional constraints were added to the product secretion reactions for butanol, acetone, 
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ethanol, and butyrate (Figure 10B, see Additional File 2 in online publication for comparisons at different 
temperatures).  As product formation is known to be associated with the generation of ATP in the cell 
[13], the effect of ATP production requirements was analyzed by altering the constraints on the non-
growth associated ATP maintenance (NGAM) reaction.   The first simulation assumed that no ATP is 
needed for non-growth associated maintenance, and resulted in a higher growth rate than expected; this is 
a biologically unrealistic assumption, but illustrates the dependency of growth rate on ATP maintenance.  
The latter simulation—with an NGAM value that guided the in silico growth rate to the experimentally 
calculated range—demonstrated that the expected experimental phenotype can be reproduced by the 
model. Thus, it was concluded that all observed secretion patterns exist within the solution space of the 
model, even though solvent secretion patterns in C. beijerinckii are not well described by the iCM925 
model when using the optimal growth objective.     
 
4.2.2 Analysis of the active reactions in iCM925  
 
After verifying that iCM925 could reproduce experimental uptake and secretion rates, the underlying flux 
distributions used by the model to achieve these rates were investigated.  Under optimal growth 
conditions for a defined minimal medium, a previous study found that genome-scale models for 
Helicobacter pylori, Staphylococcus aureus, E. coli, and S.cerevisiae have about 300 active reactions 
[222]; iCM925 had 291 active reactions.  Interestingly, 137 of these 291 reactions (Figure 11) were found 
in all three annotation databases, representing a statistically significant number of active reactions among 
the overlapping reactions (P = 3.52x10-9, Fisher’s exact test).  Because active reactions are those used by 
the model to reproduce known physiological behavior, the over-representation of reactions found in all 
three databases thus supports our assumption that overlapping reactions have the highest reliability for 
inclusion.   
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Figure 11: Origin of active reactions. Percentages represent the fraction of all active reactions (in the constrained 
simulation, based on 35°C experiments) originating from individual databases, a combination of databases, or other 
sources. 
 
To further study active reactions, reactions carrying the largest flux in glycolysis, TCA cycle, and the 
product formation pathways were diagramed (Figure 12).  In glycolysis, the model was found to use the 
PTS rather than ABC transporter to uptake extracellular glucose.  The choice of PTS over ABC suggests 
that C. beijerinckii may use the former transporter primarily as the most efficient means of converting 
glucose to biomass, a finding that is corroborated by experimental observation of PTS transport (GLCpts) 
utilization by C. beijerinckii [11, 15, 224].  Flux through the TCA cycle follows the experimentally 
observed route of oxoglutarate production [218] via citrate synthase (CS).  However, the model did not 
utilize the oxaloacetate to succinate transformation or the conversion of succinyl-CoA to succinate, as 
was observed by Amador-Noguez et al.  For succinyl-CoA synthetase (SUCOAS, an ATP generating 
reaction), it was found that increased ATP requirements resulted in activation.   
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Figure 12: Network map of important active reactions. Network fluxes were determined in 35°C fermentation 
simulations with ATPM=8.5. Blue boxes indicate substrates, red colored boxes indicate products, and yellow boxes 
indicate intracellular metabolites only. Numbers next to each reaction name represent flux predicted by the model.  
Fluxes are not necessarily consistent from one reaction to the next because other, smaller flux pathways have 
interplay with the reactions here. 
 
Contrary to experimental ethanol production which stems primarily from acetyl-CoA [2, 40], iCM925 
predicted that about 70% of ethanol was made from threonine (derived from aspartate) by the enzyme 
threonine acetaldehyde-lyase (THRA).  Butanol, butyrate, and acetone were produced using the 
54 
 
experimentally characterized pathways, and acetate was consumed using CoA-transferase (COAT1) as 
expected [2, 40].  Intriguingly, the model predicted simultaneous production and consumption of butyrate 
using butyrate kinase (BUTK) and CoA-transferase (COAT2), respectively.  The re-uptake of acids by 
solventogenic clostridia has been experimentally established, with one of the leading suggestions for this 
behavior being a means of de-toxification of the acidic environment [2].  Given that the primary objective 
in these simulations was to maximize flux through the biomass equation within the imposed constraints, it 
is most likely that the motivation for re-uptake of butyrate by the iCM925 model is the generation of 
additional ATP—a major component of biomass.  Previous experimental studies investigating acid re-
uptake [41-43] do not support this suggested motivation, however—making further investigation into the 
motivations of the model an interesting area of focus going forward.  
 
Flux variability analysis (FVA) was performed to evaluate the robustness of the diagrammed reactions 
(Figure 13, see Additional File 2 in online publication for a complete list).  FVA calculates the extent to 
which network reactions can change without affecting the simulated maximal growth rate—the model 
represents an underdetermined system, and even when optimizing for a specific objective, multiple 
solutions exist for each set of constraints [225].  ACK, PTA, BUTK, BCOPBT, COAT1, and COAT2 are 
connected to the uptake and production of acetate and butyrate. As suspected, it is possible for both 
metabolites (either together or independently) to be simultaneously produced and consumed.  The 
variation seen in BUTOHDx and HACD1x indicates that either the NAD+ or NADP+ versions of these 
reactions can be used with no effect on growth rate. Similarly, the variation observed in PFL, POR4, and 
PYK show equally optimal methods of pyruvate formation and consumption.  
 
 
 
Figure 13: Flux variability analysis of important active reactions. Bars depict the possible flux range (minimum 
and maximum calculated by flux variability analysis for reactions depicted in Figure 12). 
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Understanding butanol production: the role of molecular hydrogen 
Hydrogen formation is known to play an important role in balancing cellular redox for C. beijerinckii, and 
has been found to effect the production of butanol [13, 226, 227].  Model iCM925 simulations confirm 
this relationship, and also indicate the impact of hydrogen formation (and by extension butanol 
formation).  When grown on glucose and acetate, maximizing the specific growth rate leads to the 
formation of acetone and butyrate only; this simulation had a predicted hydrogen production rate of about 
18 mmol/gDW/hr (Figure 14).  To observe positive butanol production, hydrogen production must be 
limited to below about 10 mmol/gDW/hr, at which point the corresponding growth rate becomes sub-
optimal.  Because the production of ethanol and butanol both consume the same number of NADH 
molecules (two in each pathway), the model predicted that at low hydrogen production rates, either 
ethanol or butanol could be used to balance redox with no change in growth rate.   
 
 
Figure 14: Effect of hydrogen formation rate with fixed glucose and acetate uptake. H2 output flux was varied 
to examine the effect of hydrogen production on predicted formation rates for butyrate, acetone, butanol, ethanol, 
and biomass.  Glucose and acetate uptake rates were fixed to 9.39 and 3.41 mmol/gDW/hr, respectively, and non-
growth associated maintenance was set to 8.5 mmol/gDW/hr.  Note that while positive ethanol formation is not 
depicted in the plot, FVA found ethanol and butanol production to be interchangeable, with no detrimental result to 
growth rate—likely because the net consumption of NADH is identical in both scenarios.  Experimentally, ethanol 
formation happens at a slower rate than butanol formation. 
 
In an experimental C. acetobutylicum study, a decrease in hydrogenase activity (induced by carbon 
monoxide poisoning) when grown on glucose resulted in decreased growth rate, decreased acetone, 
acetate, and butyrate production, and increased ethanol and butanol production [227].  Model iCM925 
was found to qualitatively predict similar behavior for simulated growth on glucose only (acetate was not 
used as an input in this simulation to match experimental media conditions), suggesting that a similar 
mechanism might be involved in C. beijerinckii metabolism (Figure 15).  As with the other simulation, 
butanol and ethanol production were found to be interchangeable for these optimal growth simulations—
56 
 
in vivo, regulation likely factors in to dictate how much of each product is made.  This observation 
supports the conclusion that without hydrogen production, excess electrons are disposed of via the 
production of acids and solvents.   
 
 
Figure 15: Effect of hydrogen formation rate with fixed glucose uptake only. H2 output flux was varied to 
examine the effect of hydrogen on the production of acetate, butyrate, acetone, butanol, ethanol and biomass for 
optimal growth simulations on only glucose, with an uptake rate of 9.39 mmol/gDW/hr and a non-growth associated 
ATP maintenance of 8.5 mmol/gDW/hr. Note that while positive ethanol formation is not depicted in the plot, FVA 
found ethanol and butanol production to be interchangeable with no detrimental result to growth rate. 
 
Additionally, the simulation results show that for high levels of hydrogen formation, acetate is the only 
byproduct and growth rate is at a maximum.  The production of hydrogen eliminates the need for 
additional NADH consumption by butyrate, allowing ATP generation to occur exclusively via acetate 
formation—the most efficient method for the cell.  Maximum growth rate is observed under these 
conditions because they represent the most energy efficient means of glucose utilization for the 
microorganism.  At very low hydrogen consumption rates, production of butanol rather than butyrate is 
observed, as the production of butanol results in the consumption of two additional NADH molecules 
compared to butyrate. The overall observed effect of hydrogen formation is not only experimentally 
consistent, but it highlights the importance of this reaction in regulating butanol formation, and will be an 
area of focus in future work.  
 
4.2.3 Comparison of iCM925 with C. acetobutylicum model 
 
Although the genome of C. beijerinckii is 50% larger than that of C. acetobutylicum, the two 
microorganisms present phenotypically similar fermentation profiles.  To investigate the effect of 
additional genes in C. beijerinckii, model iCM925 was compared to one of the C. acetobutylicum models 
57 
 
(the model published by Senger and Papoutsakis in 2009 [106, 206]), using KEGG reaction IDs as a basis 
for comparison.  Of the 940 iCM925 reactions, 375 were found to overlap with the Senger model (Figure 
16); 183 of these reactions are present in our list of 291 active reactions for the 35°C (ATPM=8.5) 
fermentation simulation.  Interestingly, the pathways and database sources of the 564 reactions unique to 
iCM925 were similarly distributed as those of the full model—suggesting that (i) C. beijerinckii does not 
simply contain more reactions in a particular pathway, and (ii) that the additional reactions in iCM925 are 
not an artifact of the multiple database approach.  Of the 375 overlapping reactions, 119 have more 
connected genes per reaction in C. beijerinckii than in C. acetobutylicum—with an average of 1.3 times 
more genes per reaction in C. beijerinckii. This is not a statistically significant result, but suggests that 
several of the reactions (e.g., CoA-transferase and butyrate kinase) do have more associated genes than 
the corresponding C. acetobutylicum reactions. 
 
 
 
Figure 16: Comparison of iCM925 with the Senger & Papoutsakis C. acetobutylicum model. The number, 
database distribution, and pathway distribution of reactions in iCM925 and the Senger & Papoutsakis C. 
acetobutylicum model were compared based on KEGG IDs. (A) Numbers of reactions in common between the two 
models or unique to each are depicted by bars on the graph.  The fractions of unique and shared reactions that are 
active in iCM925 are denoted by light-shaded regions. (B) The database distribution of reactions exclusive to 
iCM925 are shown in the upper left, while the pathway distribution is shown in the bottom of the panel. 
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4.3 Conclusions 
 
Butanol, currently produced as a byproduct of petroleum refining, is appealing in industry as both an 
important chemical feedstock and an alternative transportation fuel.  I have built the first genome-scale 
model for C. beijerinckii to better understand the metabolic behavior of the microorganism, and to guide 
future metabolic engineering for increased butanol production.  Having a genome-scale model for C. 
beijerinckii is advantageous because it helps provide a global picture of metabolism—this enables 
interrogation of the interplay between the various fermentation products of the microorganism from a 
systems viewpoint.  Given the lack of detailed biochemical data available C. beijerinckii, I integrated and 
cross-checked information from three major annotation databases to reconstruct the core metabolic 
network, and then further completed the network with computational algorithms and manual curation.  I 
collected experimental fermentation data to determine production rates of acetone, ethanol, and butanol, 
and uptake rates of acetate and glucose, and these rates were used to confirm the ability of the model to 
accurately represent physiological behavior.  Interestingly, reactions found in all three annotation 
databases proved to contribute significantly to the actively used reactions in validation simulations.  Even 
though the observed experimental phenotypes were found to exist in the solution space of the model, 
optimal growth simulations on glucose did not predict the expected product profiles—suggesting the 
possibility of an alternative cellular objective or additional mechanisms not captured by the iCM925 
model.  One reaction found to have a strong impact on the predicted product formation rates was the 
hydrogenase reaction—a reaction that has been found to impact solvent formation experimentally as 
well.  Going forward, this model will play a central role in understanding and metabolic engineering 
butanol production by C. beijerinckii.  Additionally, the construction of iCM925 for a lesser-characterized 
microorganism highlighted important areas of investigation (e.g. genome annotations, objective 
functions) for future model-building efforts.  
 
4.4 Methodology 
 
Genome-scale models are built using enzyme-catalyzed reaction information encoded in the genome of an 
organism, as well as experimentally characterized reaction information.  This collection of all known 
reactions in the metabolism of the organism then serves as the foundation for the metabolic model.  The 
model is represented mathematically by the stoichiometric (S) matrix.  Each column in S represents a 
reaction in the network, where entries for each row indicate the stoichiometric relationship of 
corresponding metabolites (negative and positive coefficients denote reactants and products, respectively, 
and zero entries indicate a non-participating reaction).  Through constraint-based modeling [92, 228], a 
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series of balances and bounds (discussed below) are applied to the reactions in S, and the model is used to 
simulate cell growth by optimizing for a user-defined objective function.  These simulations can then be 
used to examine the interplay between different reactions and pathways, and to predict resulting 
metabolic phenotypes from genetic modifications.  
 
4.4.1 Semi-automated compilation of the draft metabolic network 
 
The metabolic network describes the connectivity of metabolites and reactions in a cell and characterizes 
the link between genes, proteins and reactions (GPR relationship).  The base metabolic network was built 
using the KEGG gene annotation for C. beijerinckii.  This draft network contained annotation-based 
information available for C. beijerinckii from the KEGG database, including GPR relationships, pathway 
information, reaction stoichiometry, and reaction reversibility.  The time needed to generate the initial 
draft network was drastically reduced by automatically collecting and organizing the network information 
using the KEGG FTP server.  
 
The KEGG draft network was augmented using independent annotations from The SEED and from 
BioCyc.  Annotations in The SEED database were linked to KEGG biochemical data, making integration 
of the two networks straightforward.  BioCyc, however, employs a different nomenclature, so a mapping 
between reaction and metabolite IDs in BioCyc and KEGG was constructed for C. beijerinckii.  
Specifically, metabolites were mapped using (i) BioCyc files linking to KEGG (incomplete); (ii) 
compound names and unique iNICHi identifiers; (iii) the E. coli specific mapping for iAF1260 [148]; and 
(v) manual curation.  Between-database reaction mapping was then determined as follows:  
i. using the between-database metabolite mapping the set of all compounds shared by BioCyc 
and KEGG was identified;  
ii. temporary S matrices were built (one for the BioCyc C. beijerinckii  reaction set, one for the 
our KEGG/SEED draft network set, and one for the BiGG database—including only those 
reactions involving metabolites in the shared set) with metabolites ordered identically in each 
matrix;  
iii. matching columns (reactions) were identified, assuming that identical stoichometric 
relationships between a set of metabolites represented a matching reaction between BioCyc 
and KEGG;  
iv. reactions not mapped in an automated fashion were manually inspected and curated. 
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The resulting network, based on KEGG nomenclature, consisted of the list of reaction formulas, the 
corresponding enzymes (including enzyme commission number) and genes, reaction identifiers, pathway 
information, and a note on the source database.  To enable comparison with other published genome-scale 
models (over 50 to date [229]), the metabolite and reaction identifiers were reformatted in accordance 
with models available in the BiGG database [213].  This was done similarly to the BioCyc-KEGG 
mapping.  Metabolite mapping was achieved using flat files from BiGG, and reactions were mapped 
using temporary S matrices for BiGG and the C. beijerinckii network.  Manual matching was performed 
for reactions and metabolites for which no automated connection was found.  Names were generated for 
any remaining reactions and metabolites for which no mapping existed.  
 
4.4.2 Building the genome-scale metabolic model 
 
To simulate cellular behavior based on a defined set of inputs and outputs, the network derived from 
KEGG, BioCyc, and The SEED was converted into a genome-scale metabolic model.  As described 
above, the stoichiometric matrix (S) contains the primary model information.  The fundamental equation 
used to model the system is based on the net mass balance of reactions in the network, defined by: 
dt
dx
=vS  
where dx/dt is change in metabolite concentration over time and the flux vector v represents the rate of 
biomolecular conversion for each reaction (units of mmol/gDW/hr).  Constraint-based modeling typically 
assumes steady state operation (mass into the cell equals mass out), leading to the following mass balance 
constraint: 
0=vS  
When building the model, application of physic-chemical constraints—namely mass and energy 
balance—were carefully enforced.  To mass- and charge-balance model reactions, charge information for 
each molecule was determined using (in order): (i) the BiGG database; (ii) computational pKA based 
predictions at pH 7.2; and (iii) BioCyc (see Additional File 1 in online publication for complete list).  The 
model was then mass balanced in a semi-automated fashion using charged molecular formulas.  Reactions 
with a hydrogen imbalance were balanced by altering the stoichiometric hydrogen relationship until both 
mass and charge balance were satisfied.  Reactions that could not be balanced in this manner were 
inspected manually.  Any reactions that ultimately could not be balanced were excluded from simulations.  
 
Environmental constraints were applied as bounds on individual fluxes (e.g., flux capacities, 
thermodynamics), defining the smaller solution space that represents the allowable phenotypes of the 
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model.  Irreversible reactions were constrained to positive or negative flux, depending on direction.  
Membrane transport and exchange reactions were used to transfer metabolites into and out of the cytosol 
and system boundaries, respectively.  For metabolites whose uptake or output rates were experimentally 
determined, individual bounds (e.g., glucose, acetate) were specified on the corresponding exchange 
reactions, and these were varied depending on the simulation.  Reversibility was determined by careful 
comparison of reaction direction in all databases, and the most common directionality was typically 
chosen.  Extreme pathway analysis [230, 231] was used to identify thermodynamically infeasible cycles, 
and eliminated these cycles by changing directionality of or deleting one of the participating reactions.  
 
As the constraint-based system is highly underdetermined, many solutions (i.e., flux distributions) exist 
that satisfy Sv = 0.  Therefore, Flux balance analysis (FBA) was used to determine the distribution of 
reaction fluxes that optimize a user-defined biological objective function (in our simulations, the 
commonly used biomass production objective) [93, 232].  To facilitate simulations, the model was 
formatted to be compatible with the COBRA Toolbox [225]; all model simulations were subsequently 
performed using COBRAToolbox-1.3.1 in MATLAB, with GLPK as the linear programming solver.  For 
all optimizations, the minNorm flag was on (related to the cost of enzyme production in the cell), and 
simulations were run with a negative lower bound representing a reversible reaction.  When performing 
flux variability analysis, reactions were selected that could increase or decrease by 25% of their maximal 
flux value for further analysis.  
 
To simulate biomass production, a single equation representing all macromolecules comprising one C. 
beijerinckii cell was created using known experimental compositions and compositions inferred from the 
genome.  Following the C. acetobutylicum biomass formulation used by Lee et al. [105], biomass was 
assumed to consist of: DNA, RNA, lipids, protein, peptidogylcan, and techoic acid and trace metabolites. 
DNA, RNA and protein content were calculated directly from the genome sequence, and peptiodoglycan, 
technoic acid and trace metabolites were kept similar to C. acetobutlylicum. To determine the appropriate 
lipid composition, a detailed analysis of lipid and fatty acid content in the cell was performed using data 
from [217].  See Additional File 2 in online publication for more details. 
 
4.4.3 Refinement of the genome-scale metabolic model 
 
As defined by Kumar et al., metabolites that participate in network gaps fall into two categories: non-
produced or non-consumed.  GapFind/GapFill [215] was used to identify network gaps and suggest 
reactions (from a user-specified database—in this case, the BiGG database) whose addition to the model 
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would eliminate the gap.  Suggested reactions were manually inspected for relevancy and homology 
evidence using BLASTp [214]; reactions with an E-value of 1x10-8 or less for their associated gene were 
added to the model.  This liberal cut off was used in an effort to achieve biomass growth—added 
reactions were later curated by hand, and the total number of reactions added to the final model was 
reduced. 
 
Additional model refinement was carried out using reactions described in published C. beijerinckii 
material, as well as the two published C. acetobutylicum genome-scale models [105, 106, 206].  Reactions 
added from the C. acetobutylicum models were added in the same manner as the GapFill suggestions, 
with a required BLASTp [214] E-value of no more than 1x10-8.  In only a few cases, reactions were added 
without any genomic evidence, given sufficient literature support for the reaction.  Model refinement 
continued until the model was capable of simulating accurate growth and product formation.  
 
4.4.4 Experimental data collection & analysis 
 
The four fermentation studies were conducted at different temperatures: 30°C, 33°C, 35°C, and 40°C; 
each study was run in triplicate.  Cultures of C. beijerinckii 8052 were stored in spore form at 4°C in 
sterile H2O [7].  Spores were heat shocked for 10 minutes at 80°C, immediately transferred into an ice 
bath for 5 minutes, and inoculated into a 6% glucose filter-sterilized P2YE medium [8, 233].  The 
inoculum was incubated in an anaerobic chamber under N2:CO2:H2 (volume ratio of 85:10:5) atmosphere 
for 14 hours at 35±1°C. Cell cultures were then transferred into 1 L Sixfors Bioreactors (Appropriate 
Technical Resources, Inc.) containing 400 mL 6% glucose filter-sterilized P2 medium under anaerobic 
conditions for a 100 hour total fermentation period.  Over this time period, samples were taken every 3 
hours for the first 24 hours, 6 hours for the next 12 hours, 12 hours for the next 24 hours, and then every 
24 hours for the remainder of the time.  For each sample, optical density was measured using a UV-
Visible Spectrophotometer (Thermo Scientific BioMate 3) and cell density was calculated using the 
relationship A600 = 1 equivalent to 0.28 mg/mL.  Gas chromatography (Agilent Technologies 7890A GC 
System) was used to quantify acetic acid, acetone, butyric acid, ethanol, and butanol concentrations, and 
glucose concentration was determined using high pressure liquid chromatography (Agilent Technologies 
1200 Series).  The pH was recorded throughout the fermentation. 
 
For each fermentation run, substrate uptake or product formation rates were calculated using the 
following equation [234], and then averaged across each temperature condition:  
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µ
Δ[biomass]
te]Δ[metabolirate =
. 
In this equation, [metabolite] is the metabolite concentration in mmol/L, [biomass] is the cell 
concentration in gDW/L and µ is the growth rate.  The yield Δ[metabolite]/ Δ[biomass] was determined 
by plotting metabolite concentration against biomass concentration.  Growth rate was found using an 
exponential growth fit to the biomass vs. time plots.  To test the ability of iCM925 to reproduce the 
experimental rates, an experimental “range” was defined as within one standard deviation above or below 
the mean.  This range was used to constrain the upper and lower bounds of the relevant uptake and output 
reactions in the model, and the resulting in silico growth prediction was compared to the experimental 
growth rate.  
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Chapter 54: Using the model to better understand Clostridium 
beijerinckii metabolism and predict phenotypes with improved 
butanol production  
 
A genome-scale metabolic model is a mathematical representation of the biochemical transformations in 
the metabolic network of an organism.  Models of this type provide a tool with which to interrogate 
metabolic behavior, better understand existing phenotypes, and predict the system-wide effects of genetic 
perturbations or changes in environmental conditions. This chapter includes exploration of options for 
simulating C. beijerinckii experimental phenotypes using model iCM925 [235], details on the use of that 
model to generate hypotheses for acetate and butyrate production mechanisms in C. beijerinckii mutants, 
and knockout predictions for improved butanol production.  
 
5.1 Simulating C. beijerinckii phenotypes using the iCM925 model 
 
The foundation of the genome-scale model is the stoichiometric (S) matrix, in which the entries represent 
the stoichiometric relationship between the metabolites (rows) and reactions (columns). In the constraint-
based modeling approach (see Chapter 3 and Chapter 4) [228], the steady state operation assumption 
leads to the following mass balance constraint: 
0=vS  
 
where the flux vector v represents the rate of biomolecular conversion for each reaction (units of 
mmol/gDW/hr). Environmental constraints (e.g., flux capacities, thermodynamics) are applied as bounds 
on individual fluxes to define the smaller solution saepace that represents phenotypes that can be 
simulated by the model.  In the case of metabolites for which uptake or output rates are experimentally 
determined, individual bounds can be specified (e.g., glucose, acetate) on the corresponding exchange 
reactions. As the constrained system is still highly underdetermined, many solutions (i.e., flux 
                                                      
4 Material in this chapter was reproduced with permission from portions of the following publication: Wang Y, Li X, 
Milne CB, Janssen H, Lin W, Phan G, Hu H, Jin YS, Price ND, Blaschek, HP: Development of a gene knockout 
system using mobile group II introns (Targetron) and genetic disruption of acid producing pathways in Clostridium 
beijerinckii. Appl Environ Microbiol 2013, 79(19): 5853-5863. Milne acknowledges contributions from Wang et al. 
The original publication is available online by following this link: http://aem.asm.org/content/79/19/5853.full. 
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distributions) exist that satisfy Sv = 0.  Flux balance analysis (FBA) is therefore used to determine the 
distribution of reaction fluxes that optimize a user-defined biological objective function [93, 94].  All 
model simulations discussed herein were performed using COBRAToolbox-2.0 [236] in MATLAB, with 
GUROBI 5.1.0 as the linear programming solver.   
 
Typically, the chosen objective function for use with FBA is optimal growth—it is assumed that due to 
natural selection, the primary goal of the organism is to proliferate [237].  However, with C. beijerinckii, 
the primary product of interest (butanol) is not produced until mid-exponential phase, and its production 
continues well into stationary phase. Additionally, other clostridia species are known to grow sub-
optimally in typical fermentation conditions [238]. Not surprisingly then, imposing constraints on only 
the carbon-containing substrates (e.g., glucose, acetate) and maximizing for growth with the iCM925 
model does not predict butanol production. As shown in Table 3, the model predicts that the optimal 
growth rate is achieved when acetate and hydrogen are the primary byproducts. From a mathematical 
standpoint, this is not unexpected because ATP production is stoichiometrically maximized when acetate 
and molecular hydrogen are the primary byproducts [239].  
 
Objective Biomass (h-1) Units = mmol/gDW/hr Glucose Acetate Butyrate Acetone Butanol Ethanol H2 
Max Biomass 0.35 -10 15.0 0 0 0 0 28.9 
Biomass = 0.15/hr 0.15 -10 0-23.9 0-10.2 0-10.2 0-8.8 0-17.7 0-40.6 
Min Redox1a 0.15 -10 9.3 0 0 0 10.5 6.6 
Min Redox2b 0.15 -10 14.4 0 0 0 5.2 17.9 
Min ATPc 0.15 -10 17.9 0 0 0 0 35.2 
Min Substrate 0.15 5.5 8.9 0 0 0 0 17.2 
aRedox1 is determined as the sum of the flux of all reactions facilitating the production of FDH2, NADH, NADPH, 
FDXRD bRedox2 is determined as the sum of the flux of all reactions facilitating the production of FADH2, NADH, 
NADPH (FDXRD was left out based on literature definition) cATP is defined as the sum of the flux of all reactions 
facilitating the production of ATP  
 
Table 3: Flux variability analysis for different objective functions. This table summarizes the simulated flux 
values for the following FBA objectives: biomass (both unconstrained and capped to 0.15 /hr), minimization of 
redox, minimization of ATP production, and minimization of substrate utilization. Biomass flux values as well as 
the flux values through the exchange reactions for glucose, acetate, butyrate, acetone, butanol, ethanol, and 
molecular hydrogen (H2) are reported. 
 
The inability of model iCM925 to accurately simulate C. beijerinckii phenotypes suggests either that the 
optimal growth objective is insufficient to characterize typical experimental phenotypes or that the model 
requires further refinement (e.g., filling in network gaps, accounting for thermodynamic limitations).  In 
consideration of the first explanation, simulations using the following alternative objective functions were 
compared to biomass objective function simulations: minimization of redox, minimization of ATP 
utilization, maximization of ATP utilization, and minimization of substrate uptake. These objective 
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functions were chosen because they have been evaluated on other models, though the success was varied 
[240]. The simulation results for each objective function are presented in Table 3. Also included in this 
table is a simulation where flux through the biomass equation was capped to the experimental value 
(artificially lowering the growth rate). Because FBA can result in multiple optimal solutions, flux 
variability analysis (FVA) [241] was used to calculate the range of allowable flux through the exchange 
reaction of each metabolite.  
 
The only simulation that results in a nonzero butanol flux is the one where growth is capped to the 
experimental value (Table 3). In this case, FVA finds that the butanol flux can range from 0 to 8.8 
mmol/gDW/hr, indicating that while butanol can be produced, it does not have to be produced. 
Minimization of redox resulted in simulated flux values that are closest to experimental phenotype 
because some solvent production is predicted; minimization of ATP and minimization of substrate both 
resembled maximization of biomass in that they simulated only production of acetate and hydrogen. It 
was decided that for all simulations presented herein the experimental phenotype would be represented in 
silico by either capping biomass growth to the experimental value and performing FVA to show the range 
of allowable fluxes for a given objective value or by constraining the upper and lower bounds of the main 
carbon-containing inputs and outputs (glucose, acetate, butyrate, acetone, butanol, ethanol) to their 
experimentally observed flux value.  
 
To facilitate simulations where biomass and/or substrate uptake and product secretion rates were 
constrained, the growth rate and flux rates were calculated based on experimentally determined 
fermentation profiles. Several exponential growth equations were investigated; ultimately, the best 
agreement with the experimental growth curve was found by fitting in MATLAB to the following 
equation:   𝑏𝑖𝑜𝑚𝑎𝑠𝑠 = 𝑎 + 𝑏𝑒!" 
 
where biomass can either be optical density or cell concentration, a and b are curve fitting parameters, c 
represents the growth rate, and t is time.  Substrate uptake or product formation rates were calculated 
using the following equation [234]:  
 
µ
Δ[biomass]
te]Δ[metabolirate =
. 
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In this equation, [metabolite] is the metabolite concentration in mmol/L, [biomass] is the cell 
concentration in gDW/L and µ is the growth rate.  The yield Δ[metabolite]/ Δ[biomass] was determined 
by plotting metabolite concentration against biomass concentration.    
5.2 Exploring the buk and pta mutant strains using model iCM925 
 
Previously, genetic manipulations in C. beijerinckii were very difficult to perform and therefore rationally 
engineered mutants for this strain essentially did not exist. This made it difficult to investigate the 
experimental phenotypes resulting from knockout predictions made by the iCM925 model. However, 
Wang et al. recently developed a Targetron gene knockout system for C. beijerinckii that is based on the 
mobile group II intron technology [12]. The gene knockout system was used to build pta (encoding 
phosphotransacetylase) and buk (encoding butyrate kinase) negative mutants (C. beijerinckii pta::int(17) 
and C. beijerinckii buk::int(532), respectively). Even though these strains were not predicted by the 
model, they were chosen as a starting point because they are two major byproducts in wild-type C. 
beijerinckii fermentations and they have been shown to impact solvent production in C. acetobutylicum 
[55]. They represent interesting knockout targets because (1) aside from glycolysis, the formation of 
acetate and butyrate are the main method of energy (ATP) generation for the cells, with the acetate 
pathway producing more energy per amount of glucose consumed than the butyrate pathway, and (2) the 
formation of these acids is intricately tied to the formation of butanol and other solvents.  
 
5.2.1 Details of the pta and buk negative mutants  
 
The constructed pta::int(17) and buk::int(532) mutant strains were characterized by fermentation in 3L 
Newbrunswick BioFlo® bench top bioreactors on two different growth media (P2 and MP2, differing 
only by the inclusion of acetate in the base P2 media). It was found that, compared to the wild-type strain, 
the inactivation of pta led to decreased acetate and increased butyrate accumulation during the acidogenic 
phase, and the disruption of buk resulted in a slight increase in acetate and little change in the butyrate 
production. The phenotype observed for C. beijerinckii pta::int(17) is in agreement with the energy needs 
for the cell: when one pathway is selectively disrupted, the other needs to be enhanced to make up for the 
energy shortfall [12]. Interestingly, the tradeoff was not as clearly observed in C. beijerinckii 
buk::int(532), which more closely resembled the wild-type strain. Solvent production was found to be 20-
30% higher in the buk negative mutant, and in the pta negative mutant the solvent production depended 
on the growth media (solvent production was comparable to the buk mutant only when grown on media 
without acetate). Additionally, both strains were found to utilize glucose more efficiently than the wild-
type strain.  
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Interestingly, both mutants demonstrated that the disruption of the acid production genes did not abolish 
the corresponding acid production. One explanation is residual enzyme activity; enzymatic assays 
indicated that there was still 13% Pta activity and 26% Buk activity in the pta mutant and the buk mutant, 
respectively, in contrast to the wild-type strain. Similar residual activities were found for pta and buk 
negative C. acetobutylicum strains. Another explanation is that, in the case of buk, there are three genes 
encoding for butyrate kinase (Cbei_4006, Cbei_4609, Cbei_0204), of which only one (Cbei_0204) was 
knocked out. The Cbei_0204 was chosen for the single knockout because it exhibited the highest wild-
type gene expression level of all three genes [242, 243].  It is conceivable that the observed butyrate 
production in the buk negative mutant could be attributed to the remaining two genes encoding butyrate 
kinase. In the case of pta, however, the knocked-out gene (Cbei_1164) is the only annotated gene to 
phosphate acetyl transferase. 
 
5.2.2 Simulating the pta::int(17) and buk::int(532) phenotypes using model iCM925 
 
The C. beijerinckii genome-scale model was used to explore the metabolic network of each mutant strain. 
The goal was not to use the model to predict the mutant phenotypes, but rather to simulate the observed 
network state and explore network utilization. Uptake rates and secretion rates were therefore calculated 
for glucose, acetate, butyrate, acetone, butanol, and ethanol and imposed as constraints on model iCM925. 
As described in Section 5.1, rates were calculated for the acidogenesis phase of metabolism for the wild-
type, pta::int(17), and buk::int(532) strains when grown on MP2 media.  Rates were calculated for the 
acideogensis phase of metabolism.  
 
Network states were only analyzed using model iCM925 for growth on MP2 media because it does not 
contain acetate, thereby minimizing compounding effects due to simultaneous acetate production and 
consumption. Production rates from the first 25 hours of fermentation were used because with the pta and 
buk negative mutants, the production (rather than consumption) of acetate and butyrate is of primary 
interest. To simulate each mutant, the upper and lower bounds of the model reactions corresponding to the 
gene knockouts being simulated were set to zero, preventing flux through these reactions.  In the model, 
the Cbei_1164 gene that was knocked out in the pta::int(17) mutant corresponds to the following reaction: 
 
PTA  acetyl-CoA + orthophosphate <=> acetyl phsophate + coenzyme A 
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and the Cbei_0204 gene that was knocked out in the buk::int(532) mutant corresponds to the following 
reaction:  
 
BUTK  ADP + butanoylphosphate <=> ATP + butyrate. 
 
To ensure accurate representation of the observed phenotype for each mutant, the flux through the 
biomass reaction, glucose uptake reaction, and acetate, butyrate, acetone, butanol, and ethanol secretion 
reactions were constrained by setting the upper and lower bounds of each reaction to be within 10% of the 
calculated rate.  Flux variability analysis was used to determine the flux range of each reaction in the 
model [93, 232, 241]. Simulations were run in MATLAB using the COBRA Toolbox [236], with 
GUROBI 5.1.0 as the solver.  
 
5.2.3 Insights into metabolite production rates and alternate production routes suggested by model 
iCM925  
 
The uptake and secretion rates calculated based on the experimental MP2 fermentation dynamics are 
summarized in Table 4. Interestingly, growth was found to be slightly slower for both the pta and buk 
negative mutants than for the wild-type strain, resulting in slower uptake rates and production rates for the 
mutant strains.  Also noteworthy is that while acetate was still produced by the pta negative mutant, the 
production rate was found to be significantly slower; in both the wild-type and buk negative strains the 
rate-based acetate yield (acetate rate / glucose rate) is 0.26, and in the pta negative strain it is only 0.13. 
The production rates of butyrate and butanol were found to be comparable for all three strains.  
 
Strain Growth (h-1) Calculated flux rates in units of mmol/gDW/hr Glucose Acetate Butyrate Acetone Butanol Ethanol 
NCIMB 8052 
(Wild-type) 0.11 -10.11 2.68 2.49 3.23 5.87 0.30 
pta::int(17) 0.06 -7.16 0.90 1.38 2.32 4.22 0.25 
buk::int(532) 0.07 -6.71 1.76 1.40 2.37 4.11 0.21 
 
Table 4: Calculated flux rates. Experimentally-based flux rates for growth, glucose, acetate, butyrate, acetone, 
butanol, and ethanol (a negative rate depicts an uptake rate). Rates were only calculated for fermentation on MP2 
media as this media lacks acetate and therefore gives a clear picture of the acidogenesis phase. 
 
 
Constraint-based analysis of the C. beijerinckii genome-scale model, iCM925, was used to investigate 
alternative pathways for acid production [235]. The genome-scale model is a mathematical compilation of 
genome annotation information from three independent databases, and therefore is a good representation 
of the known stoichiometric relationships in C. beijerinckii metabolism. The reaction catalyzed by 
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butyrate kinase is the only reaction capable of producing butyrate in the model; thus, the observed in vivo 
butyrate production by C. beijerinckii buk::int(532) suggests the existence of a previously uncharacterized 
mechanism, residual enzyme activity, or additional butyrate kinase encoding genes. In contrast, the model 
includes eight reactions capable of producing acetate (Table 5).  
 
*Flux balance analysis found that these reactions cannot carry flux in the pta negative mutant because they required 
actp, which is produced only in the knocked out PTA reaction. 
 
Table 5: Acetate-producing reactions in model iCM925. This table lists the seven reactions from model iCM925 
that can produce acetate (blocked reactions and reactions that only consume acetate are not included). The reaction 
name in model iCM925, the enzyme, the stoichiometric equation, and the annotated genes are included. 
 
 
Constraint-based simulations predicted that three of these seven reactions are capable of carrying 
sufficient acetate flux to meet the experimentally derived uptake and secretion rate constraints: aldehyde 
dehydrogenase (Cbei_0727, Cbei_1953), cysteine synthase (Cbei_4356, Cbei_0577, Cbei_0622, 
Cbei_0630), and acetylornithine deacetylase (Cbei_0145). These reactions offer possible mechanisms for 
the observed acetate production in C. beijerinckii pta::int(17); the corresponding production routes are 
pictured in Figure 17.   
iCM925 
Reaction  Enzyme Reaction Stoichiometry Genes 
ALDD2x aldehyde dehydrogenase acald + h2o + nad <=> ac + 2 h + nadh 
Cbei_0727 
Cbei_1953 
ADMHAH 
N6-Acetyl-LL-2,6-
diaminoheptanedioate 
amidohydrolase 
h2o + n6all26d <=> 26dap-LL + ac Cbei_1386 
ACK* ATP:acetate phosphotransferase actp + adp <=> ac + atp Cbei_1165 
ACYP_2* Acetyl phosphate phosphohydrolase actp + h2o <=> ac + h + pi Cbei_4233 
ACODA acetylornithine deacetylase acorn + h2o <=> ac + orn Cbei_0145 
NACODA N-acetylornithine deacetylase acg5sa + h2o <=> ac + glu5sa Cbei_1967 
CYSS Cysteine synthase acser + h2s <=> ac + cys-L + h 
Cbei_4356 
Cbei_0577 
Cbei_0622 
Cbei_0630 
ACCOAT acetyl-CoA hydrolase/transferase 4ohbut + accoa <=> 4hbcoa + ac Cbei_2103 
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Figure 17: Alternative acetate production pathways for the pta negative mutant as predicted by constraint-
based analysis of model iCM925. (A) aldehyde dehydrogenase route; (B) cysteine synthase route; (C) 
acetylornithine deacetylase route. The gray hashed boxes indicate a secreted product, the empty boxes indicate an 
internal metabolite, and the dotted gray lines indicate a blocked reaction as a result of the gene deletion. The thicker 
dashed lines represent the suggested alternative acetate production mechanisms. The model abbreviations for the 
metabolites and reactions included in the diagram are listed in the bottom right, along with superscripts indicated the 
reference annotation database(s) for each reaction. 
 
 
To further confirm these pathways as possible alternatives for acetate production, evidence for the 
proposed reactions was searched for in C. acetobutylicum. This was done because acid production was 
observed in the pta and buk negative C. acetobutylicum mutants, so it would seem likely that any 
alternative pathways predicted for C. beijerinckii should also be found in C. acetobutylicum [55]. 
Inclusion of the reactions in either of the two published C. acetobutylicum models was investigated as 
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well as in the KEGG and MetaCyc annotations for C. acetobutylicum. These databases were chosen as 
annotation sources for C. acetobutylicum because C. beijerinckii annotation information was largely taken 
from these two databases during construction of model iCM925. Cysteine synthase was found in both 
published genome-scale models as well as in the MetaCyc database. Aldehyde dehydrogenase was not 
found in either model or either annotation database, and evidence for acetylornithine deacetylase was only 
found in the MetaCyc annotation database (see Table 6).  
* At the time of publication of the iCM925 model, ALDD2x was not found in the MetaCyc database; however, it is 
now included in the MetaCyc annotation for C. beijerinckii. 
 
Table 6: C. acetobutylicum evidence for aldehyde dehydrogenase, cysteine synthase, and acetylornithine 
deacetylase. The inclusion of these three enzymes in the two published C. acetobutylicum genome-scale models as 
well as the KEGG and MetaCyc annotation databases is investigated. 
 
To determine whether the missing aldehyde dehydrogenase and acetylornithine deacetylase genes were 
simply a result of an incomplete annotation, a BLASTp search was conducted to look for homology 
between the C. beijerinckii genes and the C. acetobutylicum genome. For the case of aldehyde 
dehydrogenase, Cbei_0727 and Cbei_1953 showed good homology with CA_C3657 (E-value of 2E-60 
and 6E-34, respectively).  KEGG and MetaCyc have CA_C3657 annotated to glyceraldehyde-3-
phosphate dehydrogenase (EC-1.2.1.9), however, a reverse BLASTp shows an E-value of 0.0 to 
Clostridium cellulovorans and Clostridium sporogenes, suggesting that CA_C3657 could in fact encode 
for aldehyde dehydrogenase. For the case of acetylornithine deacetylase, Cbei_0145 showed good 
homology with CA_C3142 (E-value of 0.0), which matches the MetaCyc annotation. These findings 
support the possibility for acetate production in the pta negative C. acetobutylicum mutant via one or 
more of the model-predicted routes.  
 
5.3 Predicting knockouts to improve butanol production using model iCM925 
 
One of the primary goals for this dissertation was to design a C. beijerinckii strain that is capable of 
producing more butanol in fermentation cultures. Such a strain would be a step towards reducing 
Reaction Lee model [105] 
Senger model 
[106, 206] KEGG MetaCyc 
iCM925  
 
ALDD2x: EC-1.2.1.3 NO NO NO NO The SEED, MetaCyc* 
ACODA: EC-3.5.1.16 NO NO NO YES (CA_C3142) 
The SEED, 
MetaCyc 
CYSS: EC-2.5.1.47 YES (CAC0931) 
YES 
(CAC0931, 
CAC223) 
NO YES (CA_C0931) 
The SEED, 
MetaCyc 
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separation costs and increasing economic viability of sustainable butanol production.  Currently, C. 
beijerinckii NCIMB 8052 does not produce greater than 10 g/L of butanol and cannot grow in 
concentrations greater than 11 g/L (Table 7).  The discovery of BA101—a strain of C. beijerinckii 
developed using random mutagenesis—showed that if butanol production increases, tolerance to butanol 
can also go up.  In fact, C. beijerinckii BA101 was shown to produce 19 g/L of butanol and tolerate 23 
g/L [8].  In contrast, Lin and Blaschek found that tolerance could be increased by stepwise enrichment, 
and developed a strain capable of growing in up to 18.6 g/L of butanol [57]; however, there was not a 
corresponding increase in butanol production.  
 
Strain Butanol Production Butanol Tolerance 
C. beijerinckii NCIMB 8052 10 g/L 11 g/L 
C. beijerinckii BA101 19 g/L 23 g/L 
 
Table 7 – Strains of C. beijerinckii.  Comparison of butanol production and tolerance for C. beijerinckii NCIMB 
8052 and BA101. 
 
The ability of BA101 to produce nearly twice as much butanol in fermentation as NCIMB 8052 provides 
assurance that NCIMB 8052 is not stoichiometrically limited in its ability to produce butanol. This was 
shown again to be true in the pta and buk negative mutants built by Wang et al. (see Section 5.2), both of 
which showed an increase in butanol production compared to wild-type. To identify the most effective 
knockout strategies, the model was used to investigate potential metabolic modifications that would 
maximize the flow of carbon to butanol. Specifically, one to three reactions for which removal resulted in 
simulations with predicted butanol production rate were sought.  The simulations of most interest were 
those that made butanol production a requirement of growth—in other words, knockouts that redefined 
the solution space of the model such that biomass production could not be achieved without the also 
sending maximal (or close to maximal) flux through the butanol production reactions (see Figure 18).   
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Figure 18. Conceptual overview of knockout algorithms aiming to align growth with an engineering objective.  
 
Knockout predictions were generated using three main approaches: 1) OptKnock, a bilevel optimization 
algorithm published by Burgard et al. [97] seeking to align production of a target compound with 
simulated growth; 2) the “brute force” approach of simply investigating the effects of single, double, and 
triple knockouts of the reactions leading to production of the primary observed byproducts in wild-type 
fermentations (acetate, butyrate, ethanol, acetone, molecular hydrogen) were investigated; and 3) 
RobustKnock, an improved version of OptKnock published by Tepper and Shlomi in 2010 [244]. While 
the predictions from each approach differed slightly, they all converged to the same basic information: 
limiting hydrogen production and/or limiting the production of both acetate and butyrate (simultaneously) 
would lead to increased butanol production. Encouragingly, this conclusion agrees with published C. 
acetobutylicum studies as well.  
 
It is important to note that in all simulations discussed below the knockouts are reaction knockouts rather 
than gene knockouts. The leading reaction knockout candidates can be translated to experimental gene 
knockouts using the gene-protein-reaction relationships defined in model iCM925.  
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5.3.1 Understanding the relationship between butanol and other byproducts 
 
In addition to butanol, the major C. beijerinckii byproducts include acetate, butyrate, acetone, ethanol, 
molecular hydrogen, and biomass. A robustness analysis was conducted to explore the relationship 
between each of these byproducts and the formation of butanol. This analysis was performed by 
iteratively defining the flux through one reaction (the independent variable) and then maximizing the flux 
through the target reaction (the dependent variable). Such an analysis calculates the maximum flux 
possible through a target reaction given different fluxes through a particular control reaction—providing 
information the impact one reaction has on the other. A series of robustness analyses were performed with 
butanol as the objective function (target reaction) and each of the above mentioned byproducts, in turn, as 
the control reaction (Figure 19).  
 
Because C. beijerinckii can consume butyrate and acetate, the flux through the exchange for these 
reactions was allowed to be either negative (indicating consumption) or positive (indicating production). 
In the butanol-butyrate relationship (Figure 19), butanol production is maximized when the rate of 
butyrate uptake is maximized (representing the case where butyrate would be present in the media). This 
is not surprising because the consumption of butyrate produces butyrl-CoA, which is then converted to 
butanol. In the butanol-acetate relationship, it was found that butanol production is actually maximized 
when acetate is neither significantly consumed nor secreted. This relationship is more surprising because 
the addition of acetate has been found experimentally to improve final butanol concentrations [58, 245]; 
however, the disagreement is likely because the metabolic model misses the role acetate and pH play in 
stimulating the switch to solventogenesis. Simulations predicted that acetone, ethanol, and molecular 
hydrogen are all detrimental to butanol production, with maximal butanol production occurring when flux 
through the exchange reactions for these metabolites was set to zero. Biomass was also predicted to 
compete with butanol production, however, an inflection point was observed around a growth rate of 0.15 
/hr. This suggests that at growth rates lower than 0.15 /hr there would be little improvement to butanol 
production.    
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Figure 19: Butanol robustness analyses, unconstrained hydrogen. A butanol robustness analysis was conducted 
with each of the following metabolites as the control metabolite: butyrate, acetate, acetone, ethanol, hydrogen, and 
biomass. This was done to visualize the relationship between each of these metabolites and butanol production. All 
investigated metabolites were found to compete with butanol. No additional constraints were placed on hydrogen 
flux in these simulations. 
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The impact of capping hydrogen production on the butanol-biomass curve was also investigated because 
hydrogen production for optimal growth simulations in model iCM925 is unnaturally high. In Figure 20, 
hydrogen production was limited to a maximal value of 10 mmol/gDW/hr (left side) and hydrogen 
production was prevented entirely (flux = 0 mmol/gDW/hr) (right side). With a 10 mmol/gDW/hr cap on 
hydrogen production the maximum achievable growth rate (corresponding to zero butanol production) 
was lowered as compared to the case where hydrogen was unconstrained, with a minimum butanol 
production of ~2.75 mmol/gDW/hr. In the case where hydrogen flux was set to 0 mmol/gDW/hr, the 
maximal growth rate became 0.15 /hr (the inflection point discussed above) and the minimal butanol 
production was quite high. In both of these cases, the new butanol-biomass relationship was simply a 
subset of the relationship observed when hydrogen was unconstrained. NAD+ can be regenerated either 
by hydrogen production or by butanol production, so the fact that limiting hydrogen production was 
found by the model to result in required butanol production is not surprising (see Chapter 4 for a more 
detailed discussion on the butanol-hydrogen relationship).  
 
 
Figure 20: Butanol robustness analyses, hydrogen constrained. The relationship between biomass and butanol 
was investigated for two simulations where H2 flux capped by setting the upper bound of reaction ‘ex_H2(e)’ to 10 
mmol/gDW/hr (left figure) and 0 mmol/gDW/hr (right figure). Restricting hydrogen flux was found to increase the 
required butanol production and decrease the maximum growth rate. 
 
 
Each of the above robustness analyses predicts that the observed production of acetate, butyrate, acetone, 
ethanol, and hydrogen all compete with the production of butanol. This means that reducing or 
eliminating production of these byproducts should result in the highest achievable butanol production 
rates. Additionally, this analysis showed the relationship between butanol and biomass, with an 
interesting inflection point at biomass growth = 0.15 /hr.     
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5.3.2 Predicting knockouts using OptKnock 
 
The first computational approach employed for suggesting possible knockout strategies to increase 
butanol production was OptKnock, a bi-level optimization problem that aims to adjust the metabolic 
network so that production of the product of interest (butanol in this case) becomes an obligatory 
byproduct of growth (or otherwise specified cellular objective) [97].  This is achieved by nesting two 
optimization problems—the inner optimization serves to define the flux allocation for optimal biomass 
(or otherwise defined objective) and the outer problem then maximizes the engineering objective (e.g., 
butanol) by selecting reactions to delete from the inner problem.  In this way, OptKnock seeks deletions 
that do not interfere with production of necessary biomass components. OptKnock has previously been 
applied by multiple research groups to improve the production of succinate, lactate, 1,3-propanediol, and 
amino acids [153, 157, 246].  
 
The COBRA Toolbox implementation of the OptKnock algorithm was applied to model iCM925 to find 
single and double knockouts that lead to the highest improvement in butanol production. Simulations for 
the case where the production of hydrogen was left unconstrained (Table 8 and 9) were performed as 
well as the case where hydrogen was constrained to a maximal value of 20 mmol/gDW/hr (Table 10 and 
11). The alternative knockout sets listed in the table were found by removing one or both of the predicted 
reactions from the deleteable reaction set. Interestingly, in all knockout suggestions the predicted biomass 
flux was approximately 0.15 /hr, the value observed at the inflection point of the butanol-biomass 
robustness analysis. 
 
As a control for the case where hydrogen was unconstrained, a simulation for the case of zero knockouts 
was conducted; OptKnock found biomass flux to be 0.35 /hr and butanol flux to be 0 mmol/gDW/hr. As 
seen in Table 8, with unconstrained hydrogen flux, OptKnock predicted only one single knockout option 
for improved butanol production: FDXNH (ferredoxin hydrogenase, reduced ferredoxin + 2 h <=> 
oxidized ferredoxin + h2). Given the above discussed impact of hydrogen on butanol production, it is not 
surprising that OptKnock found this knockout. 
 
  
 
 
 
Table 8: Single deletion OptKnock predictions with constraints only added to glucose uptake rate. 
  
 
KO iteration # Butanol 
(mmol/gDW/hr) 
Biomass 
(/hr) 
Knockout 
1 8.77 0.155 FDXNH 
2 0 0.350 -- 
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For the case of double knockouts with unconstrained hydrogen production (Table 9), OpKnock had 36 
suggestions with slightly higher butanol production than the single knockout case. In all but two of the 
suggestions, FDXNH was suggested as one of the two knockouts—having the primary effect on the 
double knockout success. In the three leading double knockout suggestions, FDXNH is paired with 
ADMHAH, THPAT, or ADAHTA, which are as follows:  
 
ADMHAH h2o + N6-Acetyl-LL-2,6-diaminoheptanedioate <=> LL-2,6-Diaminoheptanedioate + acetate  
THPAT  acetyl-coa + h2o + 2,3,4,5-Tetrahydrodipicolinate --> coa + N-Acetyl-L-2-amino-6-oxopimelate 
ADAHTA 2-oxoglutarate + N6-Acetyl-LL-2,6-diaminoheptanedioate <=> glu-L + N-Acetyl-L-2-amino-6-oxopimelate  
 
When these three reactions are considered together, they result in the overall conversion of acetyl-coa and 
2,3,4,5-Tetrahydrodipicolinate to LL-2,6-Diaminoheptanedioate and acetate. Because the deletion of any 
of these three reactions with FDXNH results in an equally optimal prediction, it is likely that disruption of 
the overall reaction was the advantageous aspect.  2,3,4,5-Tetrahydrodipicolinate production can be traced 
back to homoserine and aspartate, and LL-2,6-Diaminoheptanedioate eventually leads to biomass 
production. The two double knockouts predicted that did not contain FDXNH were ACK/BUTK (acetate 
kinase and butyrate kinase) and PTA/BCOPBT (phosphate acetyltransferase and phosphate 
butanoyltransferase), both effectively knocking out the canonical acetate and butyrate production 
pathways.  
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KO iteration # Butanol 
(mmol/gDW/hr) 
Biomass 
(/hr) 
Knockout 1 Knockout 2 
1 8.81 0.152 ADMHAH FDXNH 
2 8.81 0.152 THPAT FDXNH 
3 8.81 0.152 ADAHTA FDXNH 
4 8.80 0.152 THRD_L FDXNH 
5 8.79 0.152 CYTK1 FDXNH 
6 8.78 0.153 ADK1 FDXNH 
7 8.78 0.153 ACK BUTK 
8 8.78 0.153 PTA BCOPBT 
9 8.78 0.143 HSK FDXNH 
10 8.78 0.143 THRS FDXNH 
11 8.78 0.154 PAPA_CB FDXNH 
12 8.78 0.154 GLUR FDXNH 
13 8.78 0.154 ALATA_D FDXNH 
14 8.78 0.154 ALAR FDXNH 
15 8.78 0.154 PPM FDXNH 
16 8.78 0.154 FRDK FDXNH 
17 8.78 0.154 PART FDXNH 
18 8.78 0.154 FMPDP FDXNH 
19 8.77 0.155 CBMK FDXNH 
20 8.77 0.155 SADT FDXNH 
21 8.77 0.155 DURAD FDXNH 
22 8.77 0.155 DHPM1 FDXNH 
23 8.77 0.155 UPPN FDXNH 
24 8.77 0.155 ORNTAC FDXNH 
25 8.77 0.155 ASP1DC FDXNH 
26 8.77 0.155 IMPD FDXNH 
27 8.77 0.155 GMPS FDXNH 
28 8.77 0.155 URIDK2 FDXNH 
29 8.77 0.155 CTPS1 FDXNH 
30 8.77 0.155 DHPS FDXNH 
31 8.77 0.155 NADS1 FDXNH 
32 8.77 0.155 ANS2 FDXNH 
33 8.77 0.155 SPT FDXNH 
34 8.77 0.155 G3PD1 FDXNH 
35 8.77 0.155 XYLI2 FDXNH 
36 8.77 0.155 FDXNRx FDXNH 
37 8.77 0.155 ---- FDXNH 
38**only if 
FDXNRx is 
added back in 
to deleteable 
reaction set 
4.67 0.246 FDXNRx HACD1x 
 
Table 9: Double deletion OptKnock predictions with constraints only added to glucose uptake rate. 
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For the simulation cases where hydrogen production was capped at a maximal value of 20 mmol/gDW/hr, 
the zero knockout simulation showed a biomass production rate of 0.29 /hr and a butanol production rate 
of 2.70—slightly higher than the case where hydrogen is unconstrained and also in agreement with the 
robustness analyses discussed above. As with the case of unconstrained hydrogen, the single best 
knockout was still predicted to be ferredoxin hydrogenase (FDXNH) (Table 10). While alternative single 
knockouts were found by OptKnock, the butanol flux rate was only slightly above the baseline value of 
2.70, so these knockout options were discarded as having too little impact. For the double knockout case, 
the one reaction set that was found (FDXNH/THPAT) was also found in the case of unconstrained 
hydrogen (Table 11).  
 
KO iteration # Butanol 
(mmol/gDW/hr) 
Biomass 
(/hr) 
Knockout 
1 8.77 0.155 FDXNH 
2 2.93 0.274 HSK 
3 2.93 0.274 THRS 
4 2.77 0.284 ADAHTA 
 
Table 10: Single deletion OptKnock predictions with constraints placed on glucose and hydrogen flux. 
 
KO iteration # Butanol 
(mmol/gDW/hr) 
Biomass 
(/hr) 
Knockout 1 Knockout 2 
1 8.81 0.152 FDXNH THPAT 
 
Table 11: Double deletion OptKnock predictions with constraints placed on glucose and hydrogen flux. 
 
The top knockout cases (FDXNH and FDXNH/ADMHAH) were implemented in model iCM925 by 
setting the upper and lower bounds of the relevant reaction to zero, and the impact on the flux distribution 
was evaluated using FBA and FVA. As can be seen in Table 12, knocking out ferredoxin hydrogenase 
does in fact enable a higher butanol flux rate.  However, it does not make a higher flux rate a requirement 
of growth, as was expected from the OptKnock algorithm. With this knockout, the simulations show that 
either butanol or ethanol can be made without changing the growth rate.  Simulations for the FDXNH and 
ADHMAH knockout showed a slightly reduced growth rate and acetate and butyrate flux capability along 
with a slightly increased ability to produce butanol and/or ethanol. This is not surprising because acetate 
is a product in the ADHMAH reaction and by reducing the carbon flow to acetate with this knockout, 
there is more carbon available to divert to either butanol or ethanol.  
 
 
 
 
82 
 
 
 
Biomass 
(h-1) 
Units = mmol/gDW/hr 
Acetate Butyrate Acetone Butanol Ethanol H2 
Wild-type 0.350 15.0 0 0 0 0 28.9 
FDXNH 0.155 0.103-0.566 0-0.463 0 0-8.77 0-17.5 0 
FDXNH+ 
ADMHAH 0.152 0.027-0.370 0-0.343 0 0-8.81 0-17.6 0 
 
Table 12: Flux variability analysis of top OptKnock predictions. 
 
The discovery that the OptKnock predictions did not yield in silico mutants for which butanol was a 
requirement of growth was a perplexing one and warranted further investigation. For better visualization, 
production envelope figures were generated for the wild-type strain and mutant strains. These were 
generated in a similar way to the robustness analyses except that here butanol flux was the independent 
variable and growth rate the dependent variable (to make growth the objective function). In these plots, 
the blue solid line describes the solution space of the model as it pertains to biomass and butanol flux, and 
the red dot indicates the optimal point found by FBA. For the wild-type strain, biomass flux is maximized 
when butanol production is minimized, at the above mentioned value of 0.35 /hr. In the case of the 
FDXNH in silico mutant, the solution space is redefined such that the optimal point found by FBA is the 
inflection point observed in the above robustness analyses—where biomass flux is 0.155 /hr and butanol 
flux is 8.77 /hr. The concern with this knockout prediction is that the value of the objective function 
(growth) does not change when butanol flux decreases—as is evident by horizontal line defining the 
solution space. The same relationship was observed for the FDXNH/ADMHAH knockout prediction 
(Figure 21).  
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Figure 21: Production envelopes for wild-type and leading OptKnock strains. (A) Wild-type; (B) FDXNH 
(ferredoxin hydrogenase) knockout; (C) FDXNH+ADMHAH (ferredoxin hydrogenase and N-
acetyldiaminopimelate deacetylase) knockout.  
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5.3.3 Effects of knocking out major byproducts – i.e., the “Brute Force” approach 
 
The OptKnock predictions were found to be unsatisfactory because they did not make butanol production 
an obligatory part of cell growth. This is an important requirement because organisms will naturally resist 
any external genetic or environmental perturbations [247]. To explore more fruitful knockout candidates a 
single, double, and triple knockout analyses that targeted the canonical production route were conducted. 
The following five major metabolites produced as byproducts to C. beijerinckii metabolism were included 
in the knockout study: acetate, butyrate, acetone, ethanol, and molecular hydrogen. Production of any 
combination of these metabolites will divert cell resources away from butanol formation. As with the 
OptKnock analysis, knockouts were assessed for the case where hydrogen is unconstrained and the case 
where hydrogen production is capped to a maximal value of 20 mmol/gDW/hr. In this study, the case 
where hydrogen production was unconstrained but biomass production was capped to a maximal value of 
0.1 /hr—slightly below the inflection point value of 0.155 /hr—was also investigated.  
 
The model reactions tested (listed in Table 13) were ACK (acetate kinase), BUTK (butyrate kinase), 
ADC (acetoacetate carboxylyase), ALCD2 (alcohol dehydrogenase), and FDXNH (ferredoxin 
hydrogenase). These are the final reactions in the production route for each of the above mentioned 
metabolites; there are of course upstream reactions (e.g., phosphate acetyltransferase) that could be 
deleted instead of these primary reactions. However, for the purposes of this study it is sufficient to 
disrupt the end reaction in the pathway, and genes for a knockout study can be chosen from either the 
primary or upstream reactions. For each in silico knockout, FVA was performed to assess the production 
range of each metabolite. All reported fluxes are in units of mmol/gDW/hr.  
 
 Model Rxn EC # Stoichiometry Genes 
Acetate ACK 2.7.2.1 acetylphosphate+ adp <=> acetate + atp Cbei_1165 
Butyrate BUTK 2.7.2.7 adp + butanoylphosphate <=> atp + butyrate 
Cbei_4006 
Cbei_4609 
Cbei_0204 
Acetone ADC 4.1.1.4 acetoacetate + h <=> acetone + co2 Cbei_3835 
Ethanol ALCD2 1.1.1.1 ethanol + nad <=> acetaldehyde + h + nadh Cbei_0305 
Hydrogen FDXNH 1.12.7.2 reduced ferredoxin + 2 h <=> oxidized ferredoxin + h2 
Cbei_0327 
Cbei_4000 
Cbei_3796 
 
Table 13: Production reactions for primary C. beijerinckii byproducts. 
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In the simulation scenario where both biomass and molecular hydrogen were unconstrained, (Table 14) 
knockouts containing FDXNH or BUTK+ACK resulted in the maximum butanol flux, as was predicted 
by OptKnock. Both of these knockout sets hit the transition point in the butanol-biomass relationship (see 
Section 5.3.1) that occurs at a biomass flux rate of approximately 0.15 /hr. This knockout approach 
showed that knocking out ALCD2 in addition to FDXNH would make butanol production an obligatory 
aspect of cell growth, a prediction OptKnock did not find. This double knockout candidate is not 
surprising because model iCM925 shows that, stoichiometrically, NAD+ can be regenerated by the 
production of molecular hydrogen, ethanol, or butanol (see Chapter 2). By knocking out two of the three 
redox balancing pathways, butanol becomes the only remaining option, making its production a 
requirement of cell growth. The minimum required butanol production was highest for the triple knockout 
BUTK+ALCD2+FDXNH. This is likely because some NAD+ is regenerated in the production of 
butyrate; by removing this pathway as well, even more flux must be sent to butanol.  
 
 Biomass 
(h-1) 
Units = mmol/gDW/hr 
Acetate Butyrate Acetone Butanol Ethanol H2 
Wild-type 0.350 15.0 0 0 0 0 28.89 
ACK 0.260 0.173 0-8.06 0-8.06 0 0 15.6-31.7 
BUTK 0.350 15.0 0 0 0 0 28.89 
ADC 0.350 15.0 0 0 0 0 28.89 
ALCD2 0.350 15.0 0 0 0 0 28.89 
FDXNH 0.155 0.103-0.566 0-0.463 0 0-8.77 0-17.5 0 
ACK + BUTK 0.153 0-17.8 0 0-8.91 0-8.78 0-17.6 0-35.1 
ACK + ADC 0.260 0.173 8.06 0 0 0 15.6 
ACK + ALCD2 0.260 0.173 0-8.06 0-8.06 0 0 15.6-31.7 
ACK + FDXNH  0.155 0.103 0.145-0.463 0 0-8.70 0-17.4 0 
BUTK + ADC 0.350 15.0 0 0 0 0 28.89 
BUTK + ALCD 0.350 15.0 0 0 0 0 28.89 
BUTK + FDXNH 0.155 0.249-0.566 0 0 0-8.77 0-17.5 0 
ADC + ALCD2 0.350 15.0 0 0 0 0 28.89 
ADC + FDXNH 0.155 0.103-0.566 0-0.463 0 0-8.76 0-17.5 0 
ALCD2 + FDXNH 0.155 0.103-0.566 0-0.463 0 8.43-8.77 0 0 
ACK+BUTK+ADC 0.153 0.246-17.8 0 0 0-8.78 0-17.6 0-35.1 
ACK+BUTK+ALCD2 0.153 0-17.8 0 0-8.91 0-8.78 0 0-35.1 
ACK+BUTK+FDXNH 0.153 0-0.247 0 0-0.123 0-8.78 0-17.6 0 
ACK+ADC+ALCD2 0.260 0.173 8.06 0 0 0 15.6 
ACK+ADC+FDXNH 0.155 0.103 0.147-0.463 0 0-8.70 0-17.4 0 
ACK+ALCD2+FDXNH 0.155 0.103 0.147-0.463 0 8.43-8.70 0 0 
BUTK + ADC + ALCD2 0.350 15.0 0 0 0 0 28.89 
BUTK + ADC + FDXNH 0.155 0.250-0.566 0 0 0-8.77 0-17.5 0 
BUTK + ALCD2 + FDXNH 0.155 0.250-0.566 0 0 8.66-8.77 0 0 
ADC + ALCD2 + FDXNH 0.155 0.103-0.566 0-0.463 0 8.43-8.77 0 0 
 
Table 14: Single, double, and triple knockout study for reactions producing acetate, butyrate, acetone, 
ethanol, and molecular hydrogen (only glucose uptake rate constrained). The entries in this table represent the 
simulated flux range for each knockout. Knocking out any combination that included ALCD2 (responsible for 
ethanol production) and FDXNH (responsible for hydrogen production) resulted in mandatory butanol production.  
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The scenario in which biomass flux was capped to a value below the 0.15 /hr inflection point was also 
investigated (Table 15). Here, the maximum butanol flux was the same for both the wild-type and 
knockout strains. The only knockout set found to require butanol production was 
BUTK+ALCD2+FDXNH—the knockout set found to have the highest minimum butanol flux in the 
scenario where biomass was not limited.  
 
 
 Biomass 
(h-1) 
Units = mmol/gDW/hr 
Acetate Butyrate Acetone Butanol Ethanol H2 
Wild-type 0.1 0-26.1 0-11.1 0-11.2 0-9.22 0-18.4 0-42.7 
ACK 0.1 0-19.6 0-11.1 0-11.2 0-9.22 0-18.4 0-41.9 
BUTK 0.1 0-26.1 0 0-11.2 0-9.22 0-18.4 0-42.7 
ADC 0.1 0.018-26.1 0-11.1 0 0-9.22 0-18.4 0-42.8 
ALCD2 0.1 0-26.1 0-11.1 0-11.2 0-9.22 0 0-42.8 
FDXNH 0.1 0-12.6 0-11.1 0-2.52 0-9.22 0-18.4 0 
ACK + BUTK 0.1 0-19.6 0 0-9.8 0-9.22 0-18.4 0-40.1 
ACK + ADC 0.1 0.018-19.6 0-11.1 0 0-9.22 0-18.4 0-40.1 
ACK + ALCD2 0.1 0-19.6 0-11.1 0-11.2 0-9.22 0 0-41.9 
ACK + FDXNH  0.1 0-3.20 0-11.1 0-2.52 0-9.22 0-18.4 0 
BUTK + ADC 0.1 0.018-26.1 0 0 0-9.22 0-18.4 0-42.8 
BUTK + ALCD 0.1 0-26.1 0 0-11.2 0-9.22 0 0-42.8 
BUTK + FDXNH 0.1 0-12.6 0 0-2.52 0-9.22 0-18.4 0 
ADC + ALCD2 0.1 0.018-26.1 0-11.1 0 0-9.22 0 0-42.8 
ADC + FDXNH 0.1 0.018-12.6 0-11.1 0 0-9.22 0-18.4 0 
ALCD2 + FDXNH 0.1 0-12.6 0-11.1 0-2.52 0-9.22 0 0 
ACK+BUTK+ADC 0.1 0.018-19.6 0 0 0-9.22 0-18.4 0-40.1 
ACK+BUTK+ALCD2 0.1 0-19.6 0 0-9.8 0-9.22 0 0-40.1 
ACK+BUTK+FDXNH 0.1 0-3.20 0 0-1.6 0-9.22 0-18.4 0 
ACK+ADC+ALCD2 0.1 0.018-19.6 0-11.1 0 0-9.22 0 0-40.1 
ACK+ADC+FDXNH 0.1 0.018-3.2 0-11.1 0 0-9.22 0-18.4 0 
ACK+ALCD2+FDXNH 0.1 0-3.2 0-11.1 0.2.52 0-9.22 0 0 
BUTK+ADC+ALCD2 0.1 0.018-26.1 0 0 0-9.22 0 0-42.8 
BUTK+ADC+FDXNH 0.1 0.018-12.6 0 0 0-9.22 0-18.4 0 
BUTK+ALCD2+FDXNH 0.1 0-12.6 0 0-2.52 5.06-9.22 0 0 
ADC+ALCD2+FDXNH 0.1 0.018-12.6 0-11.1 0 0-9.22 0 0 
 
Table 15: Single, double, and triple knockout study for reactions producing acetate, butyrate, acetone, 
ethanol, and molecular hydrogen (glucose uptake rate and biomass production constrained). The entries in this 
table represent the simulated flux range for each knockout. Knocking out BUTK (responsible for butyrate 
production), ALCD2 (responsible for ethanol production), and FDXNH (responsible for hydrogen production) 
resulted in mandatory butanol production.  
 
 
Finally, each knockout was again simulated for the case where biomass flux was unconstrained but 
hydrogen flux was capped to 20 mmol/gDW/hr. In this scenario, butanol could be produced at a low flux 
rate in the wild-type strain (Table 16). Interestingly, the ACK, ACK+ADC, ACK+ALCD2, or 
ACK+ADC+ALCD2 prevented butanol from being produced entirely. These strains all had growth rates 
just below the growth rate observed for the wild-type strain and required significant flux through the 
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butyrate pathway. In these predictions the higher growth rate is maintained by production of ATP solely 
through the butyrate kinase reaction; because butyrate contains more carbon than acetate, this likely 
leaves no carbon to be diverted to butanol. It was found that knocking out ALCD2+FDXNH, 
ACK+BUTK+ALCD2, ACK+ALCD2+FDXNH, BUTK+ALCD2+FDXNH, or ADC+ALCD2+FDXNH 
led to the highest minimum and maximum flux through butanol. The driving force between all but the 
ACK+BUTK+ALCD2 knockout set is the double ALCD2+FDXNH knockout discussed above. In an 
ACK+BUTK knockout strain, butanol would be produced via the “direct” route from acetyl-CoA as 
opposed to indirectly through butyrate. Importantly, knocking out the ability to produce acetate and 
butyrate through the canonical production pathways in C. acetobutylicum led to increased butanol 
production. ALCD2 is required as a third deletion in the predicted knockout set to eliminate the equally 
favorable regeneration of NAD+ through ethanol. Finally, BUTK+ALCD2 and BUTK+ADC+ALCD2 
were also found to require butanol production, but at a lower maximum flux rate.  
 
 Biomass 
(h-1) 
Units = mmol/gDW/hr 
Acetate Butyrate Acetone Butanol Ethanol H2 
Wild-type 0.290 5.07-11.1 0-5.40 0 0-2.70 0-5.40 20 
ACK 0.260 0.173 5.86-8.06 0-2.19 0 0 15.6-20 
BUTK 0.290 10.5-11.1 0 0 0-2.70 0-5.40 20 
ADC 0.290 5.07-11.1 0-5.40 0 0-2.70 0-5.40 20 
ALCD2 0.290 5.07-11.1 0-5.40 0 0-2.70 0 20 
FDXNH 0.155 0.103-0.566 0-0.463 0 0-8.77 0-17.5 0 
ACK + BUTK 0.153 0-10.2 0 0-5.12 0-8.78 0-17.6 0-20 
ACK + ADC 0.260 0.173 8.06 0 0 0 15.6 
ACK + ALCD2 0.260 0.173 5.86-8.06 0-2.19 0 0 15.6-20 
ACK + FDXNH  0.155 0.1028 0.147 0 0-8.70 0-17.4 0 
BUTK + ADC 0.290 10.5-11.1 0 0 0-2.70 0-5.40 20 
BUTK + ALCD2 0.290 10.5-11.1 0 0 2.50-2.70 0 20 
BUTK + FDXNH 0.155 0.249-0.566 0 0 0-8.77 0-17.5 0 
ADC + ALCD2 0.290 5.07-11.1 0-5.40 0 0-2.70 0 20 
ADC + FDXNH 0.155 0.103-0.566 0-0.463 0 0-8.77 0-17.5 0 
ALCD2 + FDXNH 0.155 0.103-0.566 0-0.463 0 8.43-8.77 0 0 
ACK+BUTK+ADC 0.153 0.246-10.2 0 0 0-8.78 0-17.6 0-20 
ACK+BUTK+ALCD2 0.153 0-10.2 0 0-5.12 3.78-8.78 0 0-20 
ACK+BUTK+FDXNH 0.153 0-0.247 0 0-0.123 0-8.78 0-17.6 0 
ACK+ADC+ALCD2 0.260 0.173 8.06 0 0 0 15.6 
ACK+ADC+FDXNH 0.155 0.103 0.147-0.463 0 0-8.70 0-17.4 0 
ACK+ALCD2+FDXNH 0.155 0.103 0.147-0.463 0 8.43 0 0 
BUTK+ADC+ALCD2 0.290 10.5-11.1 0 0 2.50-2.70 0 20 
BUTK+ADC+FDXNH 0.155 0.250-0.566 0 0 0-8.77 0-17.5 0 
BUTK+ALCD2+FDXNH 0.155 0.250-0.566 0 0 8.66-8.77 0 0 
ADC+ALCD2+FDXNH 0.155 0.103-0.566 0-0.463 0 8.43-8.77 0 0 
 
Table 16: Single, double, and triple knockout study for reactions producing acetate, butyrate, acetone, 
ethanol, and molecular hydrogen (glucose uptake rate and hydrogen production constrained). The entries in 
this table represent the simulated flux range for each knockout. Knocking out ALCD2 (responsible for ethanol 
production) and FDXNH (responsible for hydrogen production) resulted in mandatory butanol production.  
 
88 
 
 
As was done with the leading OptKnock predictions, the production envelopes for the leading predictions 
found via the “brute force” approach were generated. Production envelopes for the FDXNH+ALCD2 and 
FDXNH+ALCD2+BUTK knockout sets were created because they had a similar impact in the three 
tested scenarios (note that FDXNH+ALCD2 was not found to require butanol production in the scenario 
where biomass flux was limited). Even though it was only found as a promising option in the case where 
flux through molecular hydrogen was constrained, the production envelope for ACK+BUTK+ALCD2 
was also drawn. This was done for two reasons: (1) preventing production of acetate and butyrate through 
the canonical production routes has successfully improved butanol production in C. acetobutylicum and 
(2) hydrogen is not experimentally found to be the main byproduct in solventogenic Clostridia 
fermentations, so capping hydrogen flux mimics the more typical phenotype—lending credit to the 
knockout predictions generated under this simulation condition. In the production envelopes, the desired 
relationship between butanol production and biomass is observed because the solution space demonstrates 
that butanol and biomass flux decrease simultaneously (Figure 22).  
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Figure 22: Production envelopes for leading “brute force” predictions. (A) FDXNH+ALCD2 (ferredoxin 
hydrogenase and aldehyde dehydrogenase) knockout; (B) FDXNH+ALCD2+BUTK (ferredoxin hydrogenase, 
aldehyde dehydrogenase, and butyrate kinase) knockout; (C) BUTK+ACK+ALCD2 (butyrate kinase, acetate kinase, 
and aldehyde dehydrogenase) knockout.  
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5.3.4 Knockout predictions from RobustKnock 
 
RobustKnock was designed by Tepper and Shlomi [244] to address the limitation in the OptKnock 
algorithm that enables non-growth coupled predictions. The OptKnock limitation arises in cases where 
there are competing pathways like those found above, resulting in a range of possible product fluxes for 
the same optimal biomass value. In these cases, the OptKnock formulation chooses the highest value for 
the target reaction flux, even if the minimum flux through that reaction is zero. RobustKnock addresses 
the issue of competing pathways (thereby improving upon OptKnock) using a bi-level max-min 
optimization algorithm. The outer problem searches for knockouts that maximize the minimum flux 
through the target reaction and the inner problem maximizes biomass subject to the knockout constraints 
set by the outer problem.  
 
RobustKnock was executed to search for single, double, and triple knockout predictions guaranteed to 
couple butanol production to growth. RobustKnock did not find a single knockout reaction capable of 
stiochiometrically coupling butanol and biomass projection (Table 17).  For the double knockout, 
RobustKnock predicted that knocking out ALCD2 (aldehyde dehydrogenase, responsible for ethanol 
production) and FDXNH (ferredoxin hydrogenase, responsible for molecular hydrogen production) would 
optimize biomass-linked butanol production. Interestingly, in the case of the triple knockout, 
RobustKnock was able to find a knockout set that performed better than the ALCD2+FDXNH+BUTK 
knockout found using the “brute force” approach. Instead of BUTK as the third reaction, RobustKnock 
suggested knocking out HSK, which encodes homoserine kinase. The irreversible stoichiometric equation 
for HSK is: atp + L-homoserine => adp + O-phospho-L-homoserine. Adding HSK to the 
ALCD2+FDXNH knockout makes the minimum butanol production equivalent to the maximum butanol 
production, though it is presently unclear what role HSK plays in the metabolic network that leads to this 
effect.  
 
Deletion Type Butanol 
(mmol/gDW/hr) 
Biomass 
(/hr) 
Knockout 1 Knockout 2 Knockout 3 
Single -- -- NONE  N/A N/A 
Double 8.43-8.77 0.155 ALCD2 FDXNH N/A 
Triple 8.78 0.143 ALCD2 FDXNH HSK 
 
Table 17: Single, double, and triple deletion RobustKnock predictions, with an added flux constraint imposed 
on glucose uptake only.  
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As with the other knockout study, the leading RobustKnock prediction was visualized by generating the 
butanol-biomass production envelope (Figure 23). While the range of allowable butanol production for 
this knockout is in fact lesser than the above predicted ALCD2+FDXNH+BUTK knockout set, the impact 
on the butanol-biomass coupling is somewhat lessened. This is evident from the lesser slope to the left of 
the optimum point in the solution space; in the ALCD2+FDXNH+BUTK plot, growth rate is lower at 
zero butanol flux than in the ALCD2+FDXNH+HSK plot.  
 
 
 
Figure 23: Production envelope for leading RobustKnock prediction.  
 
 
5.3.5 Detailed simulation methodology  
 
For all simulations, model iCM925 was optimized for growth using flux balance analysis (see start of this 
chapter). When appropriate, flux variability was used to determine the minimum and maximum possible 
flux through a given reaction, thus accounting for alternative optimal solutions. Knockouts were 
simulated as reaction knockouts rather than gene knockouts by setting the upper and lower flux bounds of 
the relevant reaction to zero. Gene knockout predictions were made based on the gene-protein-reaction 
relationship for the knocked out reactions.  
 
Flux balance analysis was carried out in MATLAB using the COBRAToolbox [236], with Gurobi 5.1.0 
as the solver. OptKnock simulations were run using the COBRAToolbox implementation of this 
algorithm, again with GUROBI 5.1.0 as the solver. RobustKnock was run in MATLAB using the code 
provided with its publication (http://www.cs.technion.ac.il/~tomersh/methods.html), and for these 
simulations TOMLAB was used as the solver.  
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In each simulation, glucose uptake rate was set to the experimentally determined rate approximation of 10 
mmol/gDW/hr. It was assumed that acetate would not be present in the media, and therefore uptake was 
prevented by setting the lower bound of the exchange reaction to zero. In some simulations, the 
production of molecular hydrogen (H2) was constrained to a lower rate to determine its impact on the 
predictions; this was done because it is known that the model preferentially simulates overproduction of 
hydrogen rather than butanol. Similarly, in some simulations growth rate was capped at a lower rate; this 
was done to determine the impact of a lower growth rate on the predicted knockouts.  
 
5.4 Conclusions  
 
This chapter describes the leading simulations and predictions made using model iCM925 as part of the 
present dissertation work. Using model iCM925 to simulate typical C. beijerinckii metabolic behavior is 
challenging for three main reasons: (1) C. beijerinckii has a biphasic metabolism in which acids are 
produced and then re-assimilated for solvent production; (2) it is believed that C. beijerinckii grows sub-
optimally, making the optimal growth assumption typically used in flux balance analysis questionable; 
and (3) flux balance analysis requires a steady-state assumption and C. beijerinckii is most commonly 
grown in batch culture. However, each of these challenges was addressed as best as possible and useful 
and interesting hypotheses and predictions were derived.   
 
The first and third challenges were addressed in the same way by approximating steady-state as the 
window of time corresponding to exponential growth. Substrate uptake and product secretion rates 
corresponding to the exponential growth time period were calculated and imposed as additional 
constraints on the model when needed, and simulations were conducted only for this time period. 
Interestingly, concurrent acid production and re-assimilation was often observed in the model predicted 
flux distributions (see Chapter 4), in essence incorporating the biphasic metabolic observations. The 
challenge leading to optimal growth flux distributions that did not match experimental phenotype 
observations was overcome by imposing extra flux constraints to the biomass, acetate, butyrate, acetone, 
butanol, ethanol, and/or hydrogen exchange reactions.  
 
Model iCM925 was subsequently used to explore alternative production mechanisms for the pta and buk 
negative mutants developed by Wang et al. at the University of Illinois. No known alternatives for 
butyrate production were found in the model, but three alternatives for acetate production were found to 
be possible (aldehyde dehydrogenase, acetylornithine deacetylase, and cysteine synthase). These findings 
provide interesting hypothesis for the observed phenotype in the pta::int(17) strain, and can be used going 
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forward to investigate the actual in vivo mechanisms for acid production in both the pta and buk deficient 
strains. 
 
The model was additionally used to predict reaction knockout candidates for improved butanol 
production. The knockout sets with the greatest guaranteed effects for the least number were FDXNH 
(ferredoxin hydrogenase) + ALCD2 (aldehyde dehydrogenase) and BUTK (butyrate kinase) + ACK 
(acetate kinase) + ALDC2 (aldehyde dehydrongase). The FDXNH+ALCD2+BUTK knockout was also a 
leading candidate, but the added value as compared to just FDXNH+ALCD2 was minimal. Because 
ethanol production is typically minimal in C. beijerinckii, going forward I recommend that knockout 
strategies should first target the production of hydrogen and the production of acetate and butyrate. If 
ethanol (or another byproduct) is observed in the resulting mutants, it could be knocked out in subsequent 
engineering efforts. To remove the ability to produce molecular hydrogen or acetate and butyrate via the 
canonical pathways, the following reactions/genes should be targeted:  
 
1. FDXNH (Cbei_0327 Cbei_4000 Cbei_3796) 
2. BUTK + ACK (Cbei_4006 Cbei_4609 Cbei_0204 & Cbei_1165) or 
BCOPBT + PTA (Cbei_0203 & Cbei_1164) or  
BUTK + PTA (Cbei+4006 Cbei 4609 Cbei_0204 & Cbei_1164) or 
BCOPBT + ACK (Cbei_0203 & Cbei_1165) 
 
BCOPBT (phosphate butanolyltransferase) was included as an alternative knockout option to BUTK 
(butyrate kinase) as it is immediately upstream from BUTK in the metabolic network. Similarly, PTA 
(phosphate acetyltransferase) was included as an alternative to ACK (acetate kinase) because it is 
immediately upstream of ACK in the metabolic network. Knocking out BCOPBT and either ACK or PTA 
would result in the fewest number of gene knockouts. Thus far, the Blaschek group at the University of 
Illinois has individually knocked out Cbei_4000 encoding FDXNH (unpublished data), Cbei_0204 
encoding BUTK [12], and Cbei_1164 encoding PTA [12], in addition to jointly knocking out Cbei_0204 
and Cbei_1164 (BUTK+PTA) (unpublished data). The Cbei_4000 negative mutant presented exactly as 
the wild-type strain, suggesting that additional ferredoxin hydrogenase genes must be knocked out as well 
or an alternative approach to knock down the activity of this enzyme may be required. Some 
improvement in butanol production was observed for the buk, pta, and buk  + pta negative mutants, but 
optimization efforts and knockout approaches are ongoing.  
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Chapter 6: Time-series metabolic profiling of Clostridium 
beijerinckii NCIMB 8052 
 
The metabolome provides qualitative and/or quantitative measurements of metabolites present in a 
biochemical network under specific conditions. Metabolite concentrations observed both inside and 
outside of a cell can provide insight into the physiological state of the cell, and comparative analysis of 
global metabolomics data can reveal key differences in the abundance of specific compounds between 
conditions or time points.  A time-series analysis is a powerful tool for quantifying different metabolic 
states in the cell over the course of a fermentation, thereby adding to our understanding of dynamic shifts 
in metabolism.  For C. beijerinckii in particular, such an analysis can shed light on the underlying 
mechanisms governing the acidogenic and solventogenic phases of metabolism. The observed shifts in 
compound abundance can then be linked to differential activity in metabolic processes using the C. 
beijerinckii genome-scale metabolic model.  
 
In the present study, time-series metabolic profiling for wild-type C. beijerinckii NCIMB 8052 was 
conducted using a set of GC-MS methods at the University of Illinois Metabolomics Center. The 
observed fermentation phenotype was analyzed in the context of the genome-scale model, and metabolites 
identified by metabolic profiling were compared with the metabolites present in the model to generate 
putative new metabolite annotations. Trends in relative metabolite concentrations were analyzed over the 
course of the fermentation to obtain insight into major dynamic shifts in C. beijerinckii metabolism.  
 
6.1 Characterizing the C. beijerinckii phenotype 
 
Wild-type C. beijerinckii NCIMB was grown in minimal P2 [37] media in 3L bioreactors. Metabolite 
concentration data was used to guide simulations using model iCM925 and to obtain insight into changes 
in metabolite uptake and secretion rates.  
 
6.1.1 Choosing culture conditions   
 
C. beijerinckii is typically pre-cultured in TGY medium [242] and cultured in P2YE medium [37], both of 
which are complex media. However, it is important that the main culture be grown on a minimal media 
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for metabolomics analyses to eliminate ambiguity with the origin of any identified metabolites. C. 
beijerinckii has been successfully cultured in minimal P2 media [7, 248, 249]. Lee et al. utilized two pre-
culture steps, first in reinforced clostridia medium (at 35°C) and then in P2YE (at 35°C), and washed the 
cells before transfer into the P2 culture (grown at 33°C). Annous and Blaschek grew their pre-culture in 
TGY and then washed before transferring to P2 (both at 37°C). Despite these reported successes, 
achieving C. beijerinckii NCIMB 8052 growth on P2 minimal media for the analyses described herein 
proved to be quite challenging. Six different growth conditions (Table 18) were tested before typical 
growth and solvent production was achieved. Ultimately, C. beijerinckii was cultured for metabolomics 
analysis by performing three pre-culture steps in the anaerobic chamber at 35°C (first in TGY and then 
twice in P2) and then growing the main cultures in P2 at 37°C in bench top bioreactors (see Section 
6.4.1).  
 
Pre-culture(s)  
(in chamber at 35°C) 
Main culture  
(chamber or reactors) Results 
TGY à P2 à P2 
5% transfers 
P2 in reactors 
55 rpm agitation 
37°C 
Typical growth and 
solvent production 
TGY à P2 à P2 
5% transfers 
P2 in reactors 
no agitation 
35°C 
No growth 
TGY à P2 à P2 
5% transfers 
P2 in reactors 
55 rpm agitation 
35°C 
Long lag phase followed 
by acid crash 
TGY à P2 
1% transfer 
P2 in reactors 
55 rpm agitation 
35°C 
Reactor 1 – no growth; 
Reactor 2 – long lag phase 
followed by acid crash 
TGY 
cells washed in 60% 
glucose 
P2 in reactors 
55 rpm agitation 
35°C 
No growth 
TGY à P2 à P2 
5% transfers 
P2 in chamber 
two vitamin stocks tested 
35°C 
No growth 
 
Table 18: Culture conditions tested for C. beijerinckii NCIMB 8052 growth on P2 minimal media. 
 
Recent reports of C. beijerinckii culturing methods have chosen 35°C as the growth temperature for both 
the pre-culture and main culture steps. However, Clostridium acetobutylicum is more commonly grown at 
37°C. An exhaustive literature search revealed that prior to a 1997 publication by Fromanek et al., 37°C 
was more commonly used as a growth temperature for C. beijerinckii as well. Though it is unclear why 
variations in culturing temperatures emerged at this time, it is suspected that the belief was that better 
solvent production could be achieved at lower culturing temperatures. This was found to be true in a study 
by Bahl et al., who showed that optimal butanol production was achieved in cultures grown between 30°C 
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and 35°C [250].  In the present study, we found that the 37°C temperature was more effective for growth 
in the P2 minimal media.  
 
6.1.2 Characterizing the C. beijerinckii phenotype  
 
Traditionally, C. beijerinckii has been described has having two primary phases in its metabolism: 
acidogenesis, during which acetate and butyrate are the primary byproducts; and solventogenesis, during 
which acetate and butyrate are re-assimilated and converted into acetone, butanol, and ethanol. The 
growth, pH, and product profiles collected in our lab for this study are shown in Figure 24 (A, B, and C, 
respectively).  The switch between the acid producing phase and the solvent producing phase happened 
approximately 10 hours into the fermentation (characterized by a drop in pH, a leveling of butyrate 
concentration, and the start of butanol and acetone production). Exponential growth continued until 
approximately hour 21, spanning both the acidogenic phase and the early solventogenic phase. 
Interestingly, a second drop in pH was observed at this time. Because this pH drop does not correspond to 
peak acetate and butyrate levels as the first one does, it suggests production of a second round of acids 
between hour 15 and 20 of the fermentation. The arrows in Figure 24A indicate the time points at which 
metabolomics samples were taken. These time points were chosen because they enable a snap shot of 
phases in the production of butanol: (1) pre-butanol production, (2) butanol production coinciding with 
exponential growth, (3) butanol production as growth slows down, (4) butanol production after growth 
has stopped, and (5) post-butanol production. Note that in Figure 24C acetate does not appear to be 
increasing during the acidogenic phase; this is because acetate is in the growth media and therefore is 
simultaneously produced and consumed.  
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Figure 24: Growth, pH, and product profiles. (A) OD600; (B) pH; (C) concentrations of acetone (solid circle), 
ethanol (solid square), butanol (solid triangle), acetate (open triangle), and butyrate (open circle). Results reported 
are the average of two biological replicates. Acetone, butanol, ethanol, butyrate, and acetate were measured using 
gas chromatography. Glucose was measured using high-pressure liquid chromatography.  
A 
B 
C 
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To further characterize the different phases in C. beijerinckii metabolism and to aid in simulations with 
the iCM925 genome-scale model, the substrate uptake rates and product secretion rates were calculated as 
described previously (iCM925) [235]. This process illuminated the existence of three distinct phases 
during the first 32 hours of the fermentation—suggesting that the traditional view of a simple acidogenic 
and solventogenic phase may be too simplistic (Figure 25). In regards to acetate, there is a period of rapid 
consumption, followed by a period of slower consumption, followed by another period of rapid 
consumption. Butyrate starts with a period of rapid production, followed by a period of almost net zero 
production (during which butyrate is being simultaneously produced and consumed), followed by a 
period of rapid consumption. Acetone and butanol both begin with zero production in the first phase, 
followed by a mild production rate in phase two, and rapid production in phase three (note that the phase 
with most rapid acetone and butanol production coincides with the phase of most rapid acid 
consumption). The three observed phases correspond to the following approximate blocks of time 
(identified using the butyrate relationship): 0-7 hours (blue box), 7-19 hours (green box), and 19-32 hours 
(orange box). Beyond 32 hours cell density begins to drop, indicating cell death and/or sporulation.  
 
 
Figure 25: Relationship between product concentration and cell density. (A) Acetate; (B) Butyrate; (C) 
Acetone; (D) Butanol. Three distinct phases of metabolism were observed: phase one occurred between 0 and 7 
hours, phase two occurred between 7 and 19 hours, and phase three occurred between 19 and 32 hours (after which 
cell death began).The solid blue squares are used to illustrate phase one, the solid green triangles are used to 
illustrate phase two, and the solid orange circles are used to illustrate phase three. Linear trend lines are included for 
each phase. These plots are for only one of the biological replicates; the other replicate showed the same phase 
definitions.  
D C 
B A 
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Model iCM925 represents a repository of all metabolic reactions known to exist in C. beijerinckii [235]. 
Metabolic profiling data for metabolites present in model iCM925 can be used as a guide to simulating 
and mapping dynamic C. beijerinckii behavior onto the metabolic network. Therefore, the iCM925 
genome-scale model was used to simulate the second metabolic phase. This phase was chosen because it 
best matches the steady-state assumption needed for flux balance analysis and it contains the greatest 
number of metabolomics sampling points. As discussed in Chapter 5, the simulation was performed by 
setting the bounds on the model exchanges reactions for acetate, butyrate, acetone, butanol, and ethanol to 
be within one standard deviation of the mean experimentally-derived flux rates. The calculated and 
simulated flux rates are shown in Figure 26. The growth rate was not constrained in the simulations, but 
with the ATP maintenance value of 8.5 mmol/gDW/hr inferred during construction of the model the 
simulated growth rate fell within one standard deviation of the experimental average. Figure 26 illustrates 
that the experimental phenotype falls within the solution space of model iCM925.  
 
 
Figure 26: Comparison of iCM925 simulations with experimental phenotype. Simulated and experimental flux 
values for product fluxes, uptake fluxes and growth rates.  Error bars indicate the observed experimental range and 
diamonds represent the various simulation results.  
 
 
6.2 Metabolic profiling   
 
Metabolic profiling of the intracellular metabolites present in wild-type C. beijerinckii was conducted 
using a set of GC-MS analysis methods (see Section 6.4).  As discussed above, samples were collected 
over the entire course of the C. beijerinckii fermentation. Quantifying changes in metabolites for these 
time points allows for comparative analysis between key phases of C. beijerinckii metabolism to better 
understand metabolic states before, during, and after butanol production is activated. All data is the result 
of two independent experiments, and for each experiment, measurements were performed on duplicate 
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samples. In the analyses that follow, data represent the averages of all replicates. Relative concentration 
data was obtained for 95 metabolites, 59 of which were identified in seven out of the nine time points and 
therefore chosen as the focus of analysis.  
 
A hierarchical clustering analysis (Figure 27) of the relative concentration data for the 59 metabolites 
listed in Table 19 showed a clear ordering of metabolite abundance over time. In this figure, the rows 
represent the relative metabolite concentrations and the columns represent the fermentation time points. 
The relative concentration of each metabolite was standardized such that the mean was equal to zero and 
the standard deviation equal to one. Boxes shaded in red indicate that the relative concentration was 
higher than the mean and boxes shaded in blue indicate that the relative concentration was below the 
mean. Complete relative concentration profiles can be found in Appendix A.  
 
Time points were found to cluster in the correct fermentation order—acidogenesis/early exponential 
growth phase, mid exponential growth, slowed growth/transition to stationary phase, early stationary 
phase, and late stationary phase. The area of least metabolic activity (i.e., few metabolites are at their 
highest point) occurs at hours 19 and 21, as exponential growth is slowing down. Generally, metabolites 
important in the metabolism of carbohydrates and amino acids were found to be most abundant between 
hours 7 and 21 (exponential growth), and lipids and fatty acids were found to be most abundant in the 
later stages of the fermentation, between hours 32 and 84.  The clustering of saturated fatty acids during 
the later fermentation time points is intriguing because of the high concentrations of butanol present at 
this time. As discussed in Chapter 2, butanol toxicity causes fluidization of the C. beijerinckii membrane 
that is typically combatted by the over-production of saturated fatty acids [6].  
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Metabolite  Pathway 
10-Heptadecenoic acid 
 Tetradecanoic acid Saturated fatty acid 
Hexadecanoic acid Saturated fatty acid 
Docosanoic acid Saturated fatty acid 
3,5-di-tert-butyl-4-hydroxy-hydrocinnamic acid 
 2,4,6-Tri-tert.-butylbenzenethiol 
 Pentadecanoic acid Saturated fatty acid 
Eicosanoic acid Saturated fatty acid 
Octadecanoic acid Saturated fatty acid 
Heptadecanoic acid Saturated fatty acid 
2-Pyrrolidinone 
 Glyoxylic acid Carbohydrate metabolism, amino acid metabolism  
1-Hexadecanoylglycerol 
 1-Octadecanoylglycerol 
 N-Acetyl-L-aspartic acid Amino acid metabolism 
Ribose Carbohydrate metabolism 
2,3-Dihydroxybutane Butanoate metabolism 
Threitol 
 Erythritol 
 Arabino-Hexonic acid, 3-deoxy 
 Malic acid Carbohydrate metabolism 
2-Aminoethylphosphate 
 L-Serine Amino acid metabolism  
3-Methyl-4-hydroxybutanoic acid 
 L-Proline Amino acid metabolism  
L-Isoleucine Amino acid metabolism  
Pentitol, 3-desoxy 
 L-Glutamic acid Amino acid metabolism  
L-Valine Amino acid metabolism  
Adenosine Purine metabolism  
Glycine Amino acid metabolism  
2-Methyl-2-hydroxybutanoic acid 
 Pyroglutamic acid Amino acid metabolism  
Glycerate 3-phosphate Carbohydrate metabolism, amino acid metabolism, lipid metabolism 
L-Alanine Amino acid metabolism  
4-Hydroxybutanoic acid Butanoate metabolism  
Talose Carbohydrate metabolism 
3-Hydroxybutanoic acid Butanoate metabolism  
Succinic acid Carbohydrate metabolism 
Glycerol-3-phosphate Lipid metabolism  
beta-Alanine Amino acid metabolism  
Citramalic acid Carbohydrate metabolism 
Gluconic acid Carbohydrate metabolism 
Glucose-6-phosphate Carbohydrate metabolism 
Fructose-6-phosphate Carbohydrate metabolism 
Mannitol-6-phosphate Carbohydrate metabolism 
Lactic acid Carbohydrate metabolism 
Arabinose Carbohydrate metabolism  
Phosphoric acid Central metabolism  
Glycolic acid Carbohydrate metabolism  
Glycerol Carbohydrate metabolism, Lipid metabolism  
Glyceric acid Amino acid metabolism, Lipid metabolism, Carbohydrate metabolism  
Erythronic acid 
 2-Keto-L-gluconic acid Carbohydrate metabolism 
Galactose Carbohydrate metabolism 
4-Hydroxypyridine 
 Fructose Carbohydrate metabolism 
C18:1 [I] Fatty acid  
 
Table 19: List of 59 metabolites found to be present in the majority of time samples and included in the 
hierarchical clustering analysis. These metabolites are listed in the order in which they appear in Figure 27. 
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Figure 27: Hierarchical clustering analysis of relative metabolite concentrations. Rows represent relative 
concentrations standardized to have a mean and standard deviation equal to zero and one, respectively. Columns 
correspond to fermentation time points. Boxes shaded in red indicate a concentration above the mean, and boxes 
shaded in blue indicate a concentration below the mean.  
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The relative concentration of lactic acid was found to be maximal at the earliest time points and decreased 
rapidly in the late exponential phase and then more slowly during the remainder of the stationary phase 
(Figure 28). Because lactic acid was not supplied in the growth media, this suggests that lactic acid was 
produced rapidly during the acidogenic phase and then reutilized much like acetic and butyric acid. As 
shown in Figure 3 (Chapter 2), the solventogenic clostridia are known to produce lactic acid and in 
doing so are able to regenerate NAD+. It has been shown in C. acetobutylicum that when lactic acid is 
added to glucose media it is consumed and leads to improved butanol yields [251]. Additionally, the 
production and then reutilization of lactic acid was observed in C. beijerinckii by Wang et al. [12]. Given 
its potential role in balancing redox equilibrium, lactic acid may be an important metabolite to follow in 
future C. beijerinckii experiments.  
 
 
Figure 28: Relative concentration profile of lactic acid. Concentration data represents the average of two 
biological replicates, each with two technical replicates.  
 
 
The presence of several acids in the late exponential phase, including succinic acid, malic acid, 
pyroglutamic acid, 3-hydroxbutryic acid, and 4-hydroxbutyric acid was noted in the observed 
concentration abundance over time. As might be expected with high concentrations of acids, a drop in pH 
was observed at this time. This second drop in pH is typically only observed for C. beijerinckii when 
grown on P2 or P2YE media. However, such an obvious second drop in pH was not observed in the 
characterization of the buk::int(532) developed by Wang et al. This suggests that there may be an 
underlying mechanism in the buk negative strain that is related to the production of late exponential phase 
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acids. Two of the acids in this study that were observed at the time of the second pH drop participate in 
the butanoate pathway (3-hydroxybutryic and 4-hydroxybutyric) and thus present an interesting area of 
future work with the buk negative strain.  
  
6.3 Analysis in the context of model iCM925 and novel metabolite annotations  
 
Metabolites identified by metabolic profiling but not found in model iCM925 may be used to expand the 
genome-scale model. Such expansion can generate hypotheses about new metabolic activities or 
pathways and potentially refine genome annotations. Of the 59 metabolites analyzed above, 28 are present 
in model iCM925. Of these 28 metabolites, 17 are utilized in the simulation of the experimental 
phenotype (Section 6.1). Of the 11 that are not utilized in the simulation, seven are present in a reaction 
that is blocked in the model (i.e., cannot carry flux). The fate of these seven metabolites is currently 
unknown. Thus, they represent priority metabolites for model gapfilling going forward (beyond the scope 
of this study). The 31 metabolites not present in the model but found in the metabolic profiling data also 
offer opportunities for future molecular biology research and model expansion, particularly in the area of 
fatty acid and lipid metabolism. See Appendix B for an alignment of identified metabolites and model 
iCM925 metabolites.  
 
One metabolite that was identified in this study and is not present in model iCM925 is 3-hydroxybutyric 
acid (3HB). 3HB is a chiral molecule used in the synthesis of optically active fine chemicals, such as 
vitamins and antibiotics [252]. In the profiling experiment, intracellular 3HB is found to increase to a 
maximum concentration occurring around hour 21 of the fermentation, and then steadily decrease (Figure 
29). Because extracellular 3HB is found to follow a similar profile, it can be concluded that the decrease 
in 3HB concentration is not a result of export out of the cell. Instead, it would seem that 3HB is both 
produced and utilized by C. beijerinckii.  The KEGG database shows 3-hydroxbutyric acid to be present 
in just two reactions, one of which (3HB dehydrogenase, EC-1.1.1.30) is intriguing because it involves 
acetoacetate, a metabolite present in C. beijerinckii as a product of acetate and butyrate re-assimilation 
and a precursor to acetone production. However, compelling sequence homology was not found for this 
enzyme.  Instead, a literature search revealed that the ptb and buk enzymes (phosphobutyrl transferase and 
butyrate kinase) have been taken from C. acetobutylicum and utilized in Eschercia coli to produce 3HB 
[252]. These enzymes are present in the C. beijerinckii metabolic network, but were previously thought to 
only catalyze the reactions producing butyrate. Given the potential for involvement of this metabolite in 
butyrate production, monitoring 3HB in future fermentation experiments may provide new insights into 
butyrate metabolism in C. beijerinckii.  
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Figure 29: Relative concentration profile of intracellular and extracellular 3HB. It is important to note that the 
relative concentrations of the intracellular and extracellular version of this metabolite cannot be directly compared 
because of differences in normalization. Both profiles are shown here to demonstrate that the decrease in 3HB 
concentration is not simply a result of export out of the cell. 
 
6.4 Detailed methodology  
 
6.4.1 Cell culture, fermentation, and sampling protocol 
 
Cultures of C. beijerinckii 8052 were stored in spore form at 4°C in sterile H2O [7].  Spores were heat 
shocked for 10 minutes at 80°C, immediately transferred into an ice bath for 5 minutes, and inoculated 
into tryptone–glucose–yeast extract (TGY) medium containing 30 g/L tryptone, 20 g/L glucose, 10 g/L 
yeast extract, and 1 g/L L-cysteine [242].  The inoculum was incubated in an anaerobic chamber under 
N2:CO2:H2 (volume ratio of 85:10:5) atmosphere until they reached mid-exponential phase 
(approximately 8 hours and OD600 1.0) at 35±1°C. This culture was transferred at a 5% ratio (v/v) into 60 
g/L glucose and sterilized P2 medium [37] and grown again in the anaerobic chamber until mid-
exponential phase at 35±1°C. This transfer was repeated once more to ensure complete consumption of 
all complex media.  After the second passage into P2 media in the anaerobic chamber, actively growing 
pre-culture was transferred at a 5% ratio (v/v) into a 1.5 L working volume of P2 media in 3 L BioFlo® 
115 bench top bioreactors (New Brunswick Scientific Co., Enfield, CT). The cultures were grown in 
biological duplicates under positive N2 pressure at 37°C and 50 rpm.  
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Culture growth was measured by following optical density (OD) in the fermentation broth at A600 using a 
Beckman Coulter DU 640B UV-Vis Spectrophotometer (Beckman Coulter, Inc., Indianapolis, IN) and 
cell density was calculated using the relationship A600 = 1 equivalent to 0.28 mg/mL as determined by a 
previous dry weight calibration experiment.  Gas chromatography (Agilent Technologies 7890A GC 
System) was used to quantify acetic acid, acetone, butyric acid, ethanol, and butanol concentrations. 
Glucose concentration was determined using high pressure liquid chromatography (Agilent Technologies 
1200 Series).  The pH profiles were monitored throughout the fermentation. Samples for metabolomics 
analysis were collected in duplicate at hours 7, 11, 15, 19, 21, 32, 44, 60, and 84 after innoculation.  
Sampling volumes were chosen to ensure a 50 mg fresh weight pellet and were calculated based on OD600 
using a previously determined ratio of 15 mL / 1 OD600. Collected samples were immediately centrifuged 
at 4000 rpm for 10 minutes. The supernatant was removed and frozen at -80°C for metabolomics analysis. 
The pellet was quenched by suspension in 1 mL of 60% (v/v) -60°C methanol, and stored at -80°C for 
metabolomics analysis.  
 
6.4.2 Sample treatment and metabolite identification at the Illinois Metabolomics Center 
 
All sample analysis was performed using the facilities at the Illinois Metabolomics Center. Prior to 
extraction, derivatization, and analysis using GC/MS, each pellet sampled was lysed by sonicating with 
an ultrasonic tip (XL-2000, Qsonica, LLC) twice for thirty seconds each time.  Between sonications, 
samples were kept on ice.  Lysed pellets were then extracted and derivatized as described below, 
depending on the compounds being targeted.  
 
Metabolic Profiling 
  
Polar compounds were subsequently extracted from the lysed pellets using 1 mL HPLC grade methanol 
(EMD chemicals Inc., PA, USA) and distilled water and dried by vacuum centrifugation.  Dried polar 
extracts were derivatized with 80 µl of 20 mg/mL methoxyamine hydrochloride in pyridine (Sigma-
Aldrich, Saint Louis, MO, USA) for 60 min at 50ºC and then with 80 µl MSTFA (Sigma-Aldrich, Saint 
Louis, MO, USA) at 70ºC for 120 min with a following incubation for two hours at room temperature. 
Ten microliters (10 µL) of the internal standard (hentriacontanoic acid, 10 mg/mL) was added to each 
sample prior to derivatization. Derivitized, polar extracts were analyzed by the following two GC/MS 
systems:  
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1. An Agilent 7890 gas chromatograph, an Agilent 5975 mass selective detector, and a HP 
7683B autosampler. Gas chromatography was performed on a HP-5MS (60m×0.25mm I.D. 
and 0.25µm film thickness) capillary column (Agilent Inc, Palo Alto, CA, USA). 
2. An Agilent 6890 gas chromatograph, an Agilent 5973 mass selective detector, and a HP 
7683B autosampler.  Gas Chromatography was performed on a ZB-1MS (30m×0.32mm I.D. 
and 0.25µm film thickness) capillary column (Phenomenex, Torrance, CA, USA). 
For both systems, the inlet and MS interface temperatures were 250°C, and the ion source temperature 
was adjusted to 230°C. An aliquot of 1 µL was injected with the split ratio of 10:1. The helium carrier gas 
was kept at a constant flow rate of 1.5 mL/min. The temperature program was as follows: 5-min 
isothermal heating at 70°C, followed by an oven temperature increase of 5°C/min to 310°C, with a final 10 
min at 310°C. The mass spectrometer was operated in positive electron impact mode (EI) at 69.9 eV 
ionization energy in m/z 50-800 scan range. 
 
FAME Analysis  
 
Non-polar compounds were extracted from the lysed pellets using chloroform (Thermo Fisher Scientific 
Inc, PA, USA) and dried by vacuum centrifugation.  Free fatty acids from the non-polar extracts were 
converted to their methyl esters using Diasomethane (Sigma-Aldrich Saint Louis, MO, USA) and 1 µL 
was analyzed in split mode (5:1) using an Agilent 6890 GC and 5973MSD on a ZB1-MS capillary 
column (30m×0.32mm I.D. and 0.25 µm film thickness) (Phenomenex, Torrance, CA, USA). The 
injection port temperature was 260ºC, the interface was set to 280ºC, and the ion source was adjusted to 
230ºC. The helium carrier gas was set at a constant flow rate of 2.5 ml/min. The temperature program was 
5-min of isothermal heating at 140ºC, followed by an oven temperature increase of 5ºC/min to 300ºC, and 
then a final 2 min at this temperature. The mass spectrometer was operated in positive electron impact 
mode (EI) at 69.9 eV ionization energy in m/z 50-800 scan range. 
 
Data Analysis  
 
The spectra of all chromatogram peaks were compared with electron impact mass spectrum libraries 
NIST08 (NIST, MD, USA), W8N08 (Palisade Corporation, NY, USA), and a custom-built library. To 
allow comparison between samples, all pellet data were normalized to the internal standards in each 
chromatogram and the fresh weight of the pellet. The spectra of all chromatogram peaks were evaluated 
using the AMDIS (NIST, Gaithersburg, MD, USA) program. The final metabolome concentrations are 
reported as “analyte concentration relative to hentriacontanoic acid per sample weight (i.e., as the peak 
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area of the target compound divided by the (IS) peak area).  Hentriacontanoic acid was used as the 
internal standard for the polar analyses as it is a fatty acid rarely found in biological samples. 
Heptacosanoic acid was used as the internal standard for the FAME analysis. The obtained relative 
concentration data does not allow comparison between different metabolites within a sample due to 
different MSD responses to various compounds.  
 
6.4.3 A tool for data organization and analysis   
 
To reduce the time expenditure required for processing of GC-MS data files, I designed a semi-automated 
data organization and analysis method using MATLAB (Figure 30). Generally speaking, the approach 
that I utilized can be separated into four main steps: (1) batch analysis of Agilent files using AMDIS 
software; (2) organization of batch data into four data matrices; (3) data refinement and consistency 
check; and (4) data analysis.  
  
Step 1: Batch analysis of Agilent files using AMDIS. For each analyzed sample, AMDIS generates an 
output file containing relevant information about metabolite targets such as the metabolite name, retention 
time, peak area, and the match score of the component spectra to the library spectra. The time expenditure 
and manual involvement of this process can be vastly improved by analyzing all samples at once using 
the BATCH JOB option in AMDIS. The drawback to this analysis approach is that the output file 
contains huge amounts of data that cannot be manually organized using Excel. Data analysis in AMDIS 
was performed using an applied minimum net match score of 70. 
 
Step 2: Organize batch data and generate four data matrices. To enable utilization of batch 
processing in AMDIS I developed MATLAB code to organize the large output file. My code provides 
four data matrices containing information about each metabolite target. In each matrix, the rows represent 
the identified metabolites and the columns represent the samples. The four matrices are as follows: (1) a 
matrix containing the AMDIS match score, used to evaluate the similarity between the library and target 
metabolite m/z fragmentation patterns; (2) a matrix containing the integrated peak areas; (3) a matrix 
containing the retention times; and (4) a binary matrix in which a 1 indicates the metabolite was found in 
the sample and 0 indicates it was not found.  
 
Step 3: Data refinement and consistency check. In this step, I holistically analyzed the retention time of 
each identified metabolite. Instead of looking at the retention time of a metabolite in a single sample, I 
took advantage of the fact that retention times should only undergo a minor shift over the course of the 
109 
 
analysis by looking at the retention times of each identified metabolite over all samples. Specifically, for a 
given metabolite I looked at the maximum and minimum retention times observed for the entire set of 
samples. In this way, I could rapidly identify metabolite identifications with inconsistent retention times 
and set them aside as metabolite matches needing additional consideration. For example, if L-alanine was 
identified in Sample 1 at 13.2 min and in Sample 2 at 14.7 min, it would be a red flag that one or both of 
these metabolite matches are incorrect.  
 
Additionally in this step, I combined the integrated areas for synonymous metabolites. The utilized set of 
rules and synonym repository can be expanded going forward. The final refinement step that I conducted 
was to eliminate what I considered “sporadic” matches, perform data normalization, and average sample 
replicates. If a given metabolite was identified inconsistently across all samples, I chose to discard it as an 
unreliable match. My criteria for this was based on the number of “changes” observed in the presence or 
absence of a metabolite across all samples in addition to the total number of samples the metabolite was 
identified in. Examples of this binary evaluation can be seen in Figure 30.  
 
Step 4: Data analysis. Only metabolites present in seven or more of the nine samples (i.e., greater than 
75%) were selected for detailed analysis. For metabolites identified by more than one GC-MS method, 
the method that provided the greatest percentage of matches across all samples for that metabolite was 
chosen. In the event that each method performed the same, the metabolite identified using the Agilent 
6890 gas chromatograph and 5973 mass selective detector with the ZB-1MS capillary column (see above) 
was chosen. Relative concentrations for each metabolite were averaged across all four replicates (two 
biological X two technical replicates). Hierarchical clustering was performed in MATLAB using the 
clustergram function.  
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Figure 30: Overview of the data organization and analysis approached used to for self-analysis of 
metabolomics data collected using the Illinois Metabolomics Center facilities 
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6.5 Conclusions 
 
We conducted the first time-series metabolic profiling experiment for C. beijerinckii NCIMB 8052. The 
relative concentration data collected in this experiment serve to compliment the genome-scale C. 
beijerinckii model by adding dynamic information about metabolites in the network in addition to the 
static stoichiometric equations obtained from known genome-annotations. We observed shifts in 
metabolism over the course of the 84 hour fermentation, highlighting the transition to saturated fatty acid 
production to combat butanol toxicity as butanol concentrations become maximal. Additionally, new 
information concerning the production and consumption of lactic acid was observed, and hypotheses to 
explain the observed second drop in pH were generated. Finally, a tool was developed to assist with data 
analysis at the University of Illinois Metabolomics Center. Going forward, the hypotheses generated as 
part of this work present interesting opportunities for analysis using the C. beijerinckii genome-scale 
model as well as novel insights into the dynamics of C. beijerinckii metabolism.  
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Chapter 7: Conclusions and future directions 
 
Butanol, currently produced as a byproduct of petroleum refining, is an important chemical feedstock and 
has potential to be used as an alternative transportation fuel. Clostridium beijerinckii is an attractive 
microorganism for biological butanol production because it (1) naturally produces the highest recorded 
butanol concentrations as a byproduct of fermentation; and (2) can co-ferment pentose and hexose sugars 
(the primary products from lignocellulosic hydrolysis).  For my Ph.D. dissertation, I used constraint-based 
modeling and metabolic profiling to holistically investigate C. beijerinckii metabolism, with the ultimate 
goal of garnering new insights to guide strain design for increased butanol production. My dissertation 
work makes four important contributions to advance C. beijerinckii research: (1) the first constraint-based 
genome-scale model of C. beijerinckii metabolism (iCM925) and demonstration that constraint-based 
analysis of iCM925 can accurately reproduce physiological behavior and provide insight into the 
underlying mechanisms of microbial butanol production; (2) hypothesis generation using model iCM925 
for alternative acetate production mechanisms in mutant strain pta::int(17); (3) model-guided knockout 
candidates for improved butanol production; (4) the first time-series metabolomics study for C. 
beijerinckii, used to identify distinct metabolic phases and suggest new metabolite annotations. 
 
For the first time, more traditional reductionist approaches to manipulating C. beijerinckii metabolism 
have been and can continue to be complimented with genome-wide knowledge of well-curated 
stoichiometric relationships in the metabolic network. In this way, model iCM925 can be used to simulate 
and predict the whole-cell effects of genetic and environmental perturbations. For my dissertation work, I 
used model iCM925 to simulate energetic tradeoffs associated with production of important byproducts, 
suggest specific alternative production mechanisms for acetate in the acetate-producing pta negative 
mutant, and predict priority knockout targets for improved butanol production.  It is my hope that as 
metabolic engineering of C. beijerinckii continues, this model will be instrumental in understanding the 
system wide mechanisms of new strains and phenotypes. In addition to bringing clarity to known 
biochemical transformations in the C. beijerinckii metabolic network, my dissertation work has kick-
started metabolomics studies as an avenue for investigating dynamic changes in C. beijerinckii 
metabolism. The initial study presented herein quantified a shift in metabolite composition over time that 
reflected changes in membrane lipid composition as extracellular butanol concentrations increase. 
Additionally, metabolites were identified that are not present in model iCM925 and thus represent 
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opportunities for future model refinement and biological investigation. Finally, I developed a tool to aid 
with self-analysis of large-scale metabolomics studies that I hope will help facilitate continued 
metabolomics analyses in C. beijerinckii.  
 
Constraint-based analysis of genome-scale metabolic networks has proven to be a valuable tool for 
linking genotype to phenotype in microorganisms such as C. beijerinckii; however, clear opportunities 
still exist for expanding this modeling framework and improving the accuracy of included mechanisms. 
Among these include careful study of co-factor utilization in the metabolic network, incorporation of 
organism-specific pH measurements in both static and dynamic simulations, and expansion of fatty acid 
and lipid characterization.  Co-factor utilization and redox equilibrium has been shown over and over 
again to play an important role in byproduct formation (including butanol), and therefore accurate 
representation of co-factor containing reactions in in silico models is critical for accurate assessment of 
metabolic potential. For pH, most genome-scale models today are mass balanced for a neutral pH, but in 
many cases (such as in C. beijerinckii) the environmental and cellular pH not only may not be 7 but it 
may change with time. Therefore, novel methods to enable simulation of genome-scale metabolic models 
at non-neutral pH could provide important insight into H+ flux and its role in system wide biochemical 
mechanisms. Finally, given the complexity of fatty acid and lipid metabolism these pathways are 
typically over-simplified in genome-scale metabolic models. However, recent efforts (e.g., in the Yeast 5 
metabolic network [253]) have shown that added detail to these pathways can improve model accuracy.  
In C. beijerinckii in particular, co-factors, pH, and fatty acids have proven to be important contributors to 
systemic mechanisms for butanol production.  
 
In addition to opportunities for expanding and improving the accuracy of metabolic network modeling, 
going forward one important area of work will be the integration of more complex data types (e.g., 
transcriptomics, metabolomics, and proteomics). As more and more high-throughput data becomes 
available, it will be important to develop more sophisticated modeling approaches to harness the vast 
amount of information available in the measurements. With an effective gene knockout system now 
available for C. beijerinckii, future research will include the metabolic engineering of new mutant strains 
for improved and novel substrate utilization and production of both butanol and other important 
biochemicals. In addition to characterization of new strains via fermentation, it is likely that the highest 
performing strains will be analyzed more deeply using transcriptomic and metabolomic approaches. 
Therefore, novel approaches to integrating and analyzing the interactions between all of the collected data 
to capture the “big picture” of what is happening in the cell will be impactful in C. beijerinckii research as 
well; model iCM925 and the work presented here should provide a strong foundation for these efforts.  
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Appendix A: Additional metabolomics figures  
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Relative concentrations of identified metabolites (biological duplicate #1), cont.  
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Relative concentrations of identified metabolites (biological duplicate #1), cont.  
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Relative concentrations of identified metabolites (biological duplicate #2), cont.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 50 100
0
20
40
60
80
100
Adenosine
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0
2
4
6
8
10
Arabino-Hexonic acid, 3-deoxy
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0
5
10
15
Arabinose
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0.2
0.4
0.6
0.8
1
1.2
C18:1 [I]
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0
2
4
6
8
Citramalic acid
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0
0.05
0.1
0.15
0.2
Docosanoic acid
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0.8
1
1.2
1.4
Eicosanoic acid
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
1
2
3
4
5
6
Erythritol
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0
5
10
15
Erythronic acid
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0
200
400
600
800
Fructose
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0
2
4
6
8
Fructose-6-phosphate
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0
500
1000
1500
2000
2500
Galactose
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0
2
4
6
8
Gluconic acid
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0
10
20
30
Glucose-6-phosphate
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0
5
10
15
20
25
Glycerate 3-phosphate
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
0 50 100
0
2
4
6
8
Glyceric acid
Time (hrs)
Re
lat
ive
 c
on
ce
nt
ra
tio
n
132 
 
Relative concentrations of identified metabolites (biological duplicate #2), cont.  
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Relative concentrations of identified metabolites (biological duplicate #2), cont.  
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Appendix B: Comparison of metabolic profiling identifications with 
genome-scale model iCM925 
 
Metabolite Name iCM925 ID 
Glycerate 3-phosphate 3pg 
4-Hydroxybutanoic acid 4ohbut 
Adenosine adn 
beta-Alanine ala-B 
L-Alanine ala-L 
Arabinose arab-D 
Fructose-6-phosphate f6p 
Fructose fru 
Glucose-6-phosphate g6p 
Galactose gal 
Gluconic acid glcn 
L-Glutamic acid glu-L 
Glyoxylic acid glx 
Glycine gly 
Glycerol glyc 
Glycerol-3-phosphate glyc3p 
Glycolic acid glyclt 
Glyceric acid glyc-R 
L-Isoleucine ile-L 
Lactic acid lac-D 
Malic acid mal-L 
Mannitol-6-phosphate mnl1p 
Phosphoric acid pi 
L-Proline pro-L 
Ribose rib-D 
L-Serine ser-L 
Succinic acid succ 
L-Valine val-L 
10-Heptadecenoic acid 
 1-Hexadecanoylglycerol 
 1-Octadecanoylglycerol 
 2,3-Dihydroxybutane 
 2,4,6-Tri-tert.-butylbenzenethiol 
 2-Aminoethylphosphate 
 2-Keto-L-gluconic acid 
 2-Methyl-2-hydroxybutanoic acid 
 2-Pyrrolidinone 
 3,5-di-tert-butyl-4-hydroxy-hydrocinnamic acid 
 3-Hydroxybutanoic acid 
 3-Methyl-4-hydroxybutanoic acid 
 4-Hydroxypyridine 
 Arabino-Hexonic acid, 3-deoxy 
 Eicosanoic acid 
 Erythronic acid 
 Heptadecanoic acid 
 Pentitol, 3-desoxy 
 C18:1 [I] 
 Citramalic acid 
 Docosanoic acid 
 Erythritol 
 Hexadecanoic acid 
 N-Acetyl-L-aspartic acid 
 n-Butylamine 
 Octadecanoic acid 
 Pentadecanoic acid 
 Pyroglutamic acid 
 Talose 
 Tetradecanoic acid 
 Threitol 
  
